Heteroaryl compounds as ligand directed degraders of IRAK4
Patent Information
- Application Number
- MYPI2025000405
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-20
- Filing Date
- 2023-07-19
- Publication Date
- 2024-01-20
AI Technical Summary
Current therapies lack effective methods to modulate IRAK4 activity for treating inflammatory and autoimmune diseases, as existing approaches do not adequately target IRAK4 for degradation, which is crucial for managing conditions like rheumatoid arthritis, inflammatory bowel disease, and others.
Development of heteraryl compounds that act as ligand-directed degraders of IRAK4, utilizing the ubiquitin-proteasome pathway to selectively target and degrade IRAK4, thereby modulating its activity and reducing inflammatory responses.
The compounds effectively degrade IRAK4, providing a therapeutic approach to treat inflammatory and autoimmune diseases by reducing cytokine production and inflammatory signaling, offering potential benefits for conditions such as rheumatoid arthritis and inflammatory bowel disease.
Abstract
Description
HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to US Provisional Application No. 63 / 390,888, filed on July 20, 2022, which is incorporated herein by reference in its entirety for any purpose. FIELD
[0002] The present disclosure relates generally to compounds, compositions, and methods for their preparation and use of the compounds and compositions for treating inflammatory or autoimmune diseases. BACKGROUND
[0003] The recruitment of immune cells to sites of injury involves the concerted interactions of a large number of soluble mediators. Several cytokines appear to play key roles in these processes, including interleukin-1 (IL-1). IL-1 produces proinflammatory responses and contributes to the tissue degeneration observed in chronic inflammatory conditions. IL-1 has also been implicated in the process of bone resorption and adipose tissue regulation. Thus, IL-1 plays a key role in a large number of pathological conditions including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, diabetes, obesity, cancer, and sepsis.
[0004] IL-1 treatment of cells induces the formation of a complex consisting of the two IL-1 receptor chains, IL-1R1 and IL-1RAcP, and the resulting heterodimer recruits an adaptor molecule designated as MyD88, which binds to IL-1 receptor associated kinase (IRAK) (Wesche et al., J. Biol. Chem.1999, 274, 19403-19410; O’Neill et al., J. Leukoc. Biol.1998, 63, 650-657; Auron, Cytokine Growth Factor Rev.1998, 9:221-237; and O’Neill, Biochem. Soc. Trans.2000, 28, 557-563). Four members of the IRAK family have been identified: IRAK1, IRAK2, IRAK3, and IRAK4. These proteins are characterized by a typical N-terminal death domain that mediates interaction with MyD88-family adaptor proteins and a centrally located kinase domain. Of the four members in the mammalian IRAK family, IRAK-4 is considered to be the “master IRAK.” IRAK-4 is a serine / threonine kinase that plays an essential role in signal transduction by Toll / IL-1 receptors (TIRs). Under overexpression conditions, all IRAKs can mediate the activation of nuclear factor-kappa B and stress-induced mitogen activated protein kinase (MAPK)-signaling cascades. Studies have shown that IRAK4 kinase activity is essential for cytokine production, activation of MAPKs, and induction of NF-kappa B regulated genes in response to TLR ligands (Koziczak-Holbro M. et al., J. Biol. Chem.2007, 282, 13552-13560). Given the central role of IRAK4 in Toll-like / IL-1R signaling and immunological protection, compounds that modulate the function of IRAK4 may be useful in treating inflammatory, cell proliferative, and immune-related conditions and diseases associated with IRAK-mediatedsignal transduction such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, diabetes, obesity, allergic disease, psoriasis, asthma, graft rejection, cancer and sepsis.
[0005] Protein degradation is a highly regulated and essential process that maintains cellular homeostasis. Selective identification and removal of damaged, misfolded, or excess proteins is achieved through the ubiquitin-proteasome pathway (UPP). The UPP is central to the regulation of almost all cellular processes. Ubiquitination of the protein is accomplished by an E3 ubiquitin ligase that binds to a protein and adds ubiquitin molecules to the protein, thus marking the protein for proteasome degradation.
[0006] Harnessing the UPP for therapeutic use has received significant interest (Zhou et al., Mol. Cell 2000, 6, 751-756). One promising therapy uses proteolysis targeting chimeras, commonly referred to as PROTACs, to effect removal of unwanted proteins by protein degradation (Scheepstra et al., Comp. Struct. Biotech. J.2019, 17, 160-176). PROTACS are ligand directed degraders that bring together an E3 ligase and a target protein that is to be degraded. These bivalent molecules usually consist of an E3 ligase ligand connected through a linker moiety to small molecule that binds to the target protein. A PROTAC positions the E3 ligase at the appropriate distance and orientation to the target protein, allowing the latter to be ubiquitinated. The ubiquitinated target protein is subsequently recognized by the proteasome, where it is degraded.
[0007] Accordingly, in one aspect, provided herein are compounds that target IRAK4 for degradation. SUMMARY
[0008] Described herein, in certain embodiments, are compounds and compositions thereof for degrading IRAK4. In various embodiments, the compounds and compositions thereof may be used in treatment of inflammatory or autoimmune diseases.
[0009] The present embodiments can be understood more fully by reference to the detailed description and examples, which are intended to exemplify non-limiting embodiments.
[0010] Embodiment A1 is a compound of Formula (I’): or a pharmaceutically,Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups; each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, -(6- to 10–membered bridged heterocyclylene)-, and C1-C6alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group; L1is -NH- or a bond; L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or -( C1-C6alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N, O, and S; L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C6alkylene)z-, -(7- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups; L4enylene, -N(H)(phenylene), 5- to 6-membered heteroarylene, -N(H)(5-to 6-membered heteroarylene)-, 8- to 10-membered fused bicyclic heteroarylene, or 5- to 6- membered heterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1-3 heteroatoms selected from N, S, and O; R1aand R1bare each H or are taken together to form an oxo group; R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group; or R3and R11are taken together to form a C3-C6cycloalkylene group;Y is NH, O, or a bond; R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1- C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups; W is O, -NR5-, or a bond; R5is H or C1-C6alkyl; each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group; each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl, halo, -CN, or -OH; each R9is independently H or C1-C6alkyl; each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group; each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl; or R11and R3are taken together to form a C3-C6cycloalkylene group; x is 0 or 1; y is 0, 1, 2, 3, 4, or 5; each z is independently 0 or 1; X is N or CR13; R13is H, halo, -OH, or C1-C6alkyl; Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N.
[0011] Embodiment A2 is the compound of embodiment A1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (I):wherein: Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups; each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, and C1-C6alkoxy, or two R0groups are taken together to form an oxo group; L1is -NH- or a bond; L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or 5-membered heteroarylene containing 1-3 heteroatoms selected from N, O, and S; L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(6- to 10- membered bridged heterocyclylene)(C1-C6alkylene)z-, -(9- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1- C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups; enylene, 5- to 6-membered heteroarylene, or 5- to 6-memberedheterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1- 3 heteroatoms selected from N and O; R1aand R1bare each H or are taken together to form an oxo group; R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group;or R3and R11are taken together to form a C3-C6cycloalkylene group; Y is NH or O; R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1- C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups; W is O, -NR5-, or a bond; R5is H or C1-C6alkyl; each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group; each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl, halo, -CN, or -OH; each R9is independently H or C1-C6alkyl; each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group; each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl; or R11and R3are taken together to form a C3-C6cycloalkylene group; x is 0 or 1; y is 0, 1, 2, 3, 4, or 5; each z is independently 0 or 1; X is N or CR13; R13is H, halo, or C1-C6alkyl; Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N.
[0012] Embodiment A3 is the compound of embodiment A1 or A2, or a pharmaceutically acceptable salt thereof, wherein Ring A is: (i) phenyl optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, and C1-C3alkoxy;(ii) a monocyclic 6-membered heteroaryl containing 1-2 heteroatoms independently selected from N and O, and optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, and C1-C3alkoxy; or (iii) a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, -(6- to 8-membered bridged heterocyclylene)-, and C1-C3alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group.
[0013] Embodiment A4 is the compound of embodiment A3, or a pharmaceutically acceptable salt thereof, wherein Ring A is:
[0014] Embodiment A5 is the compound of any one of embodiments A1-A4, or a pharmaceutically acceptable salt thereof, wherein: L2is -NHC(O)- or -(C1-C3alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N and O.
[0015] Embodiment A6 is the compound of embodiment A5, or a pharmaceutically acceptable salt thereof, wherein:
[0016] Embodiment A7 is the compound of any one of embodiments A1-A6, or a pharmaceutically acceptable salt thereof, wherein: L4isO
[0017] Embodiment A8 is the compound of any one of embodiments A1-A7, or a pharmaceutically acceptable salt thereof, wherein: Wis O, -NR -, or a bond; and R5is H or C1-C3alkyl.
[0018] Embodiment A9 is the compound of any one of embodiments A1-A8, or a pharmaceutically acceptable salt thereof, wherein: X is N.
[0019] Embodiment A10 is the compound of any one of embodiments A1-A8, or apharmaceutically acceptable salt thereof, wherein: X is CR13; and R13is H, halo, -OH, or C1-C3alkyl.
[0020] Embodiment A11 is the compound of any one of embodiments A1-A10, or a pharmaceutically acceptable salt thereof, wherein: Y is NH; R4is C3-C6cycloalkyl, C1-C3alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1-C3alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C3alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1 or 2 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-2 R8groups; and each R8is independently -SO2(C1-C3alkyl), -C(O)(C1-C3alkyl), C1-C3alkyl, C1-C3haloalkyl, halo, -CN, or -OH.
[0021] Embodiment A12 is the compound of any one of embodiments A1-A11, or a pharmaceutically acceptable salt thereof, wherein: R4is methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH2CH(CH3)2, -CH2CF3, -CH2CH2F, -CH2CF2CH3, -CH(CH3)CF3, -CH2CH2CF3, -CH(CH3)CH2OH, -CH2C(CH3)2OH, -CH2CN, -CH(CH3)CN, -C(CH3)2CN, -CH(CH2CH3)CN, -CH2CH(CH3)CN,
[0022] Embodiment A13 is the compound of any one of embodiments A1-A12, or a pharmaceutically acceptable salt thereof, wherein: L3is -NR9(C1-C3alkylene)NR9-, -NR9C(O)(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C3alkylene)z-, -NR9(C1-C3alkylene)z(4- to 7-memberedheterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, -O(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C3alkylene)z-, -(7- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1 or 2 R7groups; each z is independently 0 or 1; each R9is independently H or C1-C3alkyl; each R7is independently C1-C3alkyl, halo, C1-C3haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; and each R11and R12is independently H or -CH3.
[0023] Embodiment A14 is the compound of embodiment A13, or a pharmaceutically acceptable salt thereof, wherein: L3is
[0024] Embodiment A15 is the compound of any one of embodiments A1-A14, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Ia) or (Ia’):wherein: Ring A is a fused bicyclic 9- to 10-membered heteroaryl containing 2-4 heteroatoms independently selected from N, O, and S, optionally substituted by 1-3 R0groups; R4is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl-OH, or C1-C6alkyl-CN; and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
[0025] Embodiment A16 is the compound of embodiment A15, or a pharmaceuticallyacceptable salt thereof, wherein the compound is of Formula (If) or (If’):
[0026] Embodiment A17 is a compound selected from the compounds of Table 1 or a pharmaceutically acceptable salt thereof.
[0027] Embodiment A18 is a pharmaceutical composition comprising the compound of any one of embodiments A1-A17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0028] Embodiment A19 is a method of modulating interleukin-1 (IL1) receptor-associated kinase 4 (IRAK4) activity comprising contacting IRAK4 with an effective amount of the compound of any one of embodiments A1-A17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of embodiment A18.
[0029] Embodiment A20 is a method of treating an inflammatory or autoimmune disease in a subject in need thereof, comprising administering to the subject an effective amount of the compound of any one of embodiments A1-A17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of embodiment A18, optionally wherein the inflammatory or autoimmune disease is atopic dermatitis, asthma, lupus, rheumatoid arthritis, familial mediterranean fever, psoriasis, generalized pustular psoriasis, cryoprin-associated periodic syndrome, hidradenitis suppurativa, Bechet’s syndrome, or familial cold autoinflammatory syndrome. DETAILED DESCRIPTION Definitions
[0030] As used herein, the terms “comprising” and “including” can be used interchangeably. The terms “comprising” and “including” are to be interpreted as specifying the presence of the stated features or components as referred to, but does not preclude the presence or addition of one or more features, or components, or groups thFereof. Additionally, the terms “comprising” and “including” are intended to include examples encompassed by the term “consisting of”.Consequently, the term “consisting of” can be used in place of the terms “comprising” and “including” to provide for more specific embodiments of the invention.
[0031] The term “consisting of” means that a subject-matter has at least 90%, 95%, 97%, 98% or 99% of the stated features or components of which it consists. In another embodiment the term “consisting of” excludes from the scope of any succeeding recitation any other features or components, excepting those that are not essential to the technical effect to be achieved.
[0032] As used herein, the term “or” is to be interpreted as an inclusive “or” meaning any one or any combination. Therefore, “A, B or C” means any of the following: “A; B; C; A and B; A and C; B and C; A, B and C”. An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive.
[0033] In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. Also, any number range recited herein relating to any physical feature, such as polymer subunits, size, or thickness, are to be understood to include any integer within the recited range, unless otherwise indicated. As used herein, the terms “about” and “approximately” mean ± 20%, ± 10%, ± 5%, or ± 1% of the indicated range, value, or structure, unless otherwise indicated.
[0034] An “alkyl” group is a saturated, partially saturated, or unsaturated straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms (C1-C10alkyl), typically from 1 to 8 carbons (C1-C8alkyl) or, in some embodiments, from 1 to 6 (C1-C6alkyl), 1 to 3 (C1-C3alkyl), or 2 to 6 (C2-C6alkyl) carbon atoms. In some embodiments, the alkyl group is a saturated alkyl group. Representative saturated alkyl groups include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl and -n-hexyl; while saturated branched alkyls include -isopropyl, -sec-butyl, -isobutyl, tert-butyl, -isopentyl, -neopentyl, tertpentyl, -2-methylpentyl, -3-methylpentyl, -4- methylpentyl, -2,3-dimethylbutyl and the like. In some embodiments, an alkyl group is an unsaturated alkyl group, also termed an alkenyl or alkynyl group. An “alkenyl” group is an alkyl group that contains one or more carbon-carbon double bonds. An “alkynyl” group is an alkyl group that contains one or more carbon-carbon triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, allyl, CH=CH(CH3), -CH=C(CH3)2, -C(CH3)=CH2, -C(CH3)=CH(CH3), -C(CH2CH3)=CH2, -C≡CH, -C≡C(CH3), -C≡C(CH2CH3), -CH2C≡CH, CH2C≡C(CH3) and CH2C≡C(CH2CH3), among others. An alkyl group can be substituted or unsubstituted. When the alkyl groups described herein are said to be “substituted,” they may be substituted with any substituent or substituents as those found in the exemplary compounds and embodiments disclosed herein, as well as halogen; hydroxy; alkoxy;cycloalkyloxy, aryloxy, heterocyclyloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkylalkyloxy, aralkyloxy, heterocyclylalkyloxy, heteroarylalkyloxy, heterocycloalkylalkyloxy; oxo (=O); amino, alkylamino, cycloalkylamino, arylamino, heterocyclylamino, heteroarylamino, heterocycloalkylamino, cycloalkylalkylamino, aralkylamino, heterocyclylalkylamino, heteroaralkylamino, heterocycloalkylalkylamino; imino; imido; amidino; guanidino; enamino; acylamino; sulfonylamino; urea, nitrourea; oxime; hydroxylamino; alkoxyamino; aralkoxyamino; hydrazino; hydrazido; hydrazono; azido; nitro; thio (-SH), alkylthio; =S; sulfinyl; sulfonyl; aminosulfonyl; phosphonate; phosphinyl; acyl; formyl; carboxy; ester; carbamate; amido; cyano; isocyanato; isothiocyanato; cyanato; thiocyanato; or -B(OH)2. In certain embodiments, when the alkyl groups described herein are said to be “substituted,” they may be substituted with any substituent or substituents as those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chloro, iodo, bromo, or fluoro); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; B(OH)2, or O(alkyl)aminocarbonyl.
[0035] “Alkyl-OH” refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by -OH. For example, “C1-C6alkyl-OH” refers to a C1-C6alkyl which is substituted by one or more -OH groups. An alkyl-OH may contain multiple hydroxy groups that are attached to the same carbon atom or to multiple carbon atoms.
[0036] “Alkyl-CN” refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by -CN. For example, “C1-C6alkyl-CN” refers to a C1-C6alkyl which is substituted by one or more -CN groups. An alkyl-CN may contain multiple cyano groups that are attached to the same carbon atom or to multiple carbon atoms.
[0037] An “alkoxy” group is -O-(alkyl), wherein alkyl is defined above.
[0038] A “cycloalkyl” group is a saturated, or partially saturated cyclic alkyl group of from 3 to 10 carbon atoms (C3-C10cycloalkyl) having a single cyclic ring or multiple condensed or bridged rings that can be optionally substituted. In some embodiments, the cycloalkyl group has 3 to 8 ring carbon atoms (C3-C8cycloalkyl), whereas in other embodiments the number of ring carbon atoms ranges from 3 to 5 (C3-C5cycloalkyl), 3 to 6 (C3-C6cycloalkyl), or 3 to 7 (C3-C7cycloalkyl). In some embodiments, the cycloalkyl groups are saturated cycloalkyl groups. Such saturated cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1methylcyclopropyl,2methylcyclopentyl, 2-methylcyclooctyl, and the like, or multiple or bridged ring structures such as 1-bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl and the like. In other embodiments, the cycloalkyl groups are unsaturated cycloalkyl groups. Examples of unsaturared cycloalkyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, hexadienyl, among others. A cycloalkyl group can be substituted or unsubstituted. Such substituted cycloalkyl groups include, by way of example, cyclohexanol and the like.
[0039] An “aryl” group is an aromatic carbocyclic group of from 6 to 14 carbon atoms (C6- C14aryl) having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). In some embodiments, aryl groups contain 6-14 carbons (C6-C14 aryl), and in others from 6 to 12 (C6-C12aryl) or even 6 to 10 carbon atoms (C6-C10aryl) in the ring portions of the groups. Particular aryls include phenyl, biphenyl, naphthyl and the like. An aryl group can be substituted or unsubstituted. The phrase “aryl groups” also includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like).
[0040] A “halogen” or “halo” is fluorine, chlorine, bromine or iodine.
[0041] “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2trifluoroethyl, 1,2difluoroethyl, 3bromo2fluoropropyl, 1,2dibromoethyl, and the like. In some embodiments, the haloalkyl group has one to six carbon atoms and is substituted by one or more halo radicals (C1-C6haloalkyl), or the haloalkyl group has one to three carbon atoms and is substituted by one or more halo radicals (C1-C3haloalkyl). The halo radicals may be all the same or the halo radicals may be different. Unless specifically stated otherwise, a haloalkyl group is optionally substituted.
[0042] A “heteroaryl” group is an aromatic ring system having one to four heteroatoms as ring atoms in a heteroaromatic ring system, wherein the remainder of the atoms are carbon atoms. In some embodiments, heteroaryl groups contain 3 to 6 ring atoms, and in others from 6 to 9 or even 6 to 10 atoms in the ring portions of the groups. Suitable heteroatoms include oxygen, sulfur and nitrogen. In certain embodiments, the heteroaryl ring system is monocyclic or bicyclic. Non-limiting examples include but are not limited to, groups such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, pyrolyl, pyridazinyl, pyrimidyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl (e.g., indolyl-2-onyl or isoindolin-1-onyl), azaindolyl (pyrrolopyridyl or 1Hpyrrolo[2,3b]pyridyl), indazolyl, benzimidazolyl (e.g., 1Hbenzo[d]imidazolyl), imidazopyridyl (e.g., azabenzimidazolyl or1Himidazo[4,5b]pyridyl), pyrazolopyridyl, triazolopyridyl, benzotriazolyl (e.g., 1Hbenzo[d][1,2,3]triazolyl), benzoxazolyl (e.g., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, isoxazolopyridyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl (e.g., 3,4dihydroisoquinolin-1(2H)-onyl), tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. A heteroaryl group can be substituted or unsubstituted.
[0043] A “heterocyclyl” is a non-aromatic cycloalkyl in which one to four of the ring carbon atoms are independently replaced with a heteroatom selected from O, S and N. In some embodiments, heterocyclyl groups include 3 to10 ring members, whereas other such groups have 3 to 5, 3 to 6, or 3 to 8 ring members. Heterocyclyls can also be bonded to other groups at any ring atom (i.e., at any carbon atom or heteroatom of the heterocyclic ring). A heterocycloalkyl group can be substituted or unsubstituted. Heterocyclyl groups encompass saturated and partially saturated ring systems. Further, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to an aryl or heteroaryl ring, regardless of the attachment to the remainder of the molecule. The phrase also includes bridged polycyclic ring systems containing a heteroatom. Representative examples of a heterocyclyl group include, but are not limited to, aziridinyl, azetidinyl, azepanyl, pyrrolidyl, imidazolidinyl (e.g., imidazolidin-4-onyl or imidazolidin-2,4-dionyl), pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, piperidyl, piperazinyl (e.g., piperazin-2- onyl), morpholinyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathianyl, dithianyl, 1,4dioxaspiro[4.5]decanyl, homopiperazinyl, quinuclidyl, or tetrahydropyrimidin-2(1H)-one. Representative substituted heterocyclyl groups may be monosubstituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6substituted, or disubstituted with various substituents such as those listed below.
[0044] When the groups described herein, with the exception of alkyl group, are said to be “substituted,” they may be substituted with any appropriate substituent or substituents. Illustrative examples of substituents are those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chloro, iodo, bromo, or fluoro); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxygen (=O); B(OH)2, O(alkyl)aminocarbonyl; cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocyclyl, which may bemonocyclic or fused or non-fused polycyclic (e.g., pyrrolidyl, piperidyl, piperazinyl, morpholinyl, or thiazinyl); monocyclic or fused or non-fused polycyclic aryl or heteroaryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidyl, benzimidazolyl, benzothiophenyl, or benzofuranyl) aryloxy; aralkyloxy; heterocyclyloxy; and heterocyclyl alkoxy.
[0045] Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “phenyl” group, a divalent “heteroaryl” group, a divalent “heterocyclyl” group etc., may also be referred to as an “alkylene” group, a “phenylene” group, a “heteroarylene” group, or a “heterocyclylene” group, respectively.
[0046] Embodiments of the disclosure are meant to encompass pharmaceutically acceptable salts, tautomers, isotopologues, and stereoisomers of the compounds provided herein, such as the compounds of Formula (I’) or (I).
[0047] As used herein, the term “pharmaceutically acceptable salt(s)” refers to a salt prepared from a pharmaceutically acceptable non-toxic acid or base including an inorganic acid and base and an organic acid and base. Suitable pharmaceutically acceptable base addition salts of the compounds of Formula (I’) or (I) include, but are not limited to metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N’-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (Nmethyl-glucamine) and procaine. Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and ptoluenesulfonic acid. Specific non-toxic acids include hydrochloric, hydrobromic, maleic, phosphoric, sulfuric, and methanesulfonic acids. Examples of specific salts thus include hydrochloride, formic, and mesylate salts. Others are well-known in the art, see for example, Remington’s Pharmaceutical Sciences, 18theds., Mack Publishing, Easton PA (1990) or Remington: The Science and Practice of Pharmacy, 19theds., Mack Publishing, Easton PA (1995).
[0048] As used herein and unless otherwise indicated, the term “stereoisomer” or “stereoisomerically pure” means one stereoisomer of a particular compound that is substantially free of other stereoisomers of that compound. For example, a stereoisomerically pure compoundhaving one chiral center will be substantially free of the opposite enantiomer of the compound. A stereoisomerically pure compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereoisomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound. The compounds disclosed herein can have chiral centers and can occur as racemates, individual enantiomers or diastereomers, and mixtures thereof. All such isomeric forms are included within the embodiments disclosed herein, including mixtures thereof.
[0049] The use of stereoisomerically pure forms of the compounds disclosed herein, as well as the use of mixtures of those forms, are encompassed by the embodiments disclosed herein. For example, mixtures comprising equal or unequal amounts of the enantiomers of a particular compound may be used in methods and compositions disclosed herein. These isomers may be asymmetrically synthesized or resolved using standard techniques such as chiral columns or chiral resolving agents. See, e.g., Jacques, J., et al., Enantiomers, Racemates and Resolutions (WileyInterscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L., Stereochemistry of Carbon Compounds (McGrawHill, NY, 1962); Wilen, S. H., Tables of Resolving Agents and Optical Resolutions p.268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972); Todd, M., Separation Of Enantiomers : Synthetic Methods (Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2014); Toda, F., Enantiomer Separation: Fundamentals and Practical Methods (Springer Science & Business Media, 2007); Subramanian, G. Chiral Separation Techniques: A Practical Approach (John Wiley & Sons, 2008); Ahuja, S., Chiral Separation Methods for Pharmaceutical and Biotechnological Products (John Wiley & Sons, 2011).
[0050] It should also be noted the compounds disclosed herein can include E and Z isomers, or a mixture thereof, and cis and trans isomers or a mixture thereof. In certain embodiments, the compounds are isolated as either the E or Z isomer. In other embodiments, the compounds are a mixture of the E and Z isomers.
[0051] “Tautomers” refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether thecompound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, pyrazoles may exhibit the following isomeric forms, which are referred to as tautomers of each other:
[0052] As readily understood by one skilled in the art, a wide variety of functional groups and other stuctures may exhibit tautomerism and all tautomers of compounds of Formula (I’) or (I) are within the scope of the present disclosure.
[0053] It should also be noted the compounds disclosed herein can contain unnatural proportions of atomic isotopes at one or more of the atoms. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I), sulfur35 (35S), or carbon-14 (14C), or may be isotopically enriched, such as with deuterium (2H), carbon-13 (13C), or nitrogen-15 (15N). As used herein, an “isotopologue” is an isotopically enriched compound. The term “isotopically enriched” refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom. The term “isotopic composition” refers to the amount of each isotope present for a given atom. Radiolabeled and isotopically encriched compounds are useful as therapeutic agents, e.g., cancer therapeutic agents, research reagents, e.g., binding assay reagents, and diagnostic agents, e.g., in vivo imaging agents. All isotopic variations of the compounds as described herein, whether radioactive or not, are intended to be encompassed within the scope of the embodiments provided herein. In some embodiments, there are provided isotopologues of the compounds disclosed herein, for example, the isotopologues are deuterium, carbon-13, and / or nitrogen-15 enriched compounds. As used herein, “deuterated”, means a compound wherein at least one hydrogen (H) has been replaced by deuterium (indicated by D or2H), that is, the compound is enriched in deuterium in at least one position.
[0054] It is understood that, independently of stereoisomerical or isotopic composition, each compound disclosed herein can be provided in the form of any of the pharmaceutically acceptable salts discussed herein. Equally, it is understood that the isotopic composition may vary independently from the stereoisomerical composition of each compound referred to herein. Further, the isotopic composition, while being restricted to those elements present in the respective compound or salt thereof disclosed herein, may otherwise vary independently from the selection of the pharmaceutically acceptable salt of the respective compound.
[0055] It should be noted that if there is a discrepancy between a depicted structure and a name for that structure, the depicted structure is to be accorded more weight.
[0056] “Treating” as used herein, means an alleviation, in whole or in part, of a disorder, disease or condition, or one or more of the symptoms associated with a disorder, disease, or condition, or slowing or halting of further progression or worsening of those symptoms, or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself. In one embodiment, the disorder is a neurodegenerative disease, as described herein, or a symptom thereof.
[0057] “Preventing” as used herein, means a method of delaying and / or precluding the onset, recurrence or spread, in whole or in part, of a disorder, disease or condition; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject’s risk of acquiring a disorder, disease, or condition. In one embodiment, the disorder is a neurodegenerative disease, as described herein, or symptoms thereof.
[0058] The term “effective amount” in connection with a compound disclosed herein means an amount capable of treating or preventing a disorder, disease or condition, or symptoms thereof, disclosed herein.
[0059] The term “subject” or “patient” as used herein include an animal, including, but not limited to, an animal such a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig, in one embodiment a mammal, in another embodiment a human. In one embodiment, a subject is a human having or at risk for having an S1P5 mediated disease, or a symptom thereof.
[0060] Although various features of the invention may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the invention may be described herein in the context of separate embodiments for clarity, the invention may also be implemented in a single embodiment. Compounds
[0061] In one aspect, provided herein is a compound of Formula (I’):(I’) or a pharmaceutically acceptable salt thereof, wherein: Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-memberedheteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups; each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, -(6- to 10-membered bridged heterocyclylene)-, and C1-C6alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group; L1is -NH- or a bond; L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or -(C1-C6alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N, O, and S; L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C6alkylene)z-, -(7- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups; enylene, -N(H)(phenylene), 5- to 6-membered heteroarylene, -N(H)(5-to 6-membered heteroarylene)-, 8- to 10-membered fused bicyclic heteroarylene, or 5- to 6- membered heterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1-3 heteroatoms selected from N, S, and O; R1aand R1bare each H or are taken together to form an oxo group; R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group; or R3and R11are taken together to form a C3-C6cycloalkylene group; Y is NH, O, or a bond;R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1- C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups; W is O, -NR5-, or a bond; R5is H or C1-C6alkyl; each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group; each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl, halo, -CN, or -OH; each R9is independently H or C1-C6alkyl; each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group; each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl; or R11and R3are taken together to form a C3-C6cycloalkylene group; x is 0 or 1; y is 0, 1, 2, 3, 4, or 5; each z is independently 0 or 1; X is N or CR13; R13is H, halo, -OH, or C1-C6alkyl; Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N.
[0062] In a further aspect, provided herein is a compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein: Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups; each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, and C1-C6alkoxy, or two R0groups are taken together to form an oxo group; L1is -NH- or a bond; L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or 5-membered heteroarylene containing 1-3 heteroatoms selected from N, O, and S; L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(6- to 10- membered bridged heterocyclylene)(C1-C6alkylene)z-, -(9- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1- C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups; enylene, 5- to 6-membered heteroarylene, or 5- to 6-memberedheterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1- 3 heteroatoms selected from N and O; R1aand R1bare each H or are taken together to form an oxo group; R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group; or R3and R11are taken together to form a C3-C6cycloalkylene group; Y is NH or O; R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1- C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl-OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups; W is O, -NR5-, or a bond; R5is H or C1-C6alkyl; each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group; each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl, halo, -CN, or -OH; each R9is independently H or C1-C6alkyl; each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group; each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl; or R11and R3are taken together to form a C3-C6cycloalkylene group; x is 0 or 1; y is 0, 1, 2, 3, 4, or 5; each z is independently 0 or 1; X is N or CR13; R13is H, halo, or C1-C6alkyl; Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N.
[0063] In some embodiments, Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N. In some embodiments, Z1and Z2are each CH. In some embodiments, Z1is CH, and Z2is N. In some embodiments, Z1is N, and Z2is CH.
[0064] In some embodiments, Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups.
[0065] In some embodiments, Ring A is phenyl optionally substituted by 1-3 R0groups. In some embodiments, Ring A is phenyl optionally substituted by 1-2 R0groups. In some embodiments, Ring A is phenyl optionally substituted by 1 R0group. In some embodiments,Ring A is phenyl optionally substituted by 2 R0groups. In some embodiments, Ring A is phenyl optionally substituted by 3 R0groups. In some embodiments, Ring A is unsubstituted phenyl.
[0066] In some embodiments, Ring A is monocyclic 5- to 6-membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1-4 heteroatoms independently selected from N, O, and S. In some embodiments, Ring A is monocyclic 5- to 6-membered heteroaryl optionally substituted by 1-2 R0groups, wherein the heteroaryl contains 1-4 heteroatoms independently selected from N, O, and S. In some embodiments, Ring A is monocyclic 5- to 6-membered heteroaryl optionally substituted by 1 R0group, wherein the heteroaryl contains 1-4 heteroatoms independently selected from N, O, and S. In some embodiments, Ring A is monocyclic 5- to 6-membered heteroaryl optionally substituted by 2 R0groups, wherein the heteroaryl contains 1-4 heteroatoms independently selected from N, O, and S. In some embodiments, Ring A is monocyclic 5- to 6-membered heteroaryl optionally substituted by 3 R0groups, wherein the heteroaryl contains 1-4 heteroatoms independently selected from N, O, and S. In some embodiments, Ring A is unsubstituted monocyclic 5- to 6- membered heteroaryl, wherein the heteroaryl contains 1-4 heteroatoms independently selected from N, O, and S.
[0067] In some embodiments, Ring A is monocyclic 5-membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1-4 heteroatoms independently selected from N, O, and S. In some embodiments, Ring A is monocyclic 5-membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1-2 heteroatoms independently selected from N and O. In some embodiments, Ring A is monocyclic 6- membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1- 4 heteroatoms independently selected from N, O, and S. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1-3 heteroatoms independently selected from N and O. In some embodiments, Ring A is a monocyclic 6-membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1-2 heteroatoms independently selected from N and O. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1-3 nitrogen atoms. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1-2 nitrogen atoms. In some embodiments, Ring A is monocyclic 6- membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 1 nitrogen atom. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 1-2 R0groups, wherein the heteroaryl contains 1 nitrogen atom. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 1 R0group, wherein the heteroaryl contains 1 nitrogen atom. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 2 R0groups, wherein the heteroaryl contains 1 nitrogen atom. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 1-3 R0groups, wherein the heteroaryl contains 2 nitrogen atoms. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 1-2 R0groups, wherein the heteroaryl contains 2 nitrogen atoms. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 1 R0group, wherein the heteroaryl contains 2 nitrogen atoms. In some embodiments, Ring A is monocyclic 6-membered heteroaryl optionally substituted by 2 R0groups, wherein the heteroaryl contains 2 nitrogen atoms. In some embodiments, Ring A is pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, or triazinyl, each of which is optionally substituted by 1-3 R0groups. In some embodiments, Ring A is pyridinyl or pyrimidinyl, each of which is optionally substituted by 1-3 R0groups. In some embodiments, Ring A is pyridinyl optionally substituted by 1-3 R0groups. In some embodiments, Ring A is pyrimidinyl optionally substituted by 1-3 R0groups.
[0068] In some embodiments, Ring A is
[0069] In some embodiments, Ring A fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups. In some embodiments, Ring A fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 2-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups. In some embodiments, Ring A is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 1-3 R0groups. In some embodiments, Ring A is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 1 R0group. In some embodiments, Ring A is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 2 R0groups. In some embodiments, Ring A is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 3 R0groups. In some embodiments, Ring A is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 4 R0groups. In some embodiments, Ring A is an unsubstituted fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatomsindependently selected from N, O, and S. In some embodiments, Ring A is a fused bicyclic 9- membered heteroaryl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 1-3 R0groups. In some embodiments, Ring A is a fused bicyclic 9- membered heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 1-3 R0groups.
[0070] In some embodiments, Ring A is:It is understood that when –(R0)0-3is drawn through a fused bicyclic heteroaryl or heterocyclyl, then one or both of the fused rings may be substituted by R0groups. In some embodiments, only one ring of the fused bicyclic ring is substituted by R0groups. In some embodiments, both rings of the fused bicyclic ring are substituted by R0groups, such that the total number of R0groups substituting the bicyclic ring is 0-3.
[0071] In some embodiments, each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, -(6- to 10-membered bridged heterocyclylene)-, and C1-C6alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group. In some embodiments, each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C5cycloalkyl, -(6- to 8-membered bridged heterocyclylene)-, and C1-C3alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group.
[0072] In some embodiments, R0is halo. In some embodiments, R0is Cl, F, or Br. In some embodiments, R0is Cl. In some embodiments, R0is F. In some embodiments, R0is Br.
[0073] In some embodiments, R0is -CN.
[0074] In some embodiments, R0is -NH2.
[0075] In some embodiments, R0is -NH(C1-C6alkyl). In some embodiments, R0is -NH(C1-C3alkyl). In some embodiments, R0is -NH(CH3), -NH(CH2CH3), -NH(CH2CH2CH3), or -NH(CH(CH3)2). In some embodiments, R0is -NH(CH3).
[0076] In some embodiments, R0is C1-C6alkyl. In some embodiments, R0is C1-C3alkyl. In some embodiments, R0is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R0is methyl. In some embodiments, R0is ethyl. In some embodiments, R0is n-propyl. In some embodiments, R0is isopropyl.
[0077] In some embodiments, R0is C3-C6cycloalkyl. In some embodiments, R0is C3-C5cycloalkyl. In some embodiments, R0is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R0is cyclopropyl.
[0078] In some embodiments, R0is C1-C6alkoxy. In some embodiments, R0is C1-C3alkoxy. In some embodiments, R0is -OCH3, -OCH2CH3, -OCH2CH2CH3, or -OCH(CH3)2. In some embodiments, R0is -OCH3. In some embodiments, R0is -OCH2CH3.
[0079] In some embodiments, R0is -(6- to 8-membered bridged heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O. In some embodiments, R0is -(6- to 7-membered bridged heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O. In some embodiments, R0is -(6-membered bridged heterocyclylene)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O. In some embodiments, R0is -(7-membered bridged heterocyclylene)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O. In some embodiments, R0is -(8-membered bridged heterocyclylene)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O. In some embodiments, R0is
[0080] In some embodiments, two R0groups are taken together to form an oxo group.
[0081] In some embodiments, Ring A is phenyl optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, and C1-C3alkoxy.
[0082] In some embodiments, Ring A is
[0083] In some embodiments, Ring A is a monocyclic 6-membered heteroaryl containing 1- 2 heteroatoms independently selected from N and O and is optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, and C1-C6alkoxy.
[0084] In some embodiments, Ring A is:
[0085] In some embodiments, Ring A is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, -(6- to 8-membered bridged heterocyclylene)-, and C1-C3alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group.
[0086] In some embodiments, Ring A is:
[0087] In some embodiments, L1is -NH- or a bond. In some embodiments, L1is -NH-. In some embodiments, L1is a bond.
[0088] In some embodiments, L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or -(C1-C6alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N, O, and S. In some embodiments, L2is 5-membered heteroarylene containing 1-3 heteroatoms selected from N and O. In some embodiments, L2is -NHC(O)- or triazolylene.
[0089] In some embodiments, L2is -NHC(O)-. In some embodiments, L2is -C(O)NH-. In some embodiments, L2is -SO2NH-. In some embodiments, L2is -NHSO2-.
[0090] In some embodiments, L2is 5-membered heteroarylene containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, L2is 5-membered heteroarylene containing 1-3 heteroatoms selected from N and O. In some embodiments, L2is 5-membered heteroarylene containing 2 nitrogen atoms. In some embodiments, L2is 5-membered heteroarylene containing 3 nitrogen atoms. In some embodiments, L2is 5-membered heteroarylene containing 1 nitrogen atom and 1 oxygen atom. In some embodiments, L2is 5-membered heteroarylene containing 1 nitrogen atom and 1 sulfur atom. In some embodiments, L2is 5-membered heteroarylene containing 1 nitrogen atom. In some embodiments, L2is triazolylene, imidazolylene, pyrazolylene, oxazolylene, isoxazolylene, or pyrrolylene.
[0091] In some embodiments, L2is -(C1-C6alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N, O, and S. In some embodiments, L2is -(C1-C3alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N, O, and S. In some embodiments, L2is -(C1-C3alkylene)z(5- membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N and O. In some embodiments, the 5-membered heteroarylene contains 1-3 nitrogen atoms. In some embodiments, the 5-membered heteroarylene contains 1 nitrogen atom. In some embodiments, the 5-membered heteroarylene contains 2 nitrogen atoms. In some embodiments, the 5-membered heteroarylene contains 3 nitrogen atoms. In some embodiments, the 5- membered heteroarylene contains1 nitrogen atom and 1 oxygen atom. In some embodiments,the 5-membered heteroarylene contains 1 nitrogen atom and 1 sulfur atom. In some embodiments, the 5-membered heteroarylene is triazolylene, imidazolylene, pyrazolylene, oxazolylene, isoxazolylene, or pyrrolylene. In some embodiments, z is 0. In some embodiments, z is 1. In some embodiments, -(C1-C6alkylene)z- is -CH2-. In some embodiments, -(C1-C6alkylene)z- is -CH2CH2-. In some embodiments, -(C1-C6alkylene)z- is -CH2CH2CH2-. In some embodiments, L2is
[0092] In some embodiments, L2is
[0094] In some embodiments, L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7- membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1- C6alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C6alkylene)z-, -(7- to 10- membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups.
[0095] In some embodiments, L3is -NR9(C1-C3alkylene)NR9-, -NR9C(O)(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, -NR9(C1-C3alkylene)z(4- to 7- membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, -O(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1- C3alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C3alkylene)z-, -(7- to 10- membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiroheterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1 or 2 R7groups.
[0096] In some embodiments, L3is -NR9(C1-C6alkylene)NR9-. In some embodiments, L3is -NR9(C1-C3alkylene)NR9-. In some embodiments, L3is -NR9(CH2)NR9-, -NR9(CH2CH2)NR9-, or -NR9(CH2CH2CH2)NR9-. In some embodiments, L3is -NR9(CH2CH2CH2)NR9-.
[0097] In some embodiments, L3is -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9C(O)(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9C(O)(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-3 R7groups. In some embodiments, L3is -NR9C(O)(C1-C3alkylene)z(4- to 7- membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-3 R7groups. In some embodiments, L3is -NR9C(O)(C1-C3alkylene)z(5- to 6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-3 R7groups. In some embodiments, L3is -NR9C(O)(C1-C3alkylene)z(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-3 R7groups. In some embodiments, L3is -NR9C(O)(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-3 R7groups. In some embodiments, L3is -NR9C(O)CH2(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-3 R7groups.
[0098] In some embodiments, L3is -(4- to 7-membered heterocyclylene)CR11R12-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(4- to 7-membered heterocyclylene)CR11R12-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(4- to 7- membered heterocyclylene)CR11R12-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(5- to 6-membered heterocyclylene)CR11R12-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6-membered heterocyclylene)CR11R12-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups.
[0099] In some embodiments, L3is -(4- to 7-membered heterocyclylene)(CO)z-, wherein theheterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(5- to 7-membered heterocyclylene)(CO)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(5- to 7-membered heterocyclylene)(CO)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 7-membered heterocyclylene)(CO)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 7-membered heterocyclylene)(CO)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups.
[0100] In some embodiments, L3is -(4- to 7-membered heterocyclylene)(NR9)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(4- to 7-membered heterocyclylene)(NR9)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(4- to 7- membered heterocyclylene)(NR9)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(5- to 7-membered heterocyclylene)(NR9)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 7-membered heterocyclylene)(NR9)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 7-membered heterocyclylene)(NR9)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups.
[0101] In some embodiments, L3is -(NR9)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(NR9)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(NR9)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(NR9)z(5- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein theheterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(NR9)z(6- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(NR9)z(6- to 7-membered heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(NR9)z(6- to 7-membered heterocyclylene)(CH2)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(NR9)z(6- to 7-membered heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(NR9)z(6- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 7-membered heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups.
[0102] In some embodiments, L3is -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(C1-C6alkylene)z(5- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(C1-C6alkylene)z(6- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(C1-C6alkylene)z(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(C1-C3alkylene)z(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(CH2)z(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(CH2)(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -NR9(6-membered heterocyclylene)-, wherein the heterocyclylenecontains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups.
[0103] In some embodiments, L3is -NR9C(O)(phenylene)NR9-.
[0104] In some embodiments, L3is -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C6alkylene)z(5- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C6alkylene)z(5- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C3alkylene)z(5- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C3alkylene)z(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(CH2)(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(CH2CH2)(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups.
[0105] In some embodiments, L3is -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C3alkylene)z(5- to 7-membered heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C3alkylene)z(5- to 7-membered heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(C1-C3alkylene)z(6-membered heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(CH2)(6-membered heterocyclylene)CH2-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. Insome embodiments, L3is -(5- to 6-membered heterocyclylene)CH2-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7-membered heterocyclylene)CH2-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups.
[0106] In some embodiments, L3is -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)- , wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(C1-C6alkylene)z(4- to 7- membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(C1-C3alkylene)(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(CH2)(4- to 7-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(4- to 7- membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(4- to 6-membered heterocyclylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups.
[0107] In some embodiments, L3is -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(C1-C3alkylene)(4- to 7-membered heterocyclylene)(C1-C3alkylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(4- to 7-membered heterocyclylene)(C1-C3alkylene)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. Insome embodiments, L3is -O(CH2)(4- to 7-membered heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(4- to 7-membered heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(4- to 6-membered heterocyclylene)CH2-, wherein the heterocyclylene contains 1-2 nitrogen atoms and is optionally substituted by 1-5 R7groups. In some embodiments, the heterocyclyene is saturated. In some embodiments, the heterocyclylene is partially unsaturated.
[0108] In some embodiments, L3is -(6- to 10-membered bridged heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 10-membered bridged heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7- to 9-membered bridged heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7- to 9-membered bridged heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7- to 9-membered bridged heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7- to 9-membered bridged heterocyclylene)-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7-membered bridged heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(9-membered bridged heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups.
[0109] In some embodiments, L3is -(7- to 10-membered fused bicyclic heterocyclylene)(C1- C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7- to 10-membered fused bicyclic heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7-membered fused bicyclicheterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7-membered fused bicyclic heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7-membered fused bicyclic heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(7-membered fused bicyclic heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(8-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(8-membered fused bicyclic heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(8-membered fused bicyclic heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(8-membered fused bicyclic heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(8- membered fused bicyclic heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(9-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(9-membered fused bicyclic heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(9-membered fused bicyclic heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(9-membered fused bicyclic heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(9-membered fused bicyclic heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups.
[0110] In some embodiments, L3is -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(O)z(7- to 10-memberedspiro heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(O)z(7- to 9-membered spiro heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(7- to 9-membered spiro heterocyclylene)(C1-C6alkylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(7- to 9-membered spiro heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -O(6- to 10- membered spiro heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 10-membered spiro heterocyclylene)(C1-C6alkylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 10-membered spiro heterocyclylene)(CH2)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups. In some embodiments, L3is -(6- to 10-membered spiro heterocyclylene)-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups.
[0111] In some embodiments, each R9is independently H or C1-C6alkyl. In some embodiments, each R9is independently H or C1-C3alkyl. In some embodiments, each R9is independently H or -CH3.
[0112] In some embodiments, R9is H.
[0113] In some embodiments, R9is C1-C6alkyl. In some embodiments, R9is C1-C3alkyl. In some embodiments, R9is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R9is methyl. In some embodiments, R9is ethyl. In some embodiments, R9is n-propyl. In some embodiments, R9is isopropyl.
[0114] In some embodiments, each z is independently 0 or 1. In some embodiments, z is 0. In some embodiments, z is 1.
[0115] In some embodiments, each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group. In some embodiments, each R7is independently C1-C3alkyl, halo, C1-C3haloalkyl, or -OH, or two R7groups are taken together to form an oxo group. In some embodiments, each R7is independently -CH3, -CF3, F, or -OH, or two R7groups are taken together to form an oxo group.
[0116] In some embodiments, R7is C1-C6alkyl. In some embodiments, R7is C1-C3alkyl. In some embodiments, R7is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R7ismethyl. In some embodiments, R7is ethyl. In some embodiments, R7is n-propyl. In some embodiments, R7is isopropyl.
[0117] In some embodiments, R7is halo. In some embodiments, R7is Cl, F, or Br. In some embodiments, R7is Cl. In some embodiments, R7is F. In some embodiments, R7is Br.
[0118] In some embodiments, R7is C1-C6haloalkyl. In some embodiments, R7is C1-C6haloalkyl containing 1-13 halogen atoms. In some embodiments, R7is C1-C3haloalkyl. In some embodiments, R7is C1-C3haloalkyl containing 1-7 halogen atoms. In some embodiments, R7is -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CF2Cl, -CFCl2, -CH2CF3, -CH2CHF2, or -CH2CCl3. In some embodiments, R7is -CF3. In some embodiments, R7is -CHF2.
[0119] In some embodiments, R7is -OH.
[0120] In some embodiments, two R7groups are taken together to form an oxo group.
[0121] In some embodiments, each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl. In some embodiments, each R11and R12is independently H or C1-C3alkyl. In some embodiments, each R11and R12is independently H or -CH3.
[0122] In some embodiments, R11is H. In some embodiments, R11is halo. In some embodiments, R11is Cl, F, or Br. In some embodiments, R11is Cl. In some embodiments, R11is F. In some embodiments, R11is Br.
[0123] In some embodiments, R11is C3-C6cycloalkyl. In some embodiments, R11is C3-C5cycloalkyl. In some embodiments, R11is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R11is cyclopropyl. In some embodiments, R11is cyclobutyl.
[0124] In some embodiments, R11is -OH.
[0125] In some embodiments, R11is -NH(C1-C6alkyl). In some embodiments, R11is -NH(C1-C3alkyl). In some embodiments, R11is -NH(CH3), -NH(CH2CH3), -NH(CH2CH2CH3), or -NH(CH(CH3)2). In some embodiments, R11is -NH(CH3).
[0126] In some embodiments, R11is C1-C6haloalkyl. In some embodiments, R11is C1-C6haloalkyl containing 1-13 halogen atoms. In some embodiments, R11is C1-C3haloalkyl. In some embodiments, R11is C1-C3haloalkyl containing 1-7 halogen atoms. In some embodiments, R11is -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CF2Cl, -CFCl2, -CH2CF3, -CH2CHF2, or -CH2CCl3. In some embodiments, R11is -CF3. In some embodiments, R11is -CHF2.
[0127] In some embodiments, R11is C1-C6alkyl. In some embodiments, R11is C1-C3alkyl. In some embodiments, R11is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R11is methyl. In some embodiments, R11is ethyl. In some embodiments, R11is n-propyl. In some embodiments, R11is isopropyl.
[0128] In some embodiments, R12is H.
[0129] In some embodiments, R12is halo. In some embodiments, R12is Cl, F, or Br. In some embodiments, R12is Cl. In some embodiments, R12is F. In some embodiments, R12is Br.
[0130] In some embodiments, R12is C3-C6cycloalkyl. In some embodiments, R12is C3-C5cycloalkyl. In some embodiments, R12is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R12is cyclopropyl. In some embodiments, R12is cyclobutyl.
[0131] In some embodiments, R12is -OH.
[0132] In some embodiments, R12is -NH(C1-C6alkyl). In some embodiments, R12is -NH(C1-C3alkyl). In some embodiments, R12is -NH(CH3), -NH(CH2CH3), -NH(CH2CH2CH3), or -NH(CH(CH3)2). In some embodiments, R12is -NH(CH3).
[0133] In some embodiments, R12is C1-C6haloalkyl. In some embodiments, R12is C1-C6haloalkyl containing 1-13 halogen atoms. In some embodiments, R12is C1-C3haloalkyl. In some embodiments, R12is C1-C3haloalkyl containing 1-7 halogen atoms. In some embodiments, R12is -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CF2Cl, -CFCl2, -CH2CF3, -CH2CHF2, or -CH2CCl3. In some embodiments, R12is -CF3. In some embodiments, R12is -CHF2.
[0134] In some embodiments, R12is C1-C6alkyl. In some embodiments, R12is C1-C3alkyl. In some embodiments, R12is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R12is methyl. In some embodiments, R12is ethyl. In some embodiments, R12is n-propyl. In some embodiments, R12is isopropyl.
[0135] In some embodiments, R11and R12are each H. In some embodiments, R11and R12are each -CH3. In some embodiments, one of R11and R12is H, and the other of R11and R12is -CH3.
[0136] In some embodiments, R11and R3are taken together to form a C3-C6cycloalkylene group. In some embodiments, R11and R3are taken together to form a C3-C5cycloalkylene group. In some embodiments, R11and R3are taken together to form a C4-C6cycloalkylene group. In some embodiments, R11and R3are taken together to form cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene. In some embodiments, R11and R3are taken together to form cyclopropylene.
[0137] In some embodiments, L3is:
[0138] In some embodiments, L4is ne, -N(H)(phenylene), 5- to 6- membered heteroarylene, -N(H)(5- to 6-membered heteroarylene)-, 8- to 10-membered fused bicyclic heteroarylene, or 5- to 6-membered heterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1-3 heteroatoms selected from N, S, and O.
[0139] In some embodiments, L4is1a 1bbodiments, R and R are each H or are taken together to form an oxo group. In some embodiments, R1aand R1bare each H. In some embodiments, R1aand R1bare taken together to form an oxo group. In some embodiments, L4embodiments, L4is
[0140] In some embodiments, L4is phenylene, -NH(phenylene), 5- to 6-membered heteroarylene, -N(H)(5- to 6-membered heteroarylene)-, 8- to 10-membered fused bicyclic heteroarylene, or 5- to 6-membered heterocyclylene, each of which is optionally substituted by 1-4 R10groups, and wherein the heteroarylene or heterocyclylene contains 1-3 heteroatoms selected from N, S, and O.
[0141] In some embodiments, L4is phenylene optionally substituted by 1-4 R10groups. In some embodiments, L4is phenylene optionally substituted by 1-3 R10groups. In some embodiments, L4is phenylene optionally substituted by 1-2 R10groups. In some embodiments, L4is phenylene optionally substituted by 1 R10group. In some embodiments, L4is unsubstituted phenylene.
[0142] In some embodiments, L4is -N(H)phenylene optionally substituted by 1-4 R10groups. In some embodiments, L4is -N(H)phenylene optionally substituted by 1-3 R10groups. In some embodiments, L4is -N(H)phenylene optionally substituted by 1-2 R10groups. In some embodiments, L4is -N(H)phenylene optionally substituted by 1 R10group. In some embodiments, L4is unsubstituted -N(H)phenylene.
[0143] In some embodiments, L4is 5- to 6-membered heteroarylene optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 heteroatoms selected from N, S, and O. In some embodiments, L4is 5- to 6-membered heteroarylene optionally substituted by 1- 4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is 5-membered heteroarylene optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is 6- membered heteroarylene optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is 5- to 6-membered heteroarylene optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 2 heteroatoms selected from N and S. In some embodiments, L4is 5-membered heteroarylene optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1 nitrogen atom and 1sulfur atom. In some embodiments, the 5- to 6-membered heteroarylene is pyridinylene, pyrimidinylene, pyrazinylene, pyridazinylene, triazolylene, imidazolylene, thiazolylene, pyrazolylene, or pyrrolylene, each of which is optionally substituted by 1-4 R10groups.
[0144] In some embodiments, L4is 8- to 10-membered fused bicyclic heteroarylene optionally substituted by 1-4 R10groups, and wherein the fused heteroarylene contains 1-3 heteroatoms selected from N, S, and O. In some embodiments, L4is 8- to 10-membered fused bicyclic heteroarylene optionally substituted by 1-4 R10groups, and wherein the fused heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is 8- to 10-membered fused bicyclic heteroarylene optionally substituted by 1-4 R10groups, and wherein the fused heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is 8-membered fused heteroarylene optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is 9-membered fused heteroarylene optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is 10-membered fused heteroarylene optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms.
[0145] In some embodiments, L4is -N(H)(5- to 6-membered heteroarylene) optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 heteroatoms selected from N, S, and O. In some embodiments, L4is -N(H)(5- to 6-membered heteroarylene) optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is -N(H)(5-membered heteroarylene) optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms. In some embodiments, L4is -N(H)(6-membered heteroarylene) optionally substituted by 1-4 R10groups, and wherein the heteroarylene contains 1-3 nitrogen atoms. In some embodiments, the 5- to 6- membered heteroarylene is pyridinylene, pyrimidinylene, pyrazinylene, pyridazinylene, triazolylene, imidazolylene, thiazolylene, pyrazolylene, or pyrrolylene, each of which is optionally substituted by 1-4 R10groups.
[0146] In some embodiments, L4is 5- to 6-membered heterocyclylene optionally substituted by 1-4 R10groups, and wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O. In some embodiments, L4is 5-membered heterocyclylene optionally substituted by 1-4 R10groups, and wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O. In some embodiments, L4is 6-membered heterocyclylene optionally substituted by 1-4 R10groups, and wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O. In some embodiments, L4is 5- to 6-membered heterocyclylene optionally substituted by 1-4 R10groups, and wherein the heterocyclylene contains 1-2 heteroatoms selected from N and O. In some embodiments, L4is 5- to 6-membered heterocyclylene optionally substituted by 1-4 R10groups, and wherein the heterocyclylene contains 1-2 nitrogen atoms. In some embodiments, L4is 5- to 6-membered heterocyclylene optionally substituted by 1-4 R10groups, and wherein the heterocyclylene contains one nitrogen atom.
[0147] In some embodiments, each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group. In some embodiments, each R10is independently C1-C3alkoxy, C1-C3alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group. In some embodiments, each R10is independently -OCH3, -CH3, Cl, F, or -OH, or two R10groups are taken together to form an oxo group.
[0148] In some embodiments, R10is C1-C6alkoxy. In some embodiments, R10is C1-C3alkoxy. In some embodiments, R10is -OCH3, -OCH2CH3, -OCH2CH2CH3, or -OCH(CH3)2. In some embodiments, R10is -OCH3. In some embodiments, R10is -OCH2CH3.
[0149] In some embodiments, R10is C1-C6alkyl. In some embodiments, R10is C1-C3alkyl. In some embodiments, R10is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R10is methyl. In some embodiments, R10is ethyl. In some embodiments, R10is n-propyl. In some embodiments, R10is isopropyl.
[0150] In some embodiments, R10is halo. In some embodiments, R10is Cl, F, or Br. In some embodiments, R10is Cl. In some embodiments, R10is F. In some embodiments, R10is Br.
[0151] In some embodiments, R10is -OH.
[0152] In some embodiments, two R10groups are taken together to form an oxo group.
[0153] In some embodiments, L4is:
[0154] In some embodiments, R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group. In some embodiments, R2and R3are independently H, C1-C3alkyl, or halo. In some embodiments, R2and R3are independently H, -CH3, or F. In some embodiments, R2and R3are taken together to form an oxo group.
[0155] In some embodiments, R2is H.
[0156] In some embodiments, R2is C1-C6alkyl. In some embodiments, R2is C1-C3alkyl. In some embodiments, R2is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R2is methyl. In some embodiments, R2is ethyl. In some embodiments, R2is n-propyl. In some embodiments, R2is isopropyl.
[0157] In some embodiments, R2is halo. In some embodiments, R2is Cl, F, or Br. In some embodiments, R2is Cl. In some embodiments, R2is F. In some embodiments, R2is Br.
[0158] In some embodiments, R3is H.
[0159] In some embodiments, R3is C1-C6alkyl. In some embodiments, R3is C1-C3alkyl. In some embodiments, R3is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R3is methyl. In some embodiments, R3is ethyl. In some embodiments, R3is n-propyl. In some embodiments, R3is isopropyl.
[0160] In some embodiments, R3is halo. In some embodiments, R3is Cl, F, or Br. In some embodiments, R3is Cl. In some embodiments, R3is F. In some embodiments, R3is Br.
[0161] In some embodiments, R2and R3are taken together to form an oxo group.
[0162] In some embodiments, R3and R11are taken together to form a C3-C6cycloalkylene group. In some embodiments, R3and R11are taken together to form a C3-C5cycloalkylene group. In some embodiments, R3and R11are taken together to form a C4-C6cycloalkylene group. In some embodiments, R3and R11are taken together to form cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene. In some embodiments, R3and R11are taken together to form cyclopropylene.
[0163] In some embodiments, x is 0 or 1. In some embodiments, x is 0. In some embodiments, x is 1.
[0164] In some embodiments, Y is NH, O, or a bond. In some embodiments, Y is NH. In some embodiments, Y is O. In some embodiments, Y is a bond.
[0165] In some embodiments, R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1-C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-memberedheteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl-OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups. In some embodiments, R4is C3-C6cycloalkyl, C1-C3alkylene- (C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1-C3alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C3alkylene-(5- to 6-membered heteroaryl), C1- C6alkyl, C1-C6haloalkyl, C1-C6alkyl-OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1 or 2 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-2 R8groups.
[0166] In some embodiments, R4is C3-C6cycloalkyl optionally substituted by 1-5 R8groups. In some embodiments, R4is C3-C5cycloalkyl optionally substituted by 1-5 R8groups. In some embodiments, R4is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted by 1-5 R8groups. In some embodiments, R4is cyclopropyl optionally substituted by 1-5 R8groups. In some embodiments, R4is cyclobutyl optionally substituted by 1-5 R8groups. In some embodiments, R4is cyclopentyl optionally substituted by 1-5 R8groups. In some variations, R4is C3-C6cycloalkyl substituted by 1-5 R8groups. In some variations, R4is C3-C6cycloalkyl substituted by 1-2 R8groups. In some embodiments, R4is unsubstituted C3- C6cycloalkyl.
[0167] In some embodiments, R4is C1-C6alkylene-(C3-C6cycloalkyl), wherein the cycloalkyl is optionally substituted by 1-5 R8groups. In some embodiments, R4is C1-C3alkylene-(C3-C6cycloalkyl), wherein the cycloalkyl is optionally substituted by 1-5 R8groups.
[0168] In some embodiments, R4is C1-C3alkylene-(cyclopropyl), wherein the cyclopropyl is optionally substituted by 1-5 R8groups. In some embodiments, R4is C1-C3alkylene- (cyclobutyl), wherein the cyclobutyl is optionally substituted by 1-5 R8groups. In some embodiments, R4is C1-C3alkylene-(cyclopentyl), wherein the cyclopentyl is optionally substituted by 1-5 R8groups. In some embodiments, R4is C1-C3alkylene-(cyclohexyl), wherein the cyclohexyl is optionally substituted by 1-5 R8groups. In some embodiments, R4is -CH2- (C3-C6cycloalkyl), wherein the cycloalkyl is optionally substituted by 1-5 R8groups. In some embodiments, R4is -CH2CH2-(C3-C6cycloalkyl), wherein the cycloalkyl is optionally substituted by 1-5 R8groups.
[0169] In some embodiments, R4is 4- to 6-membered heterocyclyl optionally substituted by 1-5 R8groups, wherein the heterocyclyl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is 4- to 6-membered heterocyclyl optionally substituted by 1-5 R8groups, wherein the heterocyclyl contains 1-2 heteroatoms selected from N and O. In some embodiments, R4is 4- to 6-membered heterocyclyl optionally substituted by 1-5 R8groups,wherein the heterocyclyl contains one nitrogen atom. In some embodiments, R4is 4- to 6- membered heterocyclyl optionally substituted by 1-5 R8groups, wherein the heterocyclyl contains one oxygen atom. In some variations, R4is 4- to 6-membered heterocyclyl substituted by 1-3 R8groups, wherein the heterocyclyl contains 1-3 heteroatoms selected from N and O. In some variations, R4is 4- to 6-membered heterocyclyl substituted by one R8group, wherein the heterocyclyl contains 1-3 heteroatoms selected from N and O. In some variations, R4is unsubstituted 4- to 6-membered heterocyclyl, wherein the heterocyclyl contains 1-3 heteroatoms selected from N and O. In some embodiments, the 4- to 6-membered heterocyclyl is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, pyrrolidinyl, azetidinyl, or piperazinyl, each of which is optionally substituted by 1-5 R8groups.
[0170] In some embodiments, R4is C1-C6alkylene-(4- to 6-membered heterocyclyl), wherein the heterocyclyl is optionally substituted by 1-5 R8groups, and wherein the heterocyclyl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is C1- C3alkylene-(4- to 6-membered heterocyclyl), wherein the heterocyclyl is optionally substituted by 1-5 R8groups, and wherein the heterocyclyl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is -CH2(4- to 6-membered heterocyclyl), wherein the heterocyclyl is optionally substituted by 1-5 R8groups, and wherein the heterocyclyl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is -CH2CH2(4- to 6-membered heterocyclyl), wherein the heterocyclyl is optionally substituted by 1-5 R8groups, and wherein the heterocyclyl contains 1-3 heteroatoms selected from N and O. In some embodiments, the 4- to 6-membered heterocyclyl contains 1-2 heteroatoms selected from N and O. In some embodiments, the 4- to 6-membered heterocyclyl contains one nitrogen atom. In some embodiments, the 4- to 6-membered heterocyclyl contains one oxygen atom. In some variations, the 4- to 6-membered heterocyclyl is substituted by 1-3 R8groups. In some variations, the 4- to 6-membered heterocyclyl is substituted by one R8group. In some variations, the 4- to 6-membered heterocyclyl is unsubstituted. In some embodiments, the 4- to 6-membered heterocyclyl is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, pyrrolidinyl, azetidinyl, or piperazinyl, each of which is optionally substituted by 1-5 R8groups.
[0171] In some embodiments, R4is 5- to 6-membered heteroaryl, wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is 5-membered heteroaryl, wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is 6-membered heteroaryl, wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is 5- to 6-memberedheteroaryl, wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-2 heteroatoms selected from N and O. In some embodiments, R4is 5- to 6-membered heteroaryl, wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-2 nitrogen atoms. In some variations, the 5- to 6-membered heteroaryl is substituted by 1-3 R8groups. In some variations, the 5- to 6-membered heteroaryl is substituted by one R8group. In some variations, the 5- to 6-membered heteroaryl is unsubstituted. In some embodiments, the 5- to 6-membered heteroaryl is piperidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrazolyl, or imidazolyl, each of which is optionally substituted by 1-5 R8groups.
[0172] In some embodiments, R4is C1-C6alkylene-(5- to 6-membered heteroaryl), wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is C1-C6alkylene-(5-membered heteroaryl), wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is C1-C6alkylene-(6-membered heteroaryl), wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is C1-C3alkylene-(5- to 6-membered heteroaryl), wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is -CH2-(5- to 6-membered heteroaryl), wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is -CH2CH2-(5- to 6-membered heteroaryl), wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, R4is C1-C3alkylene-(5- to 6-membered heteroaryl), wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-2 heteroatoms selected from N and O. In some embodiments, R4is C1-C3alkylene-(5- to 6-membered heteroaryl), wherein the heteroaryl is optionally substituted by 1-5 R8groups, and wherein the heteroaryl contains 1-2 nitrogen atoms. In some variations, the 5- to 6-membered heteroaryl is substituted by 1-3 R8groups. In some variations, the 5- to 6-membered heteroaryl is substituted by one R8group. In some variations, the 5- to 6-membered heteroaryl is unsubstituted. In some embodiments, the 5- to 6-membered heteroaryl is piperidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrazolyl, or imidazolyl, each of which is optionally substituted by 1-5 R8groups.
[0173] In some embodiments, R4is C1-C6alkyl. In some embodiments, R4is C1-C3alkyl. In some embodiments, R4is C1-C4alkyl. In some embodiments, R4is methyl, ethyl, n-propyl, isopropyl, tert-butyl, or -CH2CH(CH3)2. In some embodiments, R4is methyl. In someembodiments, R4is ethyl. In some embodiments, R4is n-propyl. In some embodiments, R4is isopropyl. In some embodiments, R4is tert-butyl. In some embodiments, R4is -CH2CH(CH3)2.
[0174] In some embodiments, R4is C1-C6haloalkyl. In some embodiments, R4is C1-C6haloalkyl containing 1-13 halogen atoms. In some embodiments, R4is C1-C3haloalkyl. In some embodiments, R4is C1-C3haloalkyl containing 1-7 halogen atoms. In some embodiments, R4is -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CF2Cl, -CFCl2, -CH2CF3, -CH2CHF2, or -CH2CCl3. In some embodiments, R4is -CF3. In some embodiments, R4is -CHF2. In some embodiments, R4is C2-C3haloalkyl containing 1-7 halogen atoms. In some embodiments, R4is -CH2CF3, -CH2CH2F, -CH2CF2CH3, -CH(CH3)CF3, or -CH2CH2CF3.
[0175] In some embodiments, R4is C1-C6alkyl-OH. In some embodiments, R4is C1-C3alkyl-OH. In some embodiments, R4is -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, or -CH2CH(OH)CH3. In some embodiments, R4is -CH2OH. In some embodiments, R4is -CH2CH2OH. In some embodiments, R4is C3-C4alkyl-OH. In some embodiments, R4is -CH(CH3)CH2OH or -CH2C(CH3)2OH.
[0176] In some embodiments, R4is C1-C6alkyl-CN. In some embodiments, R4is C1-C3alkyl-CN. In some embodiments, R4is -CH2CN, -CH2CH2CN, -CH2CH2CH2CN, -CH(CH3)CN, -C(CH3)2CN, or -CH2CH(CN)CH3. In some embodiments, R4is -CH2CN. In some embodiments, R4is -CH2CH2CN. In some embodiments, R4is -CH(CH3)CN. In some embodiments, R4is -C(CH3)2CN. In some embodiments, R4is -CH(CH2CH3)CN or -CH2CH(CH3)CN.
[0177] In some embodiments, each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl, halo, -CN, or -OH. In some embodiments, each R8is independently -SO2(C1-C3alkyl), -C(O)(C1-C3alkyl), C1-C3alkyl, C1-C3haloalkyl, halo, -CN, or -OH. In some embodiments, each R8is independently -SO2CH3, -C(O)CH3, methyl, ethyl, -CH2CF3, F, -CN, or -OH.
[0178] In some embodiments, R8is -SO2(C1-C6alkyl). In some embodiments, R8is -SO2(C1-C3alkyl). In some embodiments, R8is -SO2CH3. In some embodiments, R8is -SO2CH2CH3. In some embodiments, R8is -SO2CH2CH2CH3.
[0179] In some embodiments, R8is -C(O)(C1-C6alkyl). In some embodiments, R8is -C(O)(C1-C3alkyl). In some embodiments, R8is -C(O)CH3. In some embodiments, R8is -C(O)CH2CH3. In some embodiments, R8is -C(O)CH2CH2CH3.
[0180] In some embodiments, R8is C1-C6alkyl. In some embodiments, R8is C1-C3alkyl. In some embodiments, R8is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R8is methyl. In some embodiments, R8is ethyl. In some embodiments, R8is n-propyl. In some embodiments, R8is isopropyl.
[0181] In some embodiments, R8is C1-C6haloalkyl. In some embodiments, R8is C1-C6haloalkyl containing 1-13 halogen atoms. In some embodiments, R8is C1-C3haloalkyl. In some embodiments, R8is C1-C3haloalkyl containing 1-7 halogen atoms. In some embodiments, R8is -CF3, -CHF2, -CH2F, CH2CF3, -CCl3, -CHCl2, -CH2Cl, -CF2Cl, -CFCl2, -CH2CF3, -CH2CHF2, or -CH2CCl3. In some embodiments, R8is -CF3. In some embodiments, R8is -CH2CF3.
[0182] In some embodiments, R8is halo. In some embodiments, R8is Cl, F, or Br. In some embodiments, R8is Cl. In some embodiments, R8is F. In some embodiments, R8is Br.
[0183] In some embodiments, R8is -CN.
[0184] In some embodiments, R8is -OH.
[0185] In some embodiments, R4is methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH2CH(CH3)2, -CH2CF3, -CH2CH2F, -CH2CF2CH3, -CH(CH3)CF3, -CH2CH2CF3, -CH(CH3)CH2OH, -CH2C(CH3)2OH, -CH2CN, -CH(CH3)CN, -C(CH3)2CN, -CH(CH2CH3)CN, -CH2CH(CH3)CN,
[0186] In some embodiments, W is O, -NR5-, or a bond. In some embodiments, W is O, -N(H)-, -N(CH3)-, or a bond.
[0187] In some embodiments, W is O.
[0188] In some embodiments, W is a bond.
[0189] In some embodiments, W is -NR5-.
[0190] In some embodiments, R5is H or C1-C6alkyl. In some embodiments, R5is H or C1- C3alkyl.
[0191] In some embodiments, R5is H.
[0192] In some embodiments, R5is C1-C6alkyl. In some embodiments, R5is C1-C3alkyl. In some embodiments, R5is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R5is methyl. In some embodiments, R5is ethyl. In some embodiments, R5is n-propyl. In someembodiments, R5is isopropyl.
[0193] In some embodiments, W is -N(H)-. In some embodiments, W is -N(C1-C6alkyl)-. In some embodiments, W is -N(CH3)-.
[0194] In some embodiments, each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group. In some embodiments, each R6is independently C1-C3alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C2 alkylene group. In some embodiments, each R6is independently -CH3, Cl, or -OH, or two R6groups are taken together to form a bridging C1-C2alkylene group.
[0195] In some embodiments, R6is C1-C6alkyl. In some embodiments, R6is C1-C3alkyl. In some embodiments, R6is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R6is methyl. In some embodiments, R6is ethyl. In some embodiments, R6is n-propyl. In some embodiments, R6is isopropyl.
[0196] In some embodiments, R6is halo. In some embodiments, R6is Cl, F, or Br. In some embodiments, R6is Cl. In some embodiments, R6is F. In some embodiments, R6is Br.
[0197] In some embodiments, R6is -OH.
[0198] In some embodiments, two R6groups are taken together to form a bridging C1-C3alkylene group. In some embodiments, two R6groups are taken together to form a bridging C1- C2alkylene group. In some embodiments, two R6groups are taken together to form a bridging methylene group. In some embodiments, two R6groups are taken together to form a bridging ethylene group. In some embodiments, two R6groups are taken together to form a bridging propylene group.
[0199] In some embodiments, y is 0, 1, 2, 3, 4, or 5. In some embodiments, y is 0 or 1. In some embodiments, y is 0. In some embodiments, y is 1. In some embodiments, y is 2. In some embodiments, y is 3. In some embodiments, y is 4. In some embodiments, y is 5.
[0201] In some embodiments, X is N or CR3. In some embodiments, X is CR3; and R13is H, halo, -OH, or C1-C3alkyl.
[0202] In some embodiments, X is N.
[0203] In some embodiments, X is CR13.
[0204] In some embodiments, R13is H, halo, -OH, or C1-C6alkyl. In some embodiments, R13is H, halo, -OH, or C1-C3alkyl. In some embodiments, R13is H, CH3, -OH, or F.
[0205] In some embodiments, R13is H.
[0206] In some embodiments, R13is halo. In some embodiments, R13is Cl, F, or Br. In some embodiments, R13is Cl. In some embodiments, R13is F. In some embodiments, R13is Br.
[0207] In some embodiments, R13is -OH.
[0208] In some embodiments, R13is C1-C6alkyl. In some embodiments, R13is C1-C3alkyl. In some embodiments, R13is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R13is methyl. In some embodiments, R13is ethyl. In some embodiments, R13is n-propyl. In some embodiments, R13is isopropyl.
[0209] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (IA), (IB), (IC), (ID), or (IE):wherein Ring A, R2, R3, R4, R6, R10, L1, L2, L3, W, X, Y, Z1, Z2, x, and y are as described for Formula (I’) or (I).
[0210] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (IIa), (IIb), (IIIa), (IIIb), (IVa), or (IVb):wherein Ring A, R2, R3, R4, R6, L3, L4, W, X, Y, Z1, Z2, x, and y are as described for Formula (I’) or (I).
[0211] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (Ia): wherein Ring A, R2, , , , , , , , , , y (I’) or (I); and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N. In some embodiments, Ring A is a fused bicyclic 9- to 10-membered heteroaryl containing 2-4 heteroatoms independently selected from N, O, and S, optionally substituted by 1-3 R0groups, wherein R0is as described for Formula (I’) or (I).
[0212] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (Ib) or (Ic):wherein Ring A, R2, R3, R4, R6, R7, R10, R11, R12, R13, and y are as described for Formula (I’) or (I); and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
[0213] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (Id) or (Ie):(Id) wherein R0, R2, R3, R4, R6, R7, R10, R11, R12, R13, and y are as described for Formula (I ) or (I); and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
[0214] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (If) or (Ig):(If)wherein R0, R4, and R7are as described for Formula (I’) or (I); and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N. In some embodiments, each R0is independently -CN or -NH2; R4is C1-C3alkyl-CN, or C3-C6cycloalkyl optionally substituted with C1-C3alkyl; and R7is C1-C3alkyl.
[0215] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (Ia’):wherein Ring A, R2, R3, R4, R6, R7, R10, R11, R12, L2, and y are as described for Formula (I’) or (I); and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N. In some embodiments, Ring A is a fused bicyclic 9- to 10-membered heteroaryl containing 2-4 heteroatoms independently selected from N, O, and S, optionally substituted by 1-3 R0groups, wherein R0is as described for Formula (I’) or (I).
[0216] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (Ib’) or (Ic’):(Ic’) wherein Ring A, R2, R3, R4, R6, R7, R10, R11, R12, and y are as described for Formula (I’) or (I); and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
[0217] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (Id’) or (Ie’):wherein R0, R2, R3, R4, R6, R7, R10, R11, R12, and y are as described for Formula (I’) or (I); and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
[0218] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (If’) or (Ig’):wherein R0,R , and R are as described for Formula (I ) or (I); and Z and Z are independently N or CH, provided that at least one of Z3and Z4is N. In some embodiments, each R0is independently -CN or -NH2; R4is C1-C3alkyl-CN, or C3-C6cycloalkyl optionally substituted with C1-C3alkyl; and R7is C1-C3alkyl.
[0219] In some embodiments, the compound of Formula (I’) or (I) is a compound of Formula (Va) or (Vb):(Va) wherein R0, R2, R3, R4, R6, R7, R10, R11, R12, R13, X, and y are as described for Formula (I’) or (I); Ring C is phenylene or pyridylene; and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
[0220] In the descriptions herein, it is understood that every description, variation, embodiment, or aspect of a moiety may be combined with every description, variation, embodiment, or aspect of other moieties the same as if each and every combination of descriptions is specifically and individually listed. For example, every description, variation, embodiment, or aspect provided herein with respect to Ring A of Formula (I’) or (I) may be combined with every description, variation, embodiment, or aspect of L1, L2, L3, L4, R0, R1aR1b, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, W, X, Y, Z1, Z2, x, and y the same as if each and every combination were specifically and individually listed. It is also understood that all descriptions, variations, embodiments, or aspects of Formula (I’) or (I), where applicable, apply equally to other formulae detailed herein, and are equally described, the same as if each and every description, variation, embodiment, or aspect were separately and individually listed for all formulae. For example, all descriptions, variations, embodiments, or aspects of Formula (I’) or (I), where applicable, apply equally to any of the formulae as detailed herein, such as Formulae (IA), (IB), (IC), (ID), (IE), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ia’), (Ib’), (Ic’), (Id’), (Ie’), (If’), (Ig’), (IIa), (IIb), (IIIa), (IIIb), (IVa), (IVb), (Va), and (Vb) are equally described, the same as if each and every description, variation, embodiment, or aspect were separately and individually listed for all formulae.
[0221] In some embodiments, provided is a compound selected from the compounds in Table 1 or a pharmaceutically acceptable salt thereof. Although certain compounds described inthe present disclosure, including in Table 1, are presented as specific stereoisomers and / or in a non-stereochemical form, it is understood that any or all stereochemical forms, including any enantiomeric or diastereomeric forms, and any tautomers or other forms of any of the compounds of the present disclosure, including in Table 1, are herein described. Table 1.“or1” andor2 indicates that the absolute stereochemistry was not determined and the stereochemistry may be as drawn or the opposite stereochemistry drawn.
[0222] It is understood that in the present description, combinations of substituents and / or variables of the depicted formulae are permissible only if such contributions result in stable compounds.
[0223] Furthermore, all compounds of Formula (I’) or (I) that exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one skilled in the art. Salts of the compounds of Formula (I’) or (I) can be converted to their free base or acid form by standard techniques. Methods of Synthesis
[0224] The compounds described herein can be made using conventional organic syntheses and commercially available starting materials, or the methods provided herein. By way of example and not limitation, compounds of Formula (I’) or (I) can be prepared as outlined in Scheme 1, as well as in the examples set forth herein. It should be noted that one skilled in the art would know how to modify the procedures set forth in the illustrative schemes and examples to arrive at the desired products.
[0225] Compounds of Formula (X-1) can be prepared as outlined in Scheme 1. Coupling of a Cereblon Binding Moiety (CBM) intermediate (C-X) with intermediate a under basic conditions with HATU forms intermediate b, which is then deprotected under acidic conditions to form intermediate c. Subsequent coupling of intermediate c with a target binding moiety (TBM) intermediate (A-X) affords compounds of Formula (X-1).Scheme 1
[0226] Compounds of Formula (X-2) can be prepared as outlined in Scheme 2. Coupling of a CBM intermediate (C-X) with intermediate d via reductive amination using NaBH(OAc)3affords intermediate e, which is then deprotected under acidic conditions to form intermediate f. Subsequent coupling of intermediate f with a TBM intermediate (A-X) provides compounds of Formula (X-2). Scheme 2.
[0227] Compounds of Formula (X-3) can be prepared as outlined in Scheme 3. Activation of the alcohol of intermediate g to form mesylated intermediate h, followed by deoxyazidation with NaN3 affords intermediate i. Intermediate i is then coupled with a TBM intermediate (A- X) to form intermediate j, which is then deprotected to form intermediate k. Subsequent coupling of intermediate k with a CBM intermediate (C-X) provides compounds of Formula (X- 3).Scheme 3.
[0228] A synthetic route to compounds of Formula (X-4) is outlined in Scheme 4. Intermediate l can be coupled with intermediate m under basic conditions using HATU to form intermediate n, which is then activatged with mesyl chloride to form intermediate o. Subsequent deoxyazidation with NaN3provides intermediate p. Deprotection of the ester of intermediate p affords intermediate q, which is then coupled with a CBM intermediate (C-X) to form intermediate f. Intermediate f is then coupled with TBM intermediate (A-X) via copper- catalyzed azide-alkyne cycloaddition to form compounds of Formula (X-4). Scheme 4.
[0229] Compounds of Formula (X-7) can be prepared as outlined in Scheme 5. Activation of the alcohol of intermediate s with mesyl chloride forms intermediate t, and a deoxyazidation reaction with NaN3affords intermediate u. Reduction of the ester of intermediate u provides intermediate v, followed by activation with tosyl chloride to form intermediate w. Subsequent coupling of intermediate w with a CBM intermediate (C-X) under basic conditions affords intermediate x, which is then coupled with a TBM intermediate (A-X) via copper-catalyzed azide-alkyne cycloaddition to form compounds of Formula (X-7).Scheme 5.
[0230] A synthetic route to compounds of Formula (X-8) is outlined in Scheme 6. Reduction of the carboxylic acid of intermediate y forms intermediate z, which is then oxidized to form intermediate a’. Subsequent coupling of intermediate a’ with a CBM intermediate (C- X) via reductive amination forms intermediate b’, which is then deprotected to form intermediate c’. Coupling of intermediate c’ with a TBM intermediate (A-X) via copper- catalyzed azide-alkyne cycloaddition yields compounds of Formula (X-8). Scheme 6.
[0231] Compounds of Formula (X-11) can be prepared as outlined in Scheme 7. Protection of an alcohol group of intermediate c’ with TBDPS forms intermediate d’, which is then activated with mesyl chloride to form intermediate e’. The activated alcohol of intermediate e’ can be replaced with a cyano to form intermediate f’, and then reduced to an aldehyde to form intermediate g’. Further reduction affords intermediate h'. The alcohol group of intermediate h' can be protected with THP to form intermediate i’, and subsequent deprotection under acidic conditions forms intermediate j’. Intermediate j’ is then oxidized to form intermediate k’. The aldehyde of intermediate k’ can be converted to an alkyne via Seyferth-Gilbert homologation to form intermediate L-1, followed by deprotection of the alcohol to form intermediate L-2. Next, intermediate L-2 is coupled with a TBM intermediate (A-X) via copper-catalyzed azide-alkynecycloaddition to form intermediate l’, which is then coupled with a CBM intermediate (C-X) to form compounds of Formula (X-11). Scheme 7.1) IBX L-2 NaN3, Cu cat.TBMI TBM(A-X) Step 11Step 12TBMl'
[0232] Compounds of Formula (X-15) can be prepared as outlined in Scheme 8. Oxidation of the alcohol group of intermediate m’ to an aldehyde affords intermediate n’, which is then coupled with intermediate o’ via reductive amination to form compounds of Formula (X-15). Scheme 8.Methods of Use
[0233] Embodiments of the present disclosure provide a method for modulating IRAK4 in a subject in need thereof, the method comprising administering to the subject an effective amountof a compound of Formula (I’) or (I). Modulation (e.g., inhibition or activation) of IRAK4 can be assessed and demonstrated by a wide variety of ways known in the art. Kits and commercially available assays can be utilized for determining whether and to what degree IRAK4 has been modulated (e.g., inhibited or activated).
[0234] In one aspect, provided herein is a method of modulating IRAK4 comprising contacting IRAK4 with an effective amount of a compound of Formula (I’) or (I) or any embodiment or variation thereof. In some embodiments, the compound of Formula (I’) or (I) inhibits IRAK4. In other embodiments, the compound of Formula (I’) or (I) activates IRAK4. In some embodiments, the compound of Formula (I’) or (I) is an agonist of IRAK4. In some embodiments, the compound of Formula (I’) or (I) is an antagonist of IRAK4.
[0235] In some embodiments, provided herein is a method for targeting IRAK4 for degradation comprising contacting IRAK4 with an effective amount of a compound of Formula (I’) or (I) or any embodiment or variation thereof.
[0236] In some embodiments, a compound of Formula (I’) or (I) modulates the activity of IRAK4 by about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. In some embodiments, a compound of Formula (I’) or (I) modulates the activity of IRAK4 by about 1-100%, 5-100%, 10-100%, 15-100%, 20- 100%, 25-100%, 30-100%, 35-100%, 40-100%, 45-100%, 50-100%, 55-100%, 60-100%, 65- 100%, 70-100%, 75-100%, 80-100%, 85-100%, 90-100%, 95-100%, 5-95%, 5-90%, 5-85%, 5- 80%, 5-75%, 5-70%, 5-65%, 5-60%, 5-55%, 5-50%, 5-45%, 5-40%, 5-35%, 5-30%, 5-25%, 5- 20%, 5-15%, 5-10%, 10-90%, 20-80%, 30-70%, or 40-60%.
[0237] Also provided in certain embodiments of the present disclosure is a method for degrading IRAK4 in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). Degradation of IRAK4 can be assessed and demonstrated by a wide variety of ways known in the art. Kits and commercially available assays, including cell-based assays, can be utilized for determining whether and to what degree IRAK4 has been degraded.
[0238] In one aspect, provided herein is a method of degrading IRAK4 comprising contacting IRAK4 with an effective amount of a compound of Formula (I’) or (I) or any embodiment or variation thereof. In some embodiments, the compound of Formula (I’) or (I) partially degrades IRAK3. In some embodiments, the compound of Formula (I’) or (I) fully degrades IRAK4.
[0239] In some embodiments, a compound of Formula (I’) or (I) degrades IRAK4 by about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,85%, 90%, 95%, or 100%. In some embodiments, a compound of Formula (I’) or (I) degrades IRAK4 by about 1-100%, 5-100%, 10-100%, 15-100%, 20-100%, 25-100%, 30-100%, 35- 100%, 40-100%, 45-100%, 50-100%, 55-100%, 60-100%, 65-100%, 70-100%, 75-100%, 80- 100%, 85-100%, 90-100%, 95-100%, 5-95%, 5-90%, 5-85%, 5-80%, 5-75%, 5-70%, 5-65%, 5- 60%, 5-55%, 5-50%, 5-45%, 5-40%, 5-35%, 5-30%, 5-25%, 5-20%, 5-15%, 5-10%, 10-90%, 20-80%, 30-70%, or 40-60%.
[0240] In another aspect, provided herein is a method for treating an inflammatory or autoimmune disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). In some embodiments, provided herein is a method for treating an inflammatory disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). In some embodiments, provided herein is a method for treating an autoimmune disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). In some embodiments, provided herein is a method for preventing an inflammatory or autoimmune disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). In some embodiments, provided herein is a method for preventing an inflammatory disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). In some embodiments, provided herein is a method for preventing an autoimmune disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). Non-limiting examples of an inflammatory or autoimmune disease include atopic dermatitis, asthma, lupus, rheumatoid arthritis, familial mediterranean fever, psoriasis, generalized pustular psoriasis, cryoprin-associated periodic syndrome, hidradenitis suppurativa, Bechet’s syndrome, or familial cold autoinflammatory syndrome.
[0241] In some embodiments, administering a compound of Formula (I’) or (I) to a subject that is predisposed to an inflammatory or autoimmune disease prevents the subject from developing any symptoms of the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject that does not yet display symptoms of an inflammatory or autoimmune disease prevents the subject from developing any symptoms of the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof diminishes the extent of the inflammatory or autoimmune disease in the subject. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof stabilizes the inflammatory or autoimmune disease (prevents or delays the worsening of the inflammatory or autoimmune disease). In someembodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof delays the occurrence or recurrence of the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof slows the progression of the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof provides a partial remission of the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof provides a total remission of the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof decreases the dose of one or more other medications required to treat the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof enhances the effect of another medication used to treat the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof delays the progression of the inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof increases the quality of life of the subject having an inflammatory or autoimmune disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof prolongs survival of a subject having an inflammatory or autoimmune disease.
[0242] In one aspect, provided herein is method of preventing a subject that is predisposed to an inflammatory or autoimmune disease from developing any symptoms of the inflammatory or autoimmune disease, the method comprising administering a compound of Formula (I’) or (I) to the subject. In some embodiments, provided herein is a method of preventing a subject that does not yet display symptoms of an inflammatory or autoimmune disease from developing any symptoms of the inflammatory or autoimmune disease, the method comprising administering a compound of Formula (I’) or (I) to the subject.
[0243] In some aspects, provided herein is a method of diminishing the extent of an inflammatory or autoimmune disease in a subject, the method comprising administering a compound of Formula (I’) or (I) to the subject. In some embodiments, provided herein is a method of stabilizing an inflammatory or autoimmune disease in a subject, the method comprising administering a compound of Formula (I’) or (I) to the subject. In some embodiments, the method prevents the worsening of the inflammatory or autoimmune disease. In some embodiments, the method delays the worsening of the inflammatory or autoimmune disease.
[0244] In another aspect, provided herein is a method of delaying the occurrence or recurrence of an inflammatory or autoimmune disease in a subject, the method comprising administering a compound of Formula (I’) or (I) to the subject.
[0245] In some embodiments, provided herein is a method of slowing the progression of an inflammatory or autoimmune disease in a subject, the method comprising administering a compound of Formula (I’) or (I) to the subject. In some embodiments, the method provides a partial remission of the inflammatory or autoimmune disease. In some embodiments, the method provides a total remission of the inflammatory or autoimmune disease.
[0246] In further aspects, provided herein is a method of decreasing the dose of one or more other medications required to treat an inflammatory or autoimmune disease in a subject, the method comprising administering a compound of Formula (I’) or (I) to the subject. In some embodiments, provided herein is a method of enhancing the effect of another medication used to treat an inflammatory or autoimmune disease in a subject, the method comprising administering a compound of Formula (I’) or (I) to the subject.
[0247] Also provided here is a method of delaying the progression of an inflammatory or autoimmune disease in a subject, the method comprising administering a compound of Formula (I’) or (I) to the subject. In some embodiments, the method increases the quality of life of the subject having an inflammatory or autoimmune disease. In some embodiments, the method prolongs survival of the subject having an inflammatory or autoimmune disease.
[0248] In another aspect, provided herein is a method for treating inflammatory or autoimmune symptoms caused by a disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). In some embodiments, provided herein is a method for preventing inflammatory or autoimmune symptoms caused by a disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I’) or (I). In some embodiments, administering a compound of Formula (I’) or (I) to a subject that is predisposed to a disease which causes inflammatory or autoimmune symptoms prevents the subject from developing any inflammatory or autoimmune symptoms. In some embodiments, administering a compound of Formula (I’) or (I) to a subject that does not yet display inflammatory or autoimmune symptoms of a disease which causes inflammatory or autoimmune symptoms prevents the subject from developing any inflammatory or autoimmune symptoms. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof diminishes the extent of the inflammatory or autoimmune symptoms caused by the disease in the subject. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereofstabilizes the inflammatory or autoimmune symptoms of the disease (prevents or delays the worsening of the inflammatory or autoimmune symptoms). In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof delays the occurrence or recurrence of the inflammatory or autoimmune symptoms caused by the disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof slows the progression of the inflammatory or autoimmune symptoms caused by the disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof provides a partial remission of the disease which causes inflammatory or autoimmune symptoms. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof provides a total remission of the disease which causes inflammatory or autoimmune symptoms. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof decreases the dose of one or more other medications required to treat the disease which causes inflammatory or autoimmune symptoms. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof enhances the effect of another medication used to treat the inflammatory or autoimmune symptoms of the disease. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof delays the progression of the disease which causes inflammatory or autoimmune symptoms. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof increases the quality of life of the subject having a disease which causes inflammatory or autoimmune symptoms. In some embodiments, administering a compound of Formula (I’) or (I) to a subject in need thereof prolongs survival of a subject having a disease which causes inflammatory or autoimmune symptoms. In some embodiments, the disease is atopic dermatitis, asthma, lupus, rheumatoid arthritis, familial mediterranean fever, psoriasis, generalized pustular psoriasis, cryoprin-associated periodic syndrome, hidradenitis suppurativa, Bechet’s syndrome, or familial cold autoinflammatory syndrome.
[0249] In some embodiments, compounds of Formula (I’) or (I) are useful for treating a disorder selected from atopic dermatitis, asthma, lupus, rheumatoid arthritis, familial mediterranean fever, psoriasis, generalized pustular psoriasis, cryoprin-associated periodic syndrome, hidradenitis suppurativa, Bechet’s syndrome, and familial cold autoinflammatory syndrome.
[0250] In some embodiments, compounds of Formula (I’) or (I) are useful for treating a cancer. In some embodiments, the cancer is a solid tumor, skin cancer, or lymphoma. In some embodiments, the cancer is squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, cancer of the bladder, bowel, breast, cervix,colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, or stomach, leukemia, benign and malignant lymphomas, Burkitt's lymphoma, Non-Hodgkin’s lymphoma, benign and malignant melanomas, myeloproliferative diseases, sarcomas, Ewing’s sarcoma, hemangiosarcoma, Kaposi’s sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, Schwannomas, bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin’s disease, Wilms’ tumor, or teratocarcinomas. Additional cancers which may be treated using compounds of Formula (I’) or (I) include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML.
[0251] In some embodiments, the cancer is breast cancer, colorectal cancer, non-small cell lung cancer, ovarian, renal, sarcoma, melanoma, head and neck, hepatocellular, thyroid, multidrug-resistant leukemia, lymphoma, multiple myeloma, esophageal, large bowel, pancreatic, mesothelioma, carcinoma (e.g., adenocarcinoma, including esophageal adenocarcinoma), sarcoma (e.g., spindle cell sarcoma, liposarcoma, leiomyosarcoma, abdominal leiomyosarcoma, sclerosing epithelioid sarcoma) and melanoma (e.g., metastatic malignant melanoma).
[0252] In some embodiments, the compounds of Formula (I’) or (I) are useful for treating fibrosis, such as interstitial lung fibrosis, cystic fibrosis, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Pharmaceutical Compositions and Routes of Administration
[0253] The compounds provided herein can be administered to a subject orally, topically or parenterally in the conventional form of preparations, such as capsules, microcapsules, tablets, granules, powder, troches, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions and emulsions.
[0254] The compounds disclosed herein can be administered to a subject orally, topically or parenterally in the conventional form of preparations, such as capsules, microcapsules, tablets, granules, powder, troches, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions and emulsions. Suitable formulations can be preparedby methods commonly employed using conventional, organic or inorganic additives, such as an excipient (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate), a binder (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose or starch), a disintegrator (e.g., starch, carboxymethylcellulose, hydroxypropylstarch, low substituted hydroxypropylcellulose, sodium bicarbonate, calcium phosphate or calcium citrate), a lubricant (e.g., magnesium stearate, light anhydrous silicic acid, talc or sodium lauryl sulfate), a flavoring agent (e.g., citric acid, menthol, glycine or orange powder), a preservative (e.g, sodium benzoate, sodium bisulfite, methylparaben or propylparaben), a stabilizer (e.g., citric acid, sodium citrate or acetic acid), a suspending agent (e.g., methylcellulose, polyvinyl pyrroliclone or aluminum stearate), a dispersing agent (e.g., hydroxypropylmethylcellulose), a diluent (e.g., water), and base wax (e.g., cocoa butter, white petrolatum or polyethylene glycol). The effective amount of the compounds of Formula (I’) or (I) in the pharmaceutical composition may be at a level that will exercise the desired effect; for example, about 0.005 mg / kg of a subject’s body weight to about 10 mg / kg of a subject’s body weight in unit dosage for both oral and parenteral administration.
[0255] The dose of a compound of Formula (I’) or (I) to be administered to a subject is rather widely variable and can be subject to the judgment of a health-care practitioner. In general, the compounds disclosed herein can be administered one to four times a day in a dose of about 0.001 mg / kg of a subject’s body weight to about 10 mg / kg of a subject’s body weight, but the above dosage may be properly varied depending on the age, body weight and medical condition of the subject and the type of administration. In one embodiment, the dose is about 0.001 mg / kg of a subject’s body weight to about 5 mg / kg of a subject’s body weight, about 0.01 mg / kg of a subject’s body weight to about 5 mg / kg of a subject’s body weight, about 0.05 mg / kg of a subject’s body weight to about 1 mg / kg of a subject’s body weight, about 0.1 mg / kg of a subject’s body weight to about 0.75 mg / kg of a subject’s body weight or about 0.25 mg / kg of a subject’s body weight to about 0.5 mg / kg of a subject’s body weight. In one embodiment, one dose is given per day. In any given case, the amount of the compound of Formula (I’) or (I) administered will depend on such factors as the solubility of the active component, the formulation used and the route of administration.
[0256] In some embodiments, a compound of Formula (I’) or (I) is administered to a subject at a dose of about 0.01 mg / day to about 750 mg / day, about 0.1 mg / day to about 375 mg / day, about 0.1 mg / day to about 150 mg / day, about 0.1 mg / day to about 75 mg / day, about 0.1 mg / dayto about 50 mg / day, about 0.1 mg / day to about 25 mg / day, or about 0.1 mg / day to about 10 mg / day.
[0257] In another embodiment, provided herein are unit dosage formulations that comprise between about 0.1 mg and 500 mg, about 1 mg and 250 mg, about 1 mg and about 100 mg, about 1 mg and about 50 mg, about 1 mg and about 25 mg, or between about 1 mg and about 10 mg of a compound of Formula (I’) or (I).
[0258] In a particular embodiment, provided herein are unit dosage formulations comprising about 0.1 mg or 100 mg of a compound of Formula (I’) or (I).
[0259] In another embodiment, provided herein are unit dosage formulations that comprise 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 175 mg, 200 mg, 250 mg, 280 mg, 350 mg, 500 mg, 560 mg, 700 mg, 750 mg, 1000 mg or 1400 mg of a compound of Formula (I’) or (I).
[0260] A compound of Formula (I’) or (I) can be administered once, twice, three, four or more times daily. In a particular embodiment, doses of 100 mg or less are administered as a once daily dose and doses of more than 100 mg are administered twice daily in an amount equal to one half of the total daily dose.
[0261] A compound of Formula (I’) or (I) can be administered orally for reasons of convenience. In one embodiment, when administered orally, a compound of Formula (I’) or (I) is administered with a meal and water. In another embodiment, the compound of Formula (I’) or (I) is dispersed in water or juice (e.g., apple juice or orange juice) or any other liquid and administered orally as a solution or a suspension.
[0262] The compounds disclosed herein can also be administered intradermally, intramuscularly, intraperitoneally, percutaneously, intravenously, subcutaneously, intranasally, epidurally, sublingually, intracerebrally, intravaginally, transdermally, rectally, mucosally, by inhalation, or topically to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the health-care practitioner, and can depend inpart upon the site of the medical condition.
[0263] In one embodiment, provided herein are capsules containing a compound of Formula (I’) or (I) without an additional carrier, excipient or vehicle.
[0264] In another embodiment, provided herein are compositions comprising an effective amount of a compound of Formula (I’) or (I) and a pharmaceutically acceptable carrier or vehicle, wherein a pharmaceutically acceptable carrier or vehicle can comprise an excipient, diluent, or a mixture thereof. In one embodiment, the composition is a pharmaceutical composition.
[0265] The compositions can be in the form of tablets, chewable tablets, capsules, solutions, parenteral solutions, troches, suppositories and suspensions and the like. Compositions can be formulated to contain a daily dose, or a convenient fraction of a daily dose, in a dosage unit, which may be a single tablet or capsule or convenient volume of a liquid. In one embodiment, the solutions are prepared from water-soluble salts, such as the hydrochloride salt. In general, all of the compositions are prepared according to known methods in pharmaceutical chemistry. Capsules can be prepared by mixing a compound of Formula (I’) or (I) with a suitable carrier or diluent and filling the proper amount of the mixture in capsules. The usual carriers and diluents include, but are not limited to, inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.
[0266] Tablets can be prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
[0267] A lubricant might be necessary in a tablet formulation to prevent the tablet and punches from sticking in the dye. The lubricant can be chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils. Tablet disintegrators are substances that swell when wetted to break up the tablet and release the compound. They include starches, clays, celluloses, algins and gums. More particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethyl cellulose, for example, can be used as well as sodium lauryl sulfate. Tablets can be coated with sugar as a flavor and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet. The compositions can also be formulated as chewable tablets, for example, by using substances such as mannitol in the formulation.
[0268] When it is desired to administer a compound of Formula (I’) or (I) as a suppository, typical bases can be used. Cocoa butter is a traditional suppository base, which can be modifiedby addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use.
[0269] The effect of the compound of Formula (I’) or (I) can be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the compound of Formula (I’) or (I) can be prepared and incorporated in a tablet or capsule, or as a slow-release implantable device. The technique also includes making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules can be coated with a film that resists dissolution for a predictable period of time. Even the parenteral preparations can be made long- acting, by dissolving or suspending the compound of Formula (I’) or (I) in oily or emulsified vehicles that allow it to disperse slowly in the serum. Exemplary Embodiments
[0270] The present disclosure is further described by the following embodiments. The features of each of the embodiments are combinable with any of the other embodiments where appropriate and practical.
[0271] Embodiment 1. A compound of Formula (I’):or a pharmaceutically acceptable salt thereof, wherein: Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups; each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, -(6- to 10–membered bridged heterocyclylene)-, and C1-C6alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group; L1is -NH- or a bond; L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or -(C1-C6alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N, O, and S;L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C6alkylene)z-, -(7- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups;enylene, -N(H)(phenylene), 5- to 6-membered heteroarylene, -N(H)(5- to 6-membered heteroarylene)-, 8- to 10-membered fused bicyclic heteroarylene, or 5- to 6- membered heterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1-3 heteroatoms selected from N, S, and O; R1aand R1bare each H or are taken together to form an oxo group; R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group; or R3and R11are taken together to form a C3-C6cycloalkylene group; Y is NH, O, or a bond; R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1- C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups; W is O, -NR5-, or a bond; R5is H or C1-C6alkyl; each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group;each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl, halo, -CN, or -OH; each R9is independently H or C1-C6alkyl; each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group; each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl; or R11and R3are taken together to form a C3-C6cycloalkylene group; x is 0 or 1; y is 0, 1, 2, 3, 4, or 5; each z is independently 0 or 1; X is N or CR13; R13is H, halo, -OH, or C1-C6alkyl; Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N.
[0272] Embodiment 2. A compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein: Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups; each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, and C1-C6alkoxy, or two R0groups are taken together to form an oxo group; L1is -NH- or a bond; L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or 5-membered heteroarylene containing 1-3 heteroatoms selected from N, O, and S;L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(6- to 10- membered bridged heterocyclylene)(C1-C6alkylene)z-, -(9- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1- C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups;enylene, 5- to 6-membered heteroarylene, or 5- to 6-membered heterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1- 3 heteroatoms selected from N and O; R1aand R1bare each H or are taken together to form an oxo group; R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group; or R3and R11are taken together to form a C3-C6cycloalkylene group; Y is NH or O; R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1- C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups; W is O, -NR5-, or a bond; R5is H or C1-C6alkyl; each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group; each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl,halo, -CN, or -OH; each R9is independently H or C1-C6alkyl; each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group; each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl; or R11and R3are taken together to form a C3-C6cycloalkylene group; x is 0 or 1; y is 0, 1, 2, 3, 4, or 5; each z is independently 0 or 1; X is N or CR13; R13is H, halo, or C1-C6alkyl; Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N.
[0273] Embodiment 3. The compound of embodiment 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: Z1and Z2are each CH.
[0274] Embodiment 4. The compound of embodiment 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: Z1is CH; and Z2is N.
[0275] Embodiment 5. The compound of embodiment 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: Z1is N; and Z2is CH.
[0276] Embodiment 6. The compound of any one of embodiments 1-5, or a pharmaceutically acceptable salt thereof, wherein: Ring A is phenyl optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, and C1-C3alkoxy.
[0277] Embodiment 7. The compound of embodiment 6, or a pharmaceutically acceptable salt thereof, wherein:
[0278] Embodiment 8. The compound of any one of embodiments 1-5, or a pharmaceutically acceptable salt thereof, wherein: Ring A is a monocyclic 6-membered heteroaryl containing 1-2 heteroatoms independently selected from N and O and is optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, and C1-C6alkoxy.
[0279] Embodiment 9. The compound of embodiment 8, or a pharmaceutically acceptable salt thereof, wherein: Ring A is.
[0280] Embodiment 10. The compound of any one of embodiments 1-5, or a pharmaceutically acceptable salt thereof, wherein: Ring A is a fused bicyclic 9- to 10- membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and is optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, -(6- to 8-membered bridged heterocyclylene)-, and C1-C3alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group.
[0281] Embodiment 11. The compound of embodiment 10, or a pharmaceutically acceptable salt thereof, wherein: Ring A is
[0282] Embodiment 12. The compound of any one of embodiments 1-11, or a pharmaceutically acceptable salt thereof, wherein: L1is -NH-.
[0283] Embodiment 13. The compound of any one of embodiments 1-11, or a pharmaceutically acceptable salt thereof, wherein: L1is a bond.
[0284] Embodiment 14. The compound of any one of embodiments 1-13, or a pharmaceutically acceptable salt thereof, wherein:L2is -(C1-C3alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N and O.
[0285] Embodiment 15. The compound of embodiment 14, or a pharmaceutically acceptable salt thereof, wherein: L2is.
[0286] Embodiment 16. The compound of any one of embodiments 1-14, or a pharmaceutically acceptable salt thereof, wherein: L2is -NHC(O)- or triazolylene.
[0287] Embodiment 17. The compound of embodiment 16, or a pharmaceutically acceptable salt thereof, wherein: L2is -NHC(O)-.
[0288] Embodiment 18. The compound of embodiment 16, or a pharmaceutically acceptable salt thereof, wherein:
[0289] Embodiment 19. The compound of any one of embodiments 1-18, or a pharmaceutically acceptable salt thereof, wherein:R1aand R1bare each H or are taken together to form an oxo group.
[0290] Embodiment 20. The compound of embodiment 19, or a pharmaceutically acceptable salt thereof, wherein:
[0291] Embodiment 21. The compound of embodiment 19, or a pharmaceutically acceptablesalt thereof, wherein:.
[0292] Embodiment 22. The compound of any one of embodiments 1-18, or a pharmaceutically acceptable salt thereof, wherein: L4is phenylene, -NH(phenylene), 5- to 6-membered heteroarylene, -N(H)(5- to 6-membered heteroarylene)-, 8- to 10-membered fused bicyclic heteroarylene, or 5- to 6-membered heterocyclylene, each of which is optionally substituted by 1-4 R10groups, and wherein the heteroarylene or heterocyclylene contains 1-3 heteroatoms selected from N, S, and O.
[0293] Embodiment 23. The compound of embodiment 22, or a pharmaceutically acceptable salt thereof, wherein: each R10is independently C1-C3alkoxy, C1-C3alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group.
[0294] Embodiment 24. The compound of embodiment 23, or a pharmaceutically acceptable salt thereof, wherein: each R10is independently -OCH3, -CH3, Cl, F, or -OH, or two R10groups are taken together to form an oxo group.
[0295] Embodiment 25. The compound of any one of embodiments 22-24, or a pharmaceutically acceptable salt thereof, wherein: L4is.
[0296] Embodiment 26. The compound of any one of embodiments 1-25, or a pharmaceutically acceptable salt thereof, wherein: x is 0.
[0297] Embodiment 27. The compound of any one of embodiments 1-25, or a pharmaceutically acceptable salt thereof, wherein: x is 1.
[0298] Embodiment 28. The compound of any one of embodiments 1-25 and 27, or a pharmaceutically acceptable salt thereof, wherein: R2and R3are independently H, C1-C3alkyl, or halo.
[0299] Embodiment29. The compound of embodiment 28, or a pharmaceutically acceptable salt thereof, wherein: R2and R3are independently H, -CH3, or F.
[0300] Embodiment 30. The compound of any one of embodiments 1-25 and 27, or a pharmaceutically acceptable salt thereof, wherein: R2and R3are taken together to form an oxo group.
[0301] Embodiment 31. The compound of any one of embodiments 1-25 and 27, or a pharmaceutically acceptable salt thereof, wherein: R3and R11are taken together to form a C3-C5cycloalkylene group.
[0302] Embodiment 32. The compound of embodiment 31, or a pharmaceutically acceptable salt thereof, wherein: R3and R11are taken together to form a cyclopropylene group.
[0303] Embodiment 33. The compound of any one of embodiments 1-32, or apharmaceutically acceptable salt thereof, wherein: y is 0 or 1.
[0304] Embodiment 34. The compound of any one of embodiments 1-33, or a pharmaceutically acceptable salt thereof, wherein: each R6is independently C1-C3alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C2alkylene group.
[0305] Embodiment 35. The compound of embodiment 34, or a pharmaceutically acceptable salt thereof, wherein: each R6is independently -CH3, Cl, or -OH, or two R6groups are taken together to form a bridging C1-C2alkylene group.
[0306] Embodiment 36. The compound of any one of embodiments 1-35, or a pharmaceutically acceptable salt thereof, wherein:.
[0307] Embodiment 37. The compound of any one of embodiments 1-36, or a pharmaceutically acceptable salt thereof, wherein: W is O, -NR5-, or a bond; and R5is H or C1-C3alkyl.
[0308] Embodiment 38. The compound of embodiment 37, or a pharmaceutically acceptable salt thereof, wherein: W is O, -N(H)-, -N(CH3)-, or a bond.
[0309] Embodiment 39. The compound of any one of embodiments 1-38, or a pharmaceutically acceptable salt thereof, wherein: X is N.
[0310] Embodiment 40. The compound of any one of embodiments 1-38, or a pharmaceutically acceptable salt thereof, wherein: X is CR13; and R13is H, halo, -OH, or C1-C3alkyl.
[0311] Embodiment 41. The compound of embodiment 40, or a pharmaceutically acceptable salt thereof, wherein: R13is H, CH3, -OH, or F.
[0312] Embodiment 42. The compound of any one of embodiments 1-41, or a pharmaceutically acceptable salt thereof, wherein: Y is NH.
[0313] Embodiment 43. The compound of any one of embodiments 1-41, or a pharmaceutically acceptable salt thereof, wherein: Y is O or a bond.
[0314] Embodiment 44. The compound of any one of embodiments 1-43, or a pharmaceutically acceptable salt thereof, wherein: R4is C3-C6cycloalkyl, C1-C3alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1-C3alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C3alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1 or 2 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-2 R8groups.
[0315] Embodiment 45. The compound of embodiment 44, or a pharmaceutically acceptable salt thereof, wherein: each R8is independently -SO2(C1-C3alkyl), -C(O)(C1-C3alkyl), C1-C3alkyl, C1-C3haloalkyl, halo, -CN, or -OH.
[0316] Embodiment 46. The compound of embodiment 45, or a pharmaceutically acceptable salt thereof, wherein: each R8is independently -SO2CH3, -C(O)CH3, methyl, ethyl, -CH2CF3, F, -CN, or -OH.
[0317] Embodiment 47. The compound of any one of embodiments 1-46, or a pharmaceutically acceptable salt thereof, wherein: R4is methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH2CH(CH3)2, -CH2CF3, -CH2CH2F, -CH2CF2CH3, -CH(CH3)CF3, -CH2CH2CF3, -CH(CH3)CH2OH, -CH2C(CH3)2OH, -CH2CN, -CH(CH3)CN, -C(CH3)2CN, -CH(CH2CH3)CN, -CH2CH(CH3)CN,.
[0318] Embodiment 48. The compound of any one of embodiments 1-47, or a pharmaceutically acceptable salt thereof, wherein: L3is -NR9(C1-C3alkylene)NR9-, -NR9C(O)(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C3alkylene)z-, -NR9(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, -O(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C3alkylene)z-, -(7- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1 or 2 R7groups; and each z is independently 0 or 1.
[0319] Embodiment 49. The compound of any one of embodiments 1-48, or a pharmaceutically acceptable salt thereof, wherein: each R9is independently H or C1-C3alkyl.
[0320] Embodiment 50. The compound of embodiment 49, or a pharmaceutically acceptable salt thereof, wherein: each R9is independently H or -CH3.
[0321] Embodiment 51. The compound of any one of embodiments 1-50, or a pharmaceutically acceptable salt thereof, wherein: each R7is independently C1-C3alkyl, halo, C1-C3haloalkyl, or -OH, or two R7groups are taken together to form an oxo group.
[0322] Embodiment 52. The compound of embodiment 51, or a pharmaceutically acceptable salt thereof, wherein: each R7is independently -CH3, -CF3, F, or -OH, or two R7groups are taken together to form an oxo group.
[0323] Embodiment 53. The compound of any one of embodiments 1-52, or a pharmaceutically acceptable salt thereof, wherein: each R11and R12is independently H or C1-C3alkyl.
[0324] Embodiment 54. The compound of embodiment 53, or a pharmaceutically acceptable salt thereof, wherein: each R11and R12is independently H or -CH3.
[0325] Embodiment 55. The compound of any one of embodiments 1-48, or a pharmaceutically acceptable salt thereof, wherein: L3is
[0326] Embodiment 56. The compound of any one of embodiments 1-3, 10, 11, 13-18, 22- 25, 27-38, 40-42, 44-48, and 51-55, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Ia):wherein: Ring A is a fused bicyclic 9- to 10-membered heteroaryl containing 2-4 heteroatoms independently selected from N, O, and S, optionally substituted by 1-3 R0groups; and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
[0327] Embodiment 57. The compound of embodiment 56, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Ib) or (Ic):
[0328] Embodiment 58. The compound of embodiment 56 or 57, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Id) or (Ie):
[0329] Embodiment 59. The compound of any one of embodiments 56-58, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (If) or (Ig):
[0330] Embodiment 60. The compound of embodiment 59, or a pharmaceutically acceptable salt thereof, wherein: each R0is independently -CN or -NH2; R4is C1-C3alkyl-CN, or C3-C6cycloalkyl optionally substituted with C1-C3alkyl; and R7is C1-C3alkyl.
[0331] Embodiment 61. The compound of any one of embodiments 1, 2, 10, 11, 13-18, 22- 25, 27-38, 39, 42, 44-48, and 51-54, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Ia’):wherein: Ring A is a fused bicyclic 9- to 10-membered heteroaryl containing 2-4 heteroatoms independently selected from N, O, and S, optionally substituted by 1-3 R0groups; and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
[0332] Embodiment 62. The compound of embodiment 61, or a pharmaceutically acceptable
[0333] Embodiment 63. The compound of embodiment 61 or 62, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Id’) or (Ie’):
[0334] Embodiment 64. The compound of any one of embodiments 61-63, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (If’) or (Ig’):
[0335] Embodiment 65. The compound of embodiment 64, or a pharmaceutically acceptable salt thereof, wherein: each R0is independently -CN or -NH2; R4is C1-C3alkyl-CN, or C3-C6cycloalkyl optionally substituted with C1-C3alkyl; and R7is C1-C3alkyl.
[0336] Embodiment 66. A compound selected from the compounds of Table 1 or a pharmaceutically acceptable salt thereof.
[0337] Embodiment 67. A pharmaceutical composition comprising the compound of any one of embodiments 1-66, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0338] Embodiment 68. A method of modulating interleukin-1 (IL1) receptor-associated kinase 4 (IRAK4) activity comprising contacting IRAK4 with an effective amount of the compound of any one of embodiments 1-66, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of embodiment 67.
[0339] Embodiment 69. A method of treating an inflammatory or autoimmune disease in a subject in need thereof, comprising administering to the subject an effective amount of the compound of any one of embodiments 1-66, or a pharmaceutically acceptable salt thereof, or thepharmaceutical composition of embodiment 67.
[0340] Embodiment 70. The method of embodiment 69, wherein the inflammatory or autoimmune disease is atopic dermatitis, asthma, lupus, rheumatoid arthritis, familial mediterranean fever, psoriasis, generalized pustular psoriasis, cryoprin-associated periodic syndrome, hidradenitis suppurativa, Bechet’s syndrome, or familial cold autoinflammatory syndrome. EXAMPLES
[0341] The following Examples are presented by way of illustration, not limitation. Compounds are named using the automatic name generating tool provided in ChemBiodraw Ultra (Cambridgesoft), which generates systematic names for chemical structures, with support for the Cahn-Ingold-Prelog rules for stereochemistry. One skilled in the art can modify the procedures set forth in the illustrative examples to arrive at the desired products.
[0342] Salts of the compounds described herein can be prepared by standard methods, such as inclusion of an acid (for example TFA, formic acid, or HCl) in the mobile phases during chromatography purification, or stirring of the products after chromatography purification, with a solution of an acid (for example, aqueous HCl).
[0343] As used in certain of the chemical structures provided in the following Examples, designation of a particular atom with “*”, “or1”, or “or2” indicates that the absolute stereochemistry of the indicated atom was not determined.
[0344] The following abbreviations may be relevant for the application. Abbreviations ACN or MeCN: acetonitrile ADMP: 2-azido-1,3-dimethylimidazolinium hexafluorophosphate aq: aqueous BCA assay: Bicinchoninic acid assay CBM: cereblon binding moiety CV: column volume d: day(s) DABCO: 1,4-diazabicyclo[2.2.2]octane DAST: diethylaminosulfur trifluoride DCM: dichloromethane DIPEA: N, N-diisopropylethylamine DMA: dimethylacetamide DMAP: 4-dimethylaminopyridineDMAP: 4-dimethylaminopyridine DME: dimethoxyethane DMF: dimethylformamide DMP: Dess-Martin Periodinane EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Equiv or eq.: equivalents ESI: electrospray ionization EtOAc: ethyl acetate FA: formic acid FBS: fetal bovine serum FC: flash chromatography h: hour(s) HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HOBt: hydroxybenzotriazole HPLC: high-performance liquid chromatography IBX: 2-iodoxybenzoic acid LCMS: liquid chromatography mass spectrometry MeOH: methanol MeTHF: methyltetrahydrofuran min: minute(s) MsCl: mesyl chloride MSD: mass selective detector MTBE: methyl tert-butyl ether NBS: N-bromosuccinimide NFSI: N-fluorodi(benzenesulfonyl)amine Pd(dppf)Cl2: [1,1’-bis(diphenylphosphino)ferrocene]palladium(II) dichloride Pd(DTBPF)Cl2: [1,1’-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) PdCl2(dppf)CH2Cl2or Pd(dppf)Cl2·DCM: [1,1’-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane Pet ether: petroleum ether PS: penicillin-streptomycin PPTS: pyridinium p-toluenesulfonate prep: preparativequant.: quantitative RT or r.t.: room temperature rt: retention time sat.: saturated SFC: supercritical-fluid chromatography TBAF: tetrabutylammonium fluoride TBDPS: tert-butyldiphenylsilyl TBDPS: tert-butyldiphenylsilyl TBM: target binding moiety TEA: triethylamine TFA: trifluoroacetic acid TFAA: trifluoroacetic anhydride THF: tetrahydrofuran THP: tetrahydropyran TLC: thin layer chromatography UPLC: ultra-performance liquid chromatography Synthetic Examples Synthesis of the CBM molecule
[0345] The numbering of the intermediate compounds referred to in this section, as well as in other sections, is limited to each section only. For instance, intermediate 3 in General Procedure CBM-1 and intermediate 3 in General Procedure CBM-2 are described in different sections and, as such, refer to different compounds.General Procedure CBM-1wherein Z3is N or CH.
[0346] Step 1a: A sealed tube was charged with 1a, tert-butyl piperazine-1-carboxylate 2a (1.1 equiv), DIPEA (3.0 equiv) and DMSO (15 mL). The tube was sealed and heated at 90 °C for 72 h. The progress of reaction was followed by HPLC. Upon completion the reaction mixture was directly purified by reversed phase chromatography. The pure fractions were combined, and concentrated under reduced pressure to afford product.
[0347] Step 1b: To an oven-dried 40 mL vial equipped with a magnetic stir bar under ambient atmosphere, 3-(6-bromo-1-oxo-isoindolin-2-yl)piperidine-2,6-dione 1b (500 mg, 1.55 mmol) tert-butyl piperazine-1-carboxylate 2a (1.5 equiv), DABCO (3.0 equiv) and (Ir(ppy)2(dtbbpy)PF6(1 mol%) were added, followed by DMA (10 mL). Then dibromonickel; 1,2-dimethoxyethane (5 mol%) was added as a solution in DMA (0.5 mL) under N2. The reaction was placed in front of one 30 W blue LED at 25 °C for 96 h. Material was added into water dropwise, the formed solid was filtered and concentrated. The residue was purified by prep-HPLC to give product.
[0348] Step 1c: To a solution of 3-(6-bromo-1-oxo-isoindolin-2-yl)piperidine-2,6-dione 1b, potassium;(1-tert-butoxycarbonyl-4-piperidyl)-trifluoro-boranuide 2b (3.0 equiv) and 2,4,6- Trimethylpyridine (1.8 equiv) in 1,4-Dioxane (0.15 M) in a Schlenk flask was added a solution of (Ir[dF(CF3)ppy]2(dtbpy))PF6(2 mol%) in 1,4-Dioxane (1mL). A solution of Ni-dtbbpy-Br2(10 mol%) in 1,4-Dioxane (1mL), which had been sonicated for 1 minute, was then added. The reaction mixture was degassed 3 x using the freeze-pump-thaw method. The flask was thenplaced under a dry nitrogen atmosphere and sealed with a parafilm. The reaction mixture was stirred under blue LED irradiation for 4 days. The solution was evaporated until it was dry before dissolving in DMSO for purification by reverse phase chromatography. The pure fractions were combined to afford product.
[0349] Step 2: TFA (20 equiv) was added to a solution of 3 in CH2Cl2(0.2 M) and the mixture was stirred at room temperature for 2 h. Upon completion by HPLC, the volatiles removed in vacuum and the residue co-evaporated with MeCN (3x) and MTBE (2x). The residue was purified by reverse phase chromatography. The pure fractions were concentrated under reduced pressure to afford product CBM-1 as a TFA salt. Example S1.2-(2,6-dioxo-3-piperidyl)-5-piperazin-1-yl-isoindoline-1,3-dione trifluoroacetic acid salt (C-2)
[0350] Step 1’. Preparation of tert-Butyl 4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo- isoindolin-5-yl]piperazine-1-carboxylate (2’): A sealed tube was charged with 2-(2,6-dioxo-3- piperidyl)-5-fluoro-isoindoline-1,3-dione 1’ (2.0 g, 7.24 mmol), tert-butyl piperazine-1- carboxylate (1.4 g, 7.52 mmol), DIPEA (3.87 mL, 22.2 mmol) and DMSO (15 mL). The tube was sealed and heated at 90 °C for 72 h. The progress of reaction was followed by HPLC. Upon completion the reaction mixture was directly purified by reversed phase chromatography C18 RediSep Rf Gold with 5–95 % MeOH / 0.1 % formic acid in H2O as eluent. The pure fractions were combined, and concentrated under reduced pressure to afford 2’ (2.86 g, 89 % yield) as a yellow solid.
[0351] LCMS method 1: 99.9% purity at 215 nm, [M–tBu+H]+= 387.2 m / z, [M+Na]+= 466.2 m / z.
[0352] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.42 (s, 9 H), 1.99 - 2.09 (m, 1 H), 2.52 - 2.64 (m, 2 H), 2.82 - 2.95 (m, 1 H), 3.47 (m, 8 H), 5.07 (dd, J = 13.0, 5.4 Hz, 1 H), 7.24 (dd, J = 8.6, 2.2 Hz, 1 H), 7.35 (d, J = 2.0 Hz, 1 H), 7.70 (d, J = 8.3 Hz, 1 H), 11.08 (s, 1 H).
[0353] Step 2’. Preparation of 2-(2,6-dioxo-3-piperidyl)-5-piperazin-1-yl-isoindoline- 1,3-dione trifluoroacetic acid salt (C-2): TFA (10.55 mL, 129.5mmol) was added to a solution of tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]piperazine-1-carboxylate 2’ (2.87 g, 6.48 mmol) in CH2Cl2(30 mL) and the mixture was stirred at room temperature for 2 h. Upon completion by HPLC, the volatiles removed in vacuum and the residue co-evaporatedwith MeCN (3x) and MTBE (2x). The residue was purified by C18 RediSep Rf Gold reverse phase chromatography with 5–20 % MeCN / 0.05 % TFA in H2O as eluent. The pure fractions were concentrated under reduced pressure to afford C-2 (2.52 g, 85% yield) as a yellow solid as a TFA salt.
[0354] LCMS method 1: 99.9% purity at 215 nm, [M+H]+= 343.2 m / z.
[0355] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.95 - 2.10 (m, 1 H), 2.52 - 2.64 (m, 2 H), 2.82 - 2.97 (m, 1 H), 3.18 - 3.31 (m, 4 H), 3.62 - 3.73 (m, 4 H), 5.09 (dd, J = 12.8, 5.5 Hz, 1 H), 7.33 (dd, J = 8.8, 2.2 Hz, 1 H), 7.46 (d, J = 2.0 Hz, 1 H), 7.76 (d, J = 8.3 Hz, 1 H), 11.09 (s, 1 H). Example S2.3-(1-oxo-6-piperazin-1-yl-isoindolin-2-yl)piperidine-2,6-dione (C-7)
[0356] Step 1’’. Preparation of tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-3-oxo-isoindolin- 5-yl]piperazine-1-carboxylate (3’’): To an oven-dried 40 mL vial equipped with a magnetic stir bar under ambient atmosphere, 3-(6-bromo-1-oxo-isoindolin-2-yl)piperidine-2,6-dione 1’’ (500 mg, 1.55 mmol) tert-butyl piperazine-1-carboxylate 2’’ (432mg, 2.32 mmol), DABCO (521 mg, 4.64 mmol) and (Ir(ppy)2(dtbbpy)PF6(14.2 mg, 15.47 umol) were added, followed by DMA (10 mL). Then dibromonickel; 1,2-dimethoxyethane (23.9 mg, 77.4 umol) was added as a solution in DMA (0.5 mL) under N2. The reaction was placed 6 cm in front of one 30 W blue LED at 25 °C for 96 h. LCMS showed the major was product. The combined 8 batches were added into water (200 mL) dropwise, the formed solid was filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna c18250mm x100 mm x 10 um; mobile phase: [water (0.1%TFA)-ACN]; B%: 16%-46%, 25 min) to give tert-butyl 4-[2-(2,6- dioxo-3-piperidyl)-3-oxo-isoindolin-5-yl]piperazine-1-carboxylate 3’’ (2.5 g, 47.1% yield) as a gray solid.
[0357] 1H NMR (400 MHz, DMSO-d6) δ: 10.97 (s, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.30-7.27 (m, 1H), 7.20 (d, J = 2.0 Hz, 1H), 5.13-5.08 (m, 1H), 4.30 (dd, J = 16.8 Hz, 51.6 Hz, 2H), 3.48 (d, J = 4.8 Hz, 4H), 3.16 (d, J = 5.2 Hz, 4H), 2.92-2.68 (m, 1H), 2.62-2.51 (m, 1H), 2.41-2.37 (m, 1H), 2.01-1.99 (m, 1H), 1.45 (s, 9H).
[0358] Step 2’’.3-(1-oxo-6-piperazin-1-yl-isoindolin-2-yl)piperidine-2,6-dione (C-7): tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-3-oxo-isoindolin-5-yl]piperazine-1-carboxylate 3’’ (5 g, 11.7 mmol) was added to HCl (12 N, 15 mL) at 0°C. The reaction mixture was stirred at 20 °C for 1 h. LCMS showed the most was product. The reaction mixture was diluted with MeCN(500 mL) at 0-10 °C, the formed solid was filtered and the cake was dried to give product 12 g. Base on this yield, 5 g of starting material to give 3-(1-oxo-6-piperazin-1-yl-isoindolin-2- yl)piperidine-2,6-dione C-7 (4.3 g, HCl salt, yield 100%) as a gray solid.
[0359] 1H NMR (400 MHz, DMSO-d6) δ: 10.98 (s, 1H), 9.34 (s, 2H), 7.49 (d, J = 5.2 Hz, 1H), 7.33-7.27 (m, 2H), 5.13-5.09 (m, 1H), 4.30 (dd, J = 17.2 Hz, J = 58.2 Hz, 2H), 3.46 (d, J = 4.8 Hz, 4H), 3.23 (d, J = 4.8 Hz, 1H), 2.93-2.78 (m, 1H), 2.62-2.51 (m, 1H), 2.48-2.37 (m, 1H), 2.01-1.98 (m, 1H).
[0360] CBM intermediates prepared using General Procedure CBM-1 are summarized in Table 2. Table 2. CBM Intermediates Prepared via General Procedure CBM-1General Procedure CBM-2
[0361] Step 1: To a solution of amine 1 (1 eq.) and carbonyl 2 (1.2 eq.) in DCM (0.24 M) was added NaBH(OAc)3(1.2 eq.) and AcOH (1 eq.). The mixture was stirred at room temperature. After LCMS showed complete conversion, the reaction mixture was quenched with water, extracted, dried, filtrated and evaporated under reduced pressure. The crude mixture was then purified by normal phase flash chromatography, affording 3.
[0362] Step 2: To 3 (1 eq.) in THF (0.1 M) was added 4 M HCl in dioxane (15 eq.). The reaction mixture was stirred at rt. After 1 h, LCMS showed complete conversion, the solvent was removed under reduced pressure and the residue was co-evaporated with MeCN (3×). The residue was dried under high vacuum to give CBM-2. Example S3.3-[4-(4-piperidylmethylamino)phenyl]piperidine-2,6-dione (C-6)
[0363] Step 1’. Preparation of tert-butyl N-[4-[[1-[4-(2,6-dioxo-3-piperidyl)phenyl]-4 piperidyl]oxymethyl]cyclohexyl]carbamate (3): To a solution of 3-(4- aminophenyl)piperidine-2,6-dione 1’ (250 mg, 1.22 mmol, 1 eq.) and tert-butyl 4- formylpiperidine-1-carboxylate 2’ (310 mg, 1.45 mmol, 1.19 eq.) in DCM (5 mL, 0.24 M) was added NaBH(OAc)3(310 mg, 1.46 mmol, 1.19 eq.) and AcOH (0.07 mL, 1.22 mmol, 1 eq.). The mixture was stirred at room temperature. After an overnight period, LCMS showed complete conversion into compound 3. The reaction mixture was quenched with water, extracted with DCM 3 x, dried over sodium sulfate, filtrated and evaporated under reduced pressure. The crude mixture was then purified by normal phase flash chromatography (40 g column, solid deposit, elution 0% to 100% Hept. / EtOAc over 15 CV, product came out at 100 % EtOAc). Fractions were combined and concentrated, affording 3’ (440 g, 89% yield) as a white solid.
[0364] LCMS method 1: 96.8% purity at 215 nm, [M-Boc+H]+= 302.2.
[0365] 1H NMR (400 MHz, DMSO-d6) δ ppm 0.96 - 1.09 (m, 2 H), 1.39 (s, 9 H), 1.63 - 1.77 (m, 3 H), 1.94 - 2.14 (m, 2 H), 2.40 - 2.48 (m, 1 H), 2.54 - 2.76 (m, 3 H), 2.88 (br t, J = 5.7 Hz, 2 H), 3.62 (dd, J = 10.5, 5.1 Hz, 1 H), 3.94 (br d, J = 11.7 Hz, 2 H), 5.61 (t, J = 5.7 Hz, 1 H), 6.51 (d, J = 8.6 Hz, 2 H), 6.89 (d, J = 8.3 Hz, 2 H), 10.72 (s, 1 H).
[0366] Step 2’. Preparation of 3-[4-(4-piperidylmethylamino)phenyl]piperidine-2,6- dione (C-6): To tert-butyl 4-[[4-(2,6-dioxo-3-piperidyl)anilino]methyl]piperidine-1-carboxylate 3’ (419 mg, 1.04 mmol, 1 eq.) in THF (10.4 mL, 0.1 M) was added 4 M HCl in dioxane (3.91 mL, 15.65 mmol, 15 eq.). The reaction mixture was stirred at rt. After 1 h, LCMS showed complete conversion into compound 4. The solvent was removed under reduced pressure and the residue was co-evaporated with MeCN (3×). The residue was dried under high vacuum to give C-6 (353 mg, quantitative yield) as a white solid.
[0367] LCMS method 1: 97.8 % purity at 215 nm, [M+H]+= 302.2.
[0368] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.39 (q, J = 11.8 Hz, 2 H), 1.86 - 2.04 (m, 4 H), 2.06 - 2.21 (m, 1 H), 2.40 - 2.48 (m, 1 H), 2.59 - 2.71 (m, 1 H), 2.83 (q, J = 11.6 Hz, 2 H), 3.04 (br d, J = 5.6 Hz, 2 H), 3.21 - 3.31 (m, 2 H), 3.68 - 3.80 (m, 1 H), 6.80 - 7.02 (m, 2 H), 7.03 - 7.14 (m, 2 H), 8.59 - 8.77 (m, 1 H), 8.83 - 8.99 (m, 1 H), 10.79 (s, 1 H).
[0369] CBM intermediates prepared using General Procedure CBM-2 are summarized in Table 3.Table 3. CBM Intermediates Prepared via General Procedure CBM-2.General Procedure CBM-3wherein X is N or CR13as defined in Formula (I’) or (I).
[0370] Step 1: To a flask was added amine 1 (1 eq.), carboxylic acid 2 (1 eq.), and DIPEA (5 eq.) in DMF (0.12 M) under N2. The resulting solution was stirred at room temperature. Then, PyAOP (1.3 eq.) or other coupling reagent was added in one portion. The reaction was stirred at room temperature. Upon completion, the reaction mixture was directly loaded for reverse phase purification and clean factions were combined and concentrated to give product 3.
[0371] Step 2: To a solution of amide 3 (1 eq.) in DCM (0.13 M) was added TFA (15 eq.) or other deprotection reagent. The reaction mixture was stirred at room temperature. Upon completion, the reaction mixture was concentrated under reduced pressure and the residue was co-evaporated with THF and toluene to give CBM-3. Example S4.4-amino-N-[4-(2,6-dioxo-3-piperidyl)phenyl]benzamide (C-10) B HN
[0372] Step 1’. Preparation of tert-butyl N-[4-[[4-(2,6-dioxo-3- piperidyl)phenyl]carbamoyl]phenyl]carbamate (3’): To a round bottom flask was added 3- (4-aminophenyl)piperidine-2,6-dione 1’ (300 mg, 1.47 mmol, 1 eq.), 4-(tert-butoxycarbonylamino)benzoic acid 2’ (348.5 mg, 1.47 mmol, 1 eq.), and DIPEA (1.28 mL, 7.34 mmol, 5 eq.) in DMF (12.2 mL, 0.12 M) under N2. The resulting solution was stirred at room temperature for 10 minutes. Then, PyAOP (995.65 mg, 1.91 mmol, 1.3 eq.) was added in one portion. The reaction was stirred at room temperature. After 16 h, LCMS showed complete conversion into compound 2. The reaction mixture was directly loaded for reverse phase FC purification (50 g C18 column, liquid deposit (reaction mixture), 5% MeCN / 0.1% HCOOH over 3 CV, then 5 to 40% MeCN / 0.1% HCOOH over 2 CV, then 40 to 100% MeCN / 0.1% HCOOH over 15 CV, product came out at 60 % MeCN). Fractions were combined and concentrated to give 3’ (267 mg, 43 % yield) as a tan solid.
[0373] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+= 424.2.
[0374] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.49 (s, 9 H), 2.00 - 2.10 (m, 1 H), 2.13 - 2.26 (m, 1 H), 2.45 - 2.48 (m, 1 H), 2.61 - 2.73 (m, 1 H), 3.82 (dd, J = 11.2, 4.6 Hz, 1 H), 7.19 (d, J = 8.6 Hz, 2 H), 7.58 (d, J = 8.8 Hz, 2 H), 7.70 (d, J = 8.6 Hz, 2 H), 7.89 (d, J = 8.8 Hz, 2 H), 9.68 (s, 1 H), 10.07 (s, 1 H), 10.82 (s, 1 H).
[0375] Step 2’. Preparation of 4-amino-N-[4-(2,6-dioxo-3-piperidyl)phenyl]benzamide (C-10): To a solution of tert-butyl N-[4-[[4-(2,6-dioxo-3- piperidyl)phenyl]carbamoyl]phenyl]carbamate 3’ (267 mg, 0.63 mmol, 1 eq.) in DCM (5 mL, 0.13 M) was added TFA (1.03 mL, 12.61 mmol, 15 eq.). The reaction mixture was stirred at room temperature. After 30 minutes, LCMS showed full conversion into compound 4. The reaction mixture was concentrated under reduced pressure and the residue was co-evaporated with THF (2 x) and toluene (2 x) to give C-10 (207 mg, 69 % yield) as a tan solid as a trifluoroacetic acid salt.
[0376] LCMS method 1: 92.3 % purity at 215 nm, [M-CF3COOH+H]+= 324.2.
[0377] 1H NMR (400 MHz, DMSO-d6) δ ppm 2.00 - 2.06 (m, 1 H), 2.13 - 2.24 (m, 1 H), 2.44 - 2.49 (m, 1 H), 2.61 - 2.72 (m, 1 H), 3.81 (dd, J = 11.1, 5.0 Hz, 1 H), 6.72 (d, J = 8.6 Hz, 2 H), 7.16 (d, J = 8.3 Hz, 2 H), 7.69 (d, J = 8.6 Hz, 2 H), 7.76 (d, J = 8.8 Hz, 2 H), 9.83 (s, 1 H), 10.81 (s, 1 H). Three protons were missing. Example S5. N-[4-(2,4-dioxohexahydropyrimidin-1-yl)phenyl]piperidine-4-carboxamide h
[0378] Step 1’’. Preparation of tert-butyl 4-[[4-(2,4-dioxohexahydropyrimidin-1- yl)phenyl]carbamoyl]piperidine-1-carboxylate (3’’): 1-(4- aminophenyl)hexahydropyrimidine-2,4-dione 1’’ (191 mg, 0.931 mmol, 1.1 equiv) and 1-tert- Butoxycarbonylpiperidine-4-carboxylic acid 2’’ (194 mg, 0.846 mmol, 1.0 equiv) were dissolved in DMF (4.7 mL), then DIPEA (1.47 mL, 8.46 mmol, 10.0 equiv) and HATU (418 mg, 1.10 mmol, 1.3 equiv) were added in sequence. The reaction mixture was stirred for 2 hours at room temperature. The reaction mixture was injected directly in a column for reversed-phase flash chromatography purification (MeCN in 0.1% HCOOH(aq), 5% (3 CV)→100%, 100 g RediSep Rf Gold® C18Aq, 10 CV, λ = 214-254 nm). Evaporation of the fractions yielded 3’’ (211 mg, 0.507 mmol, 60% yield) as a yellow solid.
[0379] LCMS method 1: 99.9 % purity at 215 nm, [M-t-Bu+H]+= 317.2.
[0380] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.39 - 1.42 (m, 9 H), 1.42 - 1.54 (m, 2 H), 1.77 (br d, J = 11.5 Hz, 2 H), 2.44 - 2.49 (m, 1 H), 2.69 (t, J = 6.7 Hz, 2 H), 2.72 - 2.94 (m, 2 H), 3.73 (t, J = 6.7 Hz, 2 H), 3.99 (br d, J = 11.7 Hz, 2 H), 7.24 (d, J = 8.9 Hz, 2 H), 7.59 (d, J = 8.8 Hz, 2 H), 9.96 (s, 1 H), 10.32 (s, 1 H).
[0381] Step 2’’. Preparation of N-[4-(2,4-dioxohexahydropyrimidin-1- yl)phenyl]piperidine-4-carboxamide hydrochloride (C-16): HC14.0 M in 1,4-dioxane (1.5 mL, 6.00 mmol, 10.0 equiv) was added to tert-butyl 4-[[4-(2,4-dioxohexahydropyrimidin-1- yl)phenyl]carbamoyl]piperidine-1-carboxylate 3’’ (250 mg, 0.600 mmol, 1.0 equiv) and the mixture was stirred for one hour at room temperature. The solvent was evaporated under reduced pressure and the residue was then dried under high vacuum to remove all the volatiles. The crude product C-16 (212 mg, 0.600 mmol, quantitative yield) was obtained as a white solid that was used as-is in next step.
[0382] LCMS method 1: 99.9 % purity at 215 nm, [M-HCl+H]+= 317.2.
[0383] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.72 - 1.89 (m, 2 H), 1.91 - 2.03 (m, 2 H), 2.59 - 2.66 (m, 1 H), 2.69 (t, J = 6.7 Hz, 2 H), 2.84 - 3.01 (m, 2 H), 3.30 - 3.33 (m, 2 H), 3.74 (t, J = 6.7 Hz, 2 H), 7.25 (d, J = 8.8 Hz, 2 H), 7.59 (d, J = 8.8 Hz, 2 H), 8.41 (br s, 1 H), 8.70 (br s, 1 H), 10.11 (s, 1 H), 10.33 (s, 1 H).
[0384] CBM intermediates prepared using General Procedure CBM-3 are summarized in Table 4.Table 4. CBM Intermediates Prepared via General Procedure CBM-3General Procedure CBM-4 (CBM-4A and CBM-4B) General Procedure CBM-4A Iwherein R7and R10are as defined in Formula (I’) or (I).
[0385] LCMS Method 1. Column: Kinetex XB - C18, 75 x 3.0 mm, 2.6 μm. Temperature: 45 °C, Flow: 1.0 mL / min, run time: 5.0 min. Mobile Phase Conditions: Mobile Phase-A: 5.0 mm Ammonium formate pH 3.3:CH3CN (98:02), Mobile Phase-B: CH3CN: Buffer (98:02),Gradient: Initial 98% Mobile Phase A and 2% Mobile Phase B linear gradient to 100% Mobile Phase B for 4.1 min then hold for 0.5 minute. MSD positive.
[0386] LCMS Method 2. Column: Kinetex XB - C18, 75 x 3.0 mm, 2.6 μm. Temperature: 45 °C, Flow: 1.0 mL / min, run time: 5.0 min. Mobile Phase Conditions: Mobile Phase-A: 5.0 mm Ammonium formate pH 3.3:CH3CN (98:02), Mobile Phase-B: CH3CN: Buffer (98:02), Gradient: Initial 80% Mobile Phase A and 20% Mobile Phase B linear gradient to 100% Mobile Phase B for 4.0 min then hold for 0.5 minute. MSD positive.
[0387] LCMS Method 3. Column: Kinetex XB - C18, 50 x 4.6 mm, 5.0 μm. Temperature: 45 °C, Flow: 1.5 mL / min, run time: 6.0 min. Mobile Phase Conditions: Mobile Phase-A: 0.1% TFA in H2O, Mobile Phase-B: 0.1% TFA in ACN, Gradient: Initial 95% Mobile Phase A and 5% Mobile Phase B linear gradient to 95% Mobile Phase B for 2.5 min then hold for 1.5 minute. MSD positive.
[0388] Step A. Preparation of 2,6-Dibenzyloxy-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyridine BIn a sealed tube 2,6-dibenzyloxy-3-bromo-pyridine A (1.0 g, 2.701 mmol, 1.0 eq.), bis(pinacolato)diboron (1.0 g, 4.051 mmol, 1.5 eq.), KOAc (795.2 mg, 8.103 mmol, 3.0 eq.) and Pd(dppf)Cl2·DCM (220.57 mg, 0.270 mmol, 0.1 eq.) were solubilized in 1,4-dioxane (4.0 mL, 0.6 M) and nitrogen was bubbled for 10 minutes. The tube sealed and heated at 90 °C for overnight. The reaction mixture was cooled down to room temperature. The reaction was filtered over celite, washed with MeTHF and the filtrate was evaporated. The residue was purified by normal phase flash chromatography (Isco, 24 g, elution was done from 0 % EtOAc in heptane to 10 % EtOAc over 18 CVs) to give 900 mg of B contaminated by bis(pinacolato). A second purification by normal phases flash chromatography was performed (80 g SNAP column; elution: 0 % EtOAc in heptane for 2 CVs, then 0 to 4.5 % EtOAc in heptane over 15 CVs, product exited at 4.1 % EtOAc) to give 2,6-dibenzyloxy-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyridine B (210 mg, 19 % yield) as a white solid.
[0389] LCMS method 1: retention time: 1.915 min, [M-Pin+H]+= 336.2 and 2.290 min, [M+H]+= 418.2; 99.9 % purity at 215 nm.
[0390] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.28 (s, 12 H), 5.38 (d, J = 5.9 Hz, 4 H), 6.42 (d, J = 7.8 Hz, 1 H), 7.24 - 7.40 (m, 6 H), 7.40 - 7.44 (m, 2 H), 7.53 (d, J = 7.1 Hz, 2 H), 7.84 (d, J = 7.8 Hz, 1 H).
[0391] Step 1: To a flame-dried sealed tube were added Cs2CO3(2.0 eq.), heterocyclie 2 (1.1 eq.), bromo-iodo 1 (1.0 eq.), XantPhos (0.2 eq.) and Pd2(dba)3(0.1 eq.) were solubilized in dry 1,4-dioxane (0.2 M). The mixture was degassed by sparging with nitrogen for 10 minutes. The tube was sealed and the mixture was stirred at 110 °C. Upon complete conversion of the starting materials, the reaction mixture was cooled down to room temperature. Ethyl acetate and water were added, phases were separated, the aqueous phase was extracted 3 times with ethyl acetate, then the combined organic phases were washed once with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase flash chromatography before fractions were combined and concentrated to give bromide product 3.
[0392] Step 2: A sealed tube was charged with K3PO4(2.3 eq.), bromide 3 (1.0 eq.), 2,6- dibenzyloxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine B (1.2 eq.) and Pd(PPh3)4 (0.1 eq.). The mixture was degassed by sparging with nitrogen for 10 minutes. A solution of 1,4- dioxane (0.08 M) and water (0.08 M) was added, then the mixture was degassed by sparging with nitrogen for 10 minutes. The vial was sealed and the reaction was heated overnight at 90 °C. Upon complete conversion of the starting materials, the mixture was cooled down to room temperature, the reaction was filtered over celite, washed with EtOAc and the filtrate was evaporated. The residue was purified by normal phase flash chromatography before fractions were combined and concentrated to give pyridine 5.
[0393] Step 3: A solution of pyridine 5 (1.0 eq.) in THF / EtOH (0.05 M) was degassed for 15 minutes, then Pd(OH)2(0.2 eq.) was degassed by sparging with nitrogen for 5 minutes. Hydrogen was then bubbled in the reaction mixture for 5 minutes and the mixture was stirred in a hot water bath at 50 °C under a hydrogen atmosphere. The mixture was cooled down to room temperature. Ethyl acetate and water were added and phases were separated, the aqueous phase was extracted 3 times with ethyl acetate, then the combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase flash chromatography before fractions were combined and concentrated to give glutarimide 6.
[0394] Step 4: To a solution of glutarimide 6 (1.0 eq.) was added HC14 M in dioxane (54 eq.). The reaction was stirred at room temperature. After an overnight period, LCMS showed complete conversion into product. The reaction mixture was concentrated under reduced pressure and co-evaporated 3 times with acetonitrile to give product CBM-4A that was used as is directly for the next step.General Procedure CBM-4Bwherein R7and R10are as defined in Formula (I’) or (I).
[0395] Step 1: A solution of bromide 1 (1.20 g, 6.09 mmol, 1 eq.) and tert-butyl prop-2- enoate 2 (1.05 eq.) in anhydrous THF (0.5 M) was cooled down to 0 °C under nitrogen. tBuOK (0.1 eq.) was added and the reaction was stirred at 0 °C and allowed to slowly warm to room temperature. Upon completion, the reaction mixture was filtered over a pad of Celite, rinsed with EtOAc and the filtrate was concentrated to dryness. The residue was purified by reverse phase flash chromatography and fractions were combined and partially concentrated to dryness. The suspension was then partitioned between saturated aqueous NaHCO3and EtOAc. The layers were separated and the aqueous one was back extracted with EtOAc. The combined organics were dried over Na2SO4, filtered and concentrated to dryness to give 3.
[0396] Step 2: To a sealed tube were added bromide 3 (1 eq.), heterocycle 4 (1.2 eq.), Cs2CO3(2 eq.), XPhos (0.2 eq.) and 1,4-dioxane (0.1 M). The reaction mixture was sparged with nitrogen for 10 min and Pd2(dba)3.CHCl3(0.1 eq.) was quickly added. The reaction mixture was sparged with nitrogen for a further 10 min and it was then stirred at 90 °C. Upon completion, the reaction mixture was filtered over a pad of Celite, rinsed with EtOAc and the filtrate was concentrated to dryness. The residue was purified by reverse phase flash chromatography and rractions were combined and partially concentrated to dryness. The suspension was then partitioned between saturated aqueous NaHCO3and EtOAc. The layers were separated and the aqueous one was back extracted with EtOAc. The combined organics were dried over Na2SO4, filtered and concentrated to dryness to give 5.
[0397] Step 3: To a sealed tube were added 5 (1 eq.), acetic acid (0.2 M) and concentrated sulfuric acid (4 eq.). The reaction mixture was stirred at 118 °C. Upon completion, volatiles were removed under reduce pressure and the residue was purified by reverse phase flashchromatography. Fractions were combined and concentrated to give CBM-4B that was used as- is for the next step. Example S6.3-(4-(piperazin-1-yl)phenyl)piperidine-2,6-dione (C-12)
[0398] Step 1’. Preparation of (2,6-bis(benzyloxy)pyridin-3-yl)boronic acid 2’: To a stirred solution of 2,6-bis(benzyloxy)-3-bromopyridine 1’ (30.0 g, 81 mmol, 1.0 eq.) in THF (300 mL) at -78 °C was added n-BuLi (48.6 mL, 122 mmol, 1.5 eq.) and stirred at the same temperature for 30 min. Then, trimethyl borate (10.86 mL, 97 mmol, 1.2 eq.) was added dropwise and stirring was continued at the same temperature for another 30 min. The reaction was quenched with sat. aq. ammonium chloride (300 mL) and acidified using 1.5 N HCl solution to maintain the pH 3-4. The reaction mixture was extracted with ethyl acetate (3 X 500 mL), dried over sodium sulphate, concentrated under reduced pressure to give the crude product. The crude product was triturated with petroleum ether (1000 mL) to afford (2,6- bis(benzyloxy)pyridin-3-yl)boronic acid 2’ (16 g, 50.1% yield) as an off-white solid.
[0399] LCMS method 1: retention time: 3.003 min, 85.56% purity at 220 nm, [M+H]+= 336.0.
[0400] 1H NMR (400 MHz, DMSO-d6): δ ppm 5.35 (s, 2H), 5.42 (s, 2H), 6.45 (d, J = 8.0 Hz, 1H), 7.30 - 7.47 (m, 10H), 7.60 (s, 2H), 7.90 (d, J = 7.6 Hz, 1H)
[0401] Step 2’. Preparation of tert-butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3- yl)phenyl)piperazine-1-carboxylate 4’: To a stirred solution of tert-butyl 4-(4- bromophenyl)piperazine-1-carboxylate 3’ (20 g, 58.6 mmol, 1.0 eq.) in 200 mL of 1,4- dioxane:water (7:3) was added (2,6-bis(benzyloxy)pyridin-3-yl)boronic acid 2΄ (23.57 g, 70.3 mmol, 1.2 eq.) followed by potassium phosphate dibasic (20.42 g, 117 mmol, 2.0 eq.). The resulting reaction mixture was degassed with N2for 15 min. and PdCl2(dppf).CH2Cl2(4.79 g, 5.86 mmol, 0.1 eq.) was added into the reaction mixture. Then, the reaction mixture was heatedat 85 °C in a sealed tube for 3 h. The reaction mixture was cooled to RT, poured into ice-cold water, and extracted with ethyl acetate (2 x 25 mL). The combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using silica gel (230-400 mesh) with 10% ethyl acetate in pet ether to give tert-butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3- yl)phenyl)piperazine-1-carboxylate 4’ (30 g, 85% yield) as an off-white solid.
[0402] LCMS method 2: retention time: 2.326 min, 92.15% purity at 220 nm, [M+H]+= 552.2.
[0403] Step 3’. Preparation of tert-butyl 4-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperazine-1-carboxylate 5’: To a stirred solution of tert-butyl 4-(4-(2,6- bis(benzyloxy)pyridin-3-yl)phenyl)piperazine-1-carboxylate 4’ (47 g, 85 mmol, 1.0 eq.) in ethyl acetate (700 mL) was added Pd(OH)2(5.98 g, 42.6 mmol, 0.5 eq.). The reaction mixture was stirred at RT for 12 h under H2atmosphere. The reaction mixture was filtered through celite bed and the filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperazine-1-carboxylate 5’ (24 g, 71.7% yield) as an off-white solid.
[0404] LCMS method 3: retention time: 1.781 min, 95.26% purity at 220 nm, [M+H]+= 374.3.
[0405] Step 4’. Preparation of 3-(4-(piperazin-1-yl)phenyl)piperidine-2,6-dione C-12. To a stirred solution of tert-butyl 4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazine-1-carboxylate 5 (2.0g, 4.17 mmol, 1 eq.) in DCM (20 mL, 0.208 M) at 0 °C was added dry HCl in 1,4-dioxane (10.42 mL, 41.7 mmol, 4.0 M in dioxane). The reaction mixture was warmed up to RT and stirred for 2 h. It was concentrated under reduced pressure to get crude 3-(4-(piperazin-1- yl)phenyl)piperidine-2,6-dione, 2HCl C -12 (1.9 g) as a brown colour solid. It was used for the next step without further purification.
[0406] LCMS method 4: retention time: 0.307 min, [M+H]+= 274.2. Example S7.3-(2-methoxy-4-piperazin-4-ium-1-yl-phenyl)piperidine-2,6-dione hydrochloride (C-34)
[0407] Step 1’. Preparation of tert-butyl 4-(4-bromo-3-methoxy-phenyl)piperazine-1- carboxylate (3’): To a flame-dried sealed tube were added Cs2CO3(2.08 g, 6.39 mmol, 2 eq.), tert-butyl piperazine-1-carboxylate 2’ (654.7 mg, 3.52 mmol, 1.1 eq.), 1-bromo-4-iodo-2- methoxy-benzene 1’ (1 g, 3.2 mmol, 1 eq.), XantPhos (369.81 mg, 0.64 mmol, 0.2 eq.) and Pd2(dba)3(292.63 mg, 0.32 mmol, 0.1 eq.) were solubilized in dry 1,4-dioxane (16 mL, 0.2 M). The mixture was degassed by sparging with nitrogen for 10 minutes. The tube was sealed and the mixture was stirred at 110 °C. After an overnight period, LCMS showed complete conversion of the starting materials into compound 3. The reaction mixture was cooled down to room temperature. Ethyl acetate and water were added, phases were separated, the aqueous phase was extracted 3 times with ethyl acetate, then the combined organic phases were washed once with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase flash chromatography (80 g silica column, elution: 0 to 10 % MeOH / DCM over 10 CV, then 10 % MeOH until the product came out). Fractions were combined and concentrated to give 3’ (742 mg, 62 % yield) as a light-yellow solid.
[0408] LCMS method 1: 98.5 % purity at 215 nm, [M+H]+= 373.2.
[0409] 1H NMR (400 MHz, chloroform-d) δ ppm 1.49 (s, 9 H), 3.13 (t, J = 5.0 Hz, 4 H), 3.59 (t, J = 5.0 Hz, 4 H), 3.88 (s, 3 H), 6.41 (dd, J = 8.7, 2.6 Hz, 1 H), 6.45 - 6.51 (m, 1 H), 7.38 (d, J = 8.6 Hz, 1 H).
[0410] Step 2’. Preparation of tert-butyl 4-[4-(2,6-dibenzyloxy-3-pyridyl)-3-methoxy- phenyl]piperazine-1-carboxylate (5’): A sealed tube was charged with K3PO4(194.91 mg, 0.92 mmol, 2.27 eq.), tert-butyl 4-(4-bromo-3-methoxy-phenyl)piperazine-1-carboxylate 3’ (150 mg, 0.40 mmol, 1 eq.), 2,6-dibenzyloxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine B (202.32 mg, 0.48 mmol, 1.2 eq.) and Pd(PPh3)4 (46.69 mg, 0.04 mmol, 0.1 eq.). The mixture was degassed by sparging with nitrogen for 10 minutes. A solution of 1,4-dioxane (4.04 mL, 0.08 M) and water (1.01 mL, 0.08 M) was added, then the mixture was degassed by sparging with nitrogen for 10 minutes. The vial was sealed and the reaction was heated overnight at 90 °C. After an overnight period, LCMS showed complete conversion of the starting materials intocompound 5’. The mixture was cooled down to room temperature, the reaction was filtered over celite, washed with EtOAc and the filtrate was evaporated. The residue was purified by normal phase flash chromatography (40 g silica column, elution: 5 to 50 % EtOAc / Heptane over 10 CV, product exited at 25 % EtOAc). Fractions were combined and concentrated to give 5’ (195.9 mg, 77 % yield) as a yellow solid.
[0411] LCMS method 1: 92.0 % purity at 215 nm, [M+H]+= 582.2.
[0412] 1H NMR (400 MHz, chloroform-d) δ ppm 1.50 (s, 9 H), 3.19 (t, J = 5.0 Hz, 4 H), 3.61 (t, J = 5.2 Hz, 4 H), 3.72 (s, 3 H), 5.33 (s, 2 H), 5.39 (s, 2 H), 6.41 - 6.45 (m, 1 H), 6.51 - 6.57 (m, 2 H), 7.17 - 7.21 (m, 1 H), 7.22 - 7.26 (m, 1 H), 7.28 - 7.39 (m, 7 H), 7.41 - 7.45 (m, 2 H), 7.49 - 7.53 (m, 1 H).
[0413] Step 3’. Preparation of tert-butyl 4-[4-(2,6-dioxo-3-piperidyl)-3-methoxy- phenyl]piperazine-1-carboxylate (6’): A solution of tert-butyl 4-[4-(2,6-dibenzyloxy-3- pyridyl)-3-methoxy-phenyl]piperazine-1-carboxylate 5’ (140 mg, 0.24 mmol, 1 eq.) in THF / EtOH (0.86 mL:0.86 mL, 0.05 M) was degassed for 15 minutes, then Pd(OH)2(33.8 mg, 0.05 mmol, 0.2 eq.) was degassed by sparging with nitrogen for 5 minutes. Hydrogen was then bubbled in the reaction mixture for 5 minutes and the mixture was stirred in a hot water bath at 50 °C under a hydrogen atmosphere for 4 hours. The mixture was cooled down to room temperature. Ethyl acetate and water were added and phases were separated, the aqueous phase was extracted 3 times with ethyl acetate, then the combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase flash chromatography (40 g silica column, elution: 0 to 100 % MeOH / DCM over 30 CV). Fractions were combined and concentrated to give 6’ (30 mg, 23 % yield) as a light- blue solid.
[0414] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+= 404.2.
[0415] 1H NMR (400 MHz, chloroform-d) δ ppm 1.49 (s, 9 H), 2.03 - 2.15 (m, 1 H), 2.26 (s, 1 H), 2.57 - 2.67 (m, 1 H), 2.69 - 2.78 (m, 1 H), 3.14 (t, J = 5.2 Hz, 4 H), 3.58 (t, J = 5.2 Hz, 4 H), 3.80 (s, 3 H), 6.46 - 6.52 (m, 2 H), 6.97 - 7.04 (m, 1 H), 7.86 (s, 1 H).
[0416] Step 4’. Preparation of 3-(2-methoxy-4-piperazin-4-ium-1-yl-phenyl)piperidine- 2,6-dione hydrochloride (C-34): To a solution of tert-butyl 4-[4-(2,6-dioxo-3-piperidyl)-3- methoxy-phenyl]piperazine-1-carboxylate 6’ (30 mg, 0.07 mmol, 1 eq.) was added HCl 4 M in dioxane (1 mL, 4 mmol, 54 eq.). The reaction was stirred at room temperature. After an overnight period, LCMS showed complete conversion into product. The reaction mixture was concentrated under reduced pressure and co-evaporated 3 times with acetonitrile to give C-34 (35 mg, quantitative yield) as a grey solid that was used as is directly for the next step andassumed that it was in a hydrochloride salt form.
[0417] LCMS method 1: 99.9 % purity at 215 nm, [M-HCl+H]+= 304.4. Example S8.3-(2-methoxy-4-piperazin-4-ium-1-yl-phenyl)piperidine-2,6-dione hydr
[0418] Step 1’. Preparation of Tert-butyl 4-[4-[4-[tert-butoxycarbonyl(methyl)amino]- 1-piperidyl]phenyl]-4-cyano-butanoate (3’): In a flame-dried sealed tube, under nitrogen atmosphere were introduced Cs2CO3(1.01 g, 3.084 mmol, 2.0 eq.), tert-butyl N-methyl-N-(4- piperidyl)carbamate 2’ (396.6 mg, 1.850 mmol, 1.2 eq.), tert-butyl 4-(4-bromophenyl)-4-cyano- butanoate 1’ (500.0 mg, 1.542 mmol, 1.0 eq.), XPhos (110.28 mg, 0.231 mmol, 0.15 eq.), Pd2(dba)3(141.22 mg, 0.154 mmol, 0.1 eq.) and dry 1,4-Dioxane (7.7 mL, 0.2 M). The mixture was degassed by sparging with nitrogen for 10 minutes. The tube was sealed and the mixture was stirred at 90 °C for 16 hours. The reaction was filtered over celite, washed with EtOAc and the filtrate was evaporated. The residue was purified by normal phase flash chromatography (80 g silica column, elution: 0 to 50 % Heptane / EtOAc over 15 CV, product exited at 45 % EtOAc, was the only one who absorbs at 254 nm). Fractions were combined and concentrated to give tert-butyl 4-[4-[4-[tert-butoxycarbonyl(methyl)amino]-1-piperidyl]phenyl]-4-cyano-butanoate 3’ (660 mg, 83 % yield) as an orange oil.
[0419] LCMS method 1: retention time: 2.061 min, 88.3 % purity at 215 nm, [M+H]+= 458.2.
[0420] 1H NMR (400 MHz, DMSO-d6) δ ppm 0.79 - 0.88 (m, 1 H), 1.21 - 1.28 (m, 1 H), 1.36 - 1.41 (m, 18 H), 1.60 (br d, J = 9.5 Hz, 2 H), 1.68 - 1.79 (m, 2 H), 1.92 - 2.09 (m, 2 H), 2.21 - 2.29 (m, 2 H), 2.67 (s, 3 H), 2.70 - 2.75 (m, 1 H), 3.79 (br d, J = 12.7 Hz, 2 H), 4.07 (t, J = 7.5 Hz, 1 H), 6.97 (d, J = 8.6 Hz, 2 H), 7.18 (d, J = 8.8 Hz, 2 H).
[0421] Step 2’. Preparation of 3-[4-[4-(Methylamino)-1-piperidyl]phenyl]piperidine- 2,6-dione sulfuric acid (C-29): To an aqueous mixture of tert-butyl 4-[4-[4-[tert- butoxycarbonyl(methyl)amino]-1-piperidyl]phenyl]-4-cyano-butanoate 3’ (866. mg, 1.892 mmol) in acetic acid (9.5 mL, 0.2 M) was added concentrated H2SO4(0.3 mL, 5.677 mmol, 3.0 eq.). The reaction mixture was stirred vigorously at 120 °C for 1 hour, then concentrated. The crude material was dissolved in a minimal amount of water and purified by reverse-phase chromatography column using a 40 g C18 column (elution: 0% MeCN / 0.1 % HCOOH over 4CV, then 0% to 10 % MeCN / 0.1 % HCOOH over 15 CV, product exited at 5 % MeCN). The pure fractions were combined and concentrated to give 3-[4-[4-(methylamino)-1- piperidyl]phenyl]piperidine-2,6-dione sulfuric acid C-29 (265 mg, 34 % yield) as a yellow oil.
[0422] LCMS method 1: retention time: 0.588 min, 97.7 % purity at 215 nm, [M+H]+= 302.2.
[0423] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.49 - 1.62 (m, 2 H), 1.96 - 2.05 (m, 2 H), 2.10 - 2.18 (m, 1 H), 2.42 - 2.48 (m, 1 H), 2.56 (s, 3 H), 2.59 - 2.75 (m, 3 H), 3.10 (br t, J = 11.4 Hz, 1 H), 3.67 - 3.83 (m, 3 H), 4.76 (br d, J = 15.9 Hz, 1 H), 6.91 (br d, J = 8.6 Hz, 2 H), 7.05 (br d, J = 8.3 Hz, 2 H), 8.24 (s, 1 H), 10.77 (br s, 1 H). Example S9. Acetic acid; 3-(5-piperazin-1-yl-2-pyridyl)piperidine-2,6-dione (C-37)
[0424] Step 1’. Preparation of tert-butyl 4-(5-bromo-2-pyridyl)-4-cyano-butanoate (3’): A solution of 2-(5-bromo-2-pyridyl)acetonitrile 1’ (1.20 g, 6.09 mmol, 1 eq.) and tert-butyl prop-2-enoate 2’ (820 mg, 6.39 mmol, 1.05 eq.) in anhydrous THF (12 mL) was cooled down to 0 °C under nitrogen. tBuOK (74 mg, 0.61 mmol, 0.1 eq.) was added and the reaction was stirred at 0 °C (keeping the ice bath slowly warming up to room temperature). After 16 h, LCMS showed conversion not complete. The reaction mixture was filtered over a pad of Celite, rinsed with EtOAc and the filtrate was concentrated to dryness. The residue was purified by reverse phase flash chromatography (100 g C18 column, liquid deposit (DMSO), elution: 5 % MeCN / 0.1 % HCOOH over 3 CV, then 5 to 40 % MeCN / 0.1 % HCOOH over 2 CV, then 40 to 100 % MeCN / 0.1 % HCOOH over 14 CV). Fractions were combined and partially concentrated to dryness. The suspension was then partitioned between saturated aqueous NaHCO3and EtOAc. The layers were separated and the aqueous one was back extracted with EtOAc. The combined organics were dried over Na2SO4, filtered and concentrated to dryness to give 3’ (466 mg, 24 % yield) as a brown oil.
[0425] LCMS method 1: 96.6 % purity at 215 nm, [M-tBu+H]+= 269.0.
[0426] 1H NMR (400 MHz, CDCl3) δ ppm 1.46 (s, 9 H), 2.20 - 2.37 (m, 2 H), 2.38 - 2.54 (m, 2 H), 4.13 (dd, J = 8.4, 6.2 Hz, 1 H), 7.34 (d, J = 8.3 Hz, 1 H), 7.87 (dd, J = 8.3, 2.4 Hz, 1 H), 8.67 (d, J = 2.0 Hz, 1 H).
[0427] Step 2’. Preparation of tert-butyl 4-[6-(4-tert-butoxy-1-cyano-4-oxo-butyl)-3- pyridyl]piperazine-1-carboxylate (5’): To a sealed tube were added tert-butyl 4-(5-bromo-2- pyridyl)-4-cyano-butanoate 3’ (336 mg, 1.03 mmol, 1 eq.), tert-butyl piperazine-1-carboxylate 4’ (229 mg, 1.23 mmol, 1.2 eq.), Cs2CO3(664 mg, 2.04 mmol, 2 eq.), XPhos (102 mg, 0.21 mmol, 0.2 eq.) and 1,4-dioxane (10 mL). The reaction mixture was sparged with nitrogen for 10 min and Pd2(dba)3.CHCl3(98 mg, 0.09 mmol, 0.1 eq.) was quickly added. The reaction mixture was sparged with nitrogen for a further 10 min and it was then stirred at 90 °C. After 14.5 h, LCMS showed full conversion. The reaction mixture was filtered over a pad of Celite, rinsed with EtOAc and the filtrate was concentrated to dryness. The residue was purified by reverse phase flash chromatography (100 g C18 column, liquid deposit (DMSO), elution: 5 % MeCN / 0.1 % HCOOH over 3 CV, then 5 to 30 % MeCN / 0.1 % HCOOH over 2 CV, then 30 to 80 % MeCN / 0.1 % HCOOH over 17 CV). Fractions were combined and partially concentrated to dryness. The suspension was then partitioned between saturated aqueous NaHCO3and EtOAc. The layers were separated and the aqueous one was back extracted with EtOAc. The combined organics were dried over Na2SO4, filtered and concentrated to dryness to give 5’ (285 mg, 60 % yield) as an orange oil.
[0428] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+= 431.3.
[0429] 1H NMR (400 MHz, CDCl3) δ ppm 1.45 (s, 9 H), 1.49 (s, 9 H), 2.22 - 2.34 (m, 2 H), 2.36 - 2.49 (m, 2 H), 3.16 - 3.22 (m, 4 H), 3.58 - 3.63 (m, 4 H), 4.05 (t, J = 7.3 Hz, 1 H), 7.16 - 7.22 (m, 1 H), 7.24 - 7.30 (m, 1 H), 8.27 (d, J = 2.7 Hz, 1 H).
[0430] Step 3’. Preparation of acetic acid;3-(5-piperazin-1-yl-2-pyridyl)piperidine-2,6- dione (C-37): To a sealed tube were added tert-butyl 4-[6-(4-tert-butoxy-1-cyano-4-oxo-butyl)- 3-pyridyl]piperazine-1-carboxylate 5’ (280 mg, 0.65 mmol, 1 eq.), acetic acid (3.3 mL) and concentrated sulfuric acid (255 mg, 2.60 mmol, 4 eq.). The reaction mixture was stirred at 118 °C. After 70 min, LCMS showed full conversion. Volatiles were removed under reduce pressure and the residue was purified by reverse phase flash chromatography (20 g C18 Aq column, liquid deposit (H2O), elution: 0 % MeCN / 0.1 % HCOOH over 8 CV). Fractions were combined and concentrated to give C-37 (300 mg, 98 % yield) as a yellow solid, which was used as-is for the next step.
[0431] LCMS method 1: 85.5 % purity at 215 nm, [M-2CH3COOH+H]+= 275.1.
[0432] CBM intermediates prepared using General Procedure CBM-4 are summarized inTable 5. Table 5. CBM Intermediates Prepared via General Procedure CBM-4 C C C C C C C C CC C C CCC C C CC C C C C C C C C CC C C C C C C C C CC C C C C C C CCGeneral Procedure CBM-5 Example S10.3-[4-[2-(4-Piperidyl)ethynyl]phenyl]piperidine-2,6-dione hydrochloride (C-
[0433] Step 1. Preparation of Tert-butyl 4-[2-[4-(2,6-dioxo-3- piperidyl)phenyl]ethynyl]piperidine-1-carboxylate (3): A solution of 3-(4- bromophenyl)piperidine-2,6-dione 1 (250 mg, 0.932 mmol, 1.0 eq.), tert-butyl 4- ethynylpiperidine-1-carboxylate 2 (234.1 mg, 1.118 mmol, 1.2 eq.), CuI (17.76 mg, 0.093 mmol, 0.1 eq.), DIPEA (1.62 mL, 9.320 mmol, 10.0 eq.) and PdCl2(PPh3)2(65.45 mg, 0.093 mmol, 0.1 eq.) in THF (6.2 mL, 0.15 M) was degassed by sparging with nitrogen for 20 minutes. The reaction was stirred at room temperature for 48 hours. The reaction was filtered over celite, washed with MeTHF and the filtrate was evaporated. The residue was purified by normal phase flash chromatography (40 g silica column, elution: 0 to 20 % CH2Cl2 / EtOAc over 15 CV, product exited at 7 % EtOAc). Fractions were combined and concentrated to give tert-butyl 4-[2- [4-(2,6-dioxo-3-piperidyl)phenyl]ethynyl]piperidine-1-carboxylate 3 (183 mg, 49 % yield) as yellow solid.
[0434] LCMS method 1: retention time: 1.820 min, 92.8 % purity at 215 nm, [M-Boc+H]+= 297.2; [M-tBu+H]+= 341.2; [M+Na]+= 419.2.
[0435] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.40 (s, 9 H), 1.44 - 1.55 (m, 3 H), 1.76 - 1.85 (m, 2 H), 1.96 - 2.05 (m, 1 H), 2.13 - 2.26 (m, 1 H), 2.60 - 2.71 (m, 1 H), 2.81 - 2.90 (m, 1 H), 3.14 (br t, J = 9.7 Hz, 2 H), 3.59 - 3.68 (m, 2 H), 3.88 (dd, J = 11.7, 4.9 Hz, 1 H), 7.20 (d, J = 8.1 Hz, 2 H), 7.36 (d, J = 8.3 Hz, 2 H), 10.84 (s, 1 H).
[0436] Step 2. Preparation of 3-[4-[2-(4-Piperidyl)ethynyl]phenyl]piperidine-2,6-dione hydrochloride (C-21): Under nitrogen, a mixture of tert-butyl 4-[2-[4-(2,6-dioxo-3- piperidyl)phenyl]ethynyl]piperidine-1-carboxylate 3 (180. mg, 0.454 mmol, 1.0 eq.) and 4 M HCl in 1,4-dioxane (1.5 mL, 6.0 mmol, 13.0 eq.) in DCM (4.5 mL, 0.1 M) was stirred at room temperature for 0.5 hour. The mixture was concentrated under reduced pressure and co- evaporated 3 times with acetonitrile to give 3-[4-[2-(4-piperidyl)ethynyl]phenyl]piperidine-2,6- dione;hydrochloride C-21 (150 mg, 98 % yield) as a yellow solid.
[0437] LCMS method 1: retention time: 1.121 min, 99.9 % purity at 215 nm, [M-HCl+H]+= 297.2.
[0438] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.75 - 1.85 (m, 3 H), 2.00 - 2.05 (m, 2 H), 2.19 (qd, J = 12.3, 4.4 Hz, 1 H), 2.61 - 2.72 (m, 1 H), 2.96 - 3.04 (m, 4 H), 3.17 - 3.24 (m, 2 H), 3.89 (dd, J = 11.7, 4.9 Hz, 1 H), 7.22 (d, J = 8.1 Hz, 2 H), 7.38 (d, J = 8.3 Hz, 2 H), 8.78 - 8.95 (m, 2 H), 10.85 (s, 1 H).
[0439] CBM intermediates prepared using General Procedure CBM-5 are summarized in Table 6. Table 6. CBM Intermediates Prepared via General Procedure CBM-5 C-General Procedure CBM-6 Example S11.3-(4-(piperidin-4-yl)phenyl)piperidine-2,6-dione (C-25) B
[0440] Step 1. Preparation of tert-butyl 4-[4-(2,6-dioxo-3-piperidyl)phenyl]piperidine- 1-carboxylate (3): A solution of tert-butyl 4-(p-tolylsulfonyloxy)piperidine-1-carboxylate 1 (1.01 g, 2.84 mmol), 3-(4-bromophenyl)piperidine-2,6-dione 2 (772.8 mg, 2.88 mmol), 4,4′-di- tert-butyl-2,2′-dipyridyl (74.9 mg, 0.28 mmol), KI (535.7 mg, 3.23 mmol), 4-ethylpyridine (0.3 mL, 2.64 mmol) and Mn (339.1 mg, 6.18 mmol) in DMA (14 mL) was purged with nitrogen for 10 min. NiBr2.DME (104.6 mg, 0.34 mmol) was then added and nitrogen was bubbled through the solution for 5 more min. After 19 h at 80 °C, the reaction mixture was cooled down to RT and partitioned between EtOAc (50 mL) and brine (50 mL). The organic phase was separated, washed with brine (2x50 mL), dried over Na2SO4, filtered and concentrated in vacuo. Purification by reverse phase chromatography (C18-100 g, 5-100% MeCN / 0.1% formic acid in water, 20 CV) afforded tert-butyl 4-[4-(2,6-dioxo-3-piperidyl)phenyl]piperidine-1-carboxylate 3 (504.6 mg, 1.35 mmol, 48% yield) as a slightly pink solid.
[0441] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.41 (s, 9 H), 1.44 - 1.54 (m, 2 H), 1.74 (br d, J = 12.6 Hz, 2 H), 1.98 - 2.06 (m, 1 H), 2.10 - 2.23 (m, 1 H), 2.45 (br t, J = 3.9 Hz, 1 H), 2.60 -2.71 (m, 2 H), 2.73 - 2.91 (m, 2 H), 3.81 (dd, J = 11.4, 4.8 Hz, 1 H), 4.07 (br d, J = 11.2 Hz, 2 H), 7.11 - 7.16 (m, 2 H), 7.18 - 7.23 (m, 2 H), 10.81 (s, 1 H). LCMS (ESI+, m / z): [M-tBu+H]+= 317.2.
[0442] Step 2. Preparation of 3-(4-(piperidin-4-yl)phenyl)piperidine-2,6-dione (C-25): To a solution of tert-butyl 4-[4-(2,6-dioxo-3-piperidyl)phenyl]piperidine-1-carboxylate 3 (137. mg, 0.3700 mmol) in 1,4-Dioxane (1.8 mL) at room temperature was added HCl in dioxane (1.8 mL, 7.2 mmol) (3:03 PM). The resulting solution was stirred at room temperature. After an hour, the reaction mixture was concentrated on the rotovap. The residue was dissolved in 1,4- Dioxane (1.8 mL), and HCl in dioxane (1.8 mL, 7.2 mmol) was added. The mixture was stirred at room temperature for 3.5 h. After HPLC analysis showed complete conversion the mixture was concentrated on the rotovap to give 119.6 mg of the product C-25 as a light-yellow solid (quant. yield). The product was 99.9% pure by HPLC (2.5 min. run, 215 nm).
[0443] Luna C1850x3mm 45 °C C-25 ret. time (product) = 1.170 min.
[0444] CBM intermediates prepared using General Procedure CBM-6 are summarized in Table 7. Table 7. CBM Intermediates Prepared via General Procedure CBM-6 CGeneral Procedure CBM-7 Example S12.3-[4-(4-piperidylmethoxy)phenyl]piperidine-2,6-dione;2,2,2-trifluoroacetic acid (C-33)
[0445] Step 1. Preparation of tert-butyl 4-[[4-(2,6-dioxo-3- piperidyl)phenoxy]methyl]piperidine-1-carboxylate (3): To a Schlenk flask were added Quinuclidine (8.29 mg, 0.07 mmol, 0.1 eq.), NiCl2.DME (8.2 mg, 0.04 mmol, 0.05 eq.), 3-(4- bromophenyl)piperidine-2,6-dione 1 (200 mg, 0.75 mmol, 1 eq.), Ir[dF(CF3)ppy]2(dtbbpy)PF6(8.37 mg, 0.01 mmol, 0.01 eq.), K2CO3(103.1 mg, 0.75 mmol, 1 eq.) and dtbbpy (10.01 mg, 0.04 mmol, 0.05 eq.) in MeCN (5 mL, 0.15 M). The flask was placed under nitrogen and thentert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate 2 (401.5 mg, 1.86 mmol, 2 eq.) was added. The Schlenk was then frozen at -78 °C, put on the high vacuum pump under nitrogen and heated slowly to room temperature with a water bath. This procedure was made three times, making sure that there was no oxygen left in the Schlenk tube. The tube was then irradiated under blue LEDs for the week-end. After three days, LCMS showed major conversion into compound 3. The solvent was evaporated under reduce pressure and the crude mixture was purified by reverse phase FC purification (50 g C18 gold column, liquid deposit (DMSO), 5% MeOH / 0.1% HCOOH over 4 CV, then 5 to 80% MeOH / 0.1% HCOOH over 10 CV, then 80 % MeOH / 0.1% HCOOH over 4 CV, the product came out at 80 % MeOH). Fractions were combined and concentrated to give 3 (126 mg, 42 % yield) as a yellow solid.
[0446] LCMS method 1: 99.9 % purity at 215 nm, [M-t-Bu+H]+= 347.2.
[0447] 1H NMR (400 MHz, chloroform-d) δ ppm 1.13 - 1.35 (m, 4 H), 1.46 - 1.48 (m, 9 H), 1.82 (br d, J = 14.7 Hz, 2 H), 1.90 - 2.03 (m, 1 H), 2.18 - 2.32 (m, 2 H), 2.60 - 2.81 (m, 4 H), 3.74 (dd, J = 9.5, 5.4 Hz, 1 H), 3.80 (d, J = 6.4 Hz, 2 H), 6.89 (d, J = 8.6 Hz, 2 H), 7.13 (d, J = 8.6 Hz, 2 H), 7.92 (br s, 1 H).
[0448] Step 2. Preparation of 3-[4-(4-piperidylmethoxy)phenyl]piperidine-2,6- dione;2,2,2-trifluoroacetic acid (C-33): To a solution of tert-butyl 4-[[4-(2,6-dioxo-3- piperidyl)phenoxy]methyl]piperidine-1-carboxylate 3 (126 mg, 0.31 mmol, 1 eq.) in DCM (1 mL, 0.31 M) was added TFA (0.36 mL,4.7 mmol, 15 eq.). The reaction mixture was stirred at room temperature. After 2 h, LCMS showed full conversion into compound 4. The reaction mixture was concentrated under reduced pressure and the residue was co-evaporated with Toluene (2 x) and MeCN (2 x) to give C-33 (157 mg, quantitative yield) as a yellow solid as a trifluoroacetic acid salt.
[0449] LCMS method 1: 91.8 % purity at 215 nm, [M-CF3COOH+H]+= 303.2.
[0450] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.37 - 1.52 (m, 2 H), 1.88 - 1.96 (m, 2 H), 1.96 - 2.20 (m, 3 H), 2.43 - 2.48 (m, 1 H), 2.60 - 2.70 (m, 1 H), 2.84 - 2.97 (m, 2 H), 3.28 - 3.33 (m, 1 H), 3.73 - 3.81 (m, 1 H), 3.81 - 3.87 (m, 2 H), 6.89 (d, J = 8.6 Hz, 2 H), 7.12 (d, J = 8.6 Hz, 2 H), 8.14 - 8.29 (m, 1 H), 8.48 - 8.61 (m, 1 H), 10.78 (s, 1 H).One proton was missing in the1H NMR spectrum.
[0451] CBM intermediates prepared using General Procedure CBM-7 are summarized in Table 8.Table 8. CBM Intermediates Prepared via General Procedure CBM-7 C-General Procedure CBM-8 Example S13.3-[4-[4-(hydroxymethyl)-1-piperidyl]phenyl]piperidine-2,6-dione (C-38) H
[0452] Step 1. Preparation of tert-butyl-(cyclopent-3-en-1-ylmethoxy)-dimethyl-silane (2): To a solution of Cyclopent-3-en-1-ylmethanol 1 (1 g, 10.19 mmol, 1eq.) in DMF (4 mL, 2.5 M) was added imidazole (0.83 g, 12.23 mmol, 1.2 eq.) and tert-Butyldimethylsilyl chloride (2.0 g, 13.25 mmol, 1.3 eq.). After stirring for 30 minutes at room temperature under nitrogen atmosphere, TLC showed full conversion into compound 2. Water was added to the reaction mixture and it was extracted twice with EtOAc. The organic phases were washed twice with water and then with brine, dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude mixture was then purified by normal phase flash chromatography (80 g gold column, solid deposit, elution 0% to 40% Hept. / EtOAc over 20 CV, product came out at 10 % EtOAc). Fractions were combined and concentrated, affording 2 (2.28 g, quantitative yield) as a colorless oil.
[0453] 1H NMR (400 MHz, chloroform-d) δ ppm 0.05 (s, 6 H), 0.90 (s, 9 H), 2.04 - 2.19 (m, 2 H), 2.35 - 2.52 (m, 3 H), 3.49 (d, J = 6.8 Hz, 2 H), 5.65 (s, 2 H).
[0454] Step 2. Preparation of (5R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]hexane-1,5- diol (3): Under nitrogen, a solution of tert-butyl-(cyclopent-3-en-1-ylmethoxy)-dimethyl-silane 2 (2.2 g, 10.36 mmol, 1 eq.) in t-BuOH (35 mL, 0.2 M) and THF (17.5 mL, 0.2 M) was stirred at room temperature for 5 minutes, then OsO4(0.66 mL, 4.0 % w / w in H2O, 0.104 mmol, 0.01 eq.) and NMO (1.46 g, 12.43 mmol, 1.2 eq.) were successively added. After stirring for 18 h. at room temperature under nitrogen atmosphere, TLC showed full conversion into compound 3. Themixture was concentrated to remove t-BuOH and THF, then the residue was dissolved in ethyl acetate (150 mL) and washed with 10 % aq. Na2SO3 (2 x 15 mL), sat. aq. NaHCO3 (15 mL) and sat. aq. NaCl (15 mL). The organic phase was dried over sodium sulfate, filtered and concentrated to dryness. The residue was then purified by normal phase flash chromatography (80 g silica column, elution: 0 to 10 % methanol / dichloromethane over 14 CV, product exited at 10 % methanol). Fractions were combined and concentrated to give 3 (2.44 g, 88 % yield) as a brown oil.
[0455] 1H NMR (400 MHz, chloroform-d) δ ppm 0.04 (s, 6 H), 0.89 (s, 9 H), 1.64 - 1.74 (m, 2 H), 1.75 - 1.87 (m, 2 H), 2.40 - 2.53 (m, 1 H), 3.47 (d, J = 5.4 Hz, 2 H), 4.09 - 4.17 (m, 2 H).
[0456] Step 3. Preparation of 3-[[tert-butyl(dimethyl)silyl]oxymethyl]pentanedial (4): Under nitrogen, a solution of (1S,2R)-4-[[tert-butyl(dimethyl)silyl]oxymethyl]cyclopentane-1,2- diol 3 (2.4 g, 9.74 mmol, 1 eq.) in THF (35 mL, 0.19 M) and H2O (17.5 mL, 0.19 M) was stirred at room temperature for 5 minutes, then NaIO4(2.5 g, 11.69 mmol, 1.2 eq.) was added. After stirring for 1 h. at room temperature under nitrogen atmosphere, TLC (CH2Cl2 / MeoH 95:5, KMnO4stain) showed full conversion into compound 4. The mixture was concentrated to remove THF, then brine (40 mL) was added. The aqueous phase was then extracted 3 times with ethyl acetate (3 x 75 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was dissolved in dichloromethane (150 mL) and stirred for 16 h. at room temperature in the presence of a large excess of magnesium sulfate. The solid was filtered, then the organic phase was concentrated and dried under high vacuum to give 4 (2.04 g, 86 % yield) as a colorless oil.
[0457] 1H NMR (400 MHz, chloroform-d) δ ppm 0.03 (s, 6 H), 0.88 (s, 9 H), 2.41 - 2.49 (m, 2 H), 2.51 - 2.60 (m, 2 H), 2.69 - 2.82 (m, 1 H), 3.57 (d, J = 5.6 Hz, 2 H), 9.78 (s, 2 H).
[0458] Step 4. Preparation of 3-[4-[4-[[tert-butyl(dimethyl)silyl]oxymethyl]-1- piperidyl]phenyl]piperidine-2,6-dione (6): To a solution of 3-(4-aminophenyl)piperidine-2,6- dione 5 (250 mg, 1.22 mmol, 1 eq.) and 3-[[tert-butyl(dimethyl)silyl]oxymethyl]pentanedial 4 (360 mg, 1.47 mmol, 1.2 eq.) in DCE (12.2 mL, 0.1 M) was added NaBH(OAc)3(649 mg, 3.06 mmol, 2.5 eq.). The mixture was stirred at room temperature. After 2 h, LCMS showed complete conversion into compound 6. The reaction mixture was partitioned between DCM (20 mL) and sat. NaHCO3(15 mL). The organic phase was separated and the aqueous layer was extracted with DCM (2 x 30 mL). The combined organic phases were dried over sodium sulfate, filtrated and evaporated under reduced pressure, affording 6 (413 mg, 81% yield) as a white solid that was used as is without further purification.
[0459] LCMS method 1: 99.9% purity at 215 nm, [M+H]+= 417.4.
[0460] 1H NMR (400 MHz, chloroform-d) δ ppm 0.06 (s, 6 H), 0.91 (s, 9 H), 1.28 - 1.41 (m, 2 H), 1.61 - 1.68 (m, 1 H), 1.82 (br d, J = 12.5 Hz, 2 H), 2.19 - 2.33 (m, 2 H), 2.57 - 2.77 (m, 4 H), 3.49 (d, J = 6.4 Hz, 2 H), 3.66 - 3.76 (m, 3 H), 6.93 (d, J = 8.8 Hz, 2 H), 7.08 (d, J = 8.6 Hz, 2 H), 7.90 (br s, 1 H).
[0461] Step 5. Preparation of 3-[4-[4-(hydroxymethyl)-1-piperidyl]phenyl]piperidine- 2,6-dione (C-38): To 3-[4-[4-[[tert-butyl(dimethyl)silyl]oxymethyl]-1- piperidyl]phenyl]piperidine-2,6-dione 6 (410 mg, 0.98 mmol, 1 eq.) in DCM (12.2 mL, 0.08 M) was added 4 M HCl in dioxane (12.3 mL, 49.20 mmol, 50 eq.). The reaction mixture was stirred at rt. After 1.5 h, LCMS showed complete conversion into compound 7. The solvent was removed under reduced pressure and the residue was co-evaporated with toluene followed by MeCN. The residue was dried under high vacuum, affording C-38 (453 mg, quantitative yield) as an off-white solid that was used as is directly for the next step.
[0462] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+= 303.4.
[0463] CBM intermediates prepared using General Procedure CBM-8 are summarized in Table 9. Table 9. CBM Intermediates Prepared via General Procedure CBM-8 C-General Procedure CBM-9 Example S14. Tert-butyl 4-(4-(3-methyl-2,6-dioxopiperidin-3-yl)phenyl)piperazine-1- carbox Br
[0464] Step 1. General procedure for preparation of compound (2): To a solution of 2- (4-bromophenyl)acetonitrile 1 (100 g, 510 mmol) in DMF (1000 mL) was added Me2NH-BH3(30 g, 510 mmol) and t-BuONa (73.5 g, 765 mmol). After addition, the reaction was stirred at 80 °C for 1hour. TLC (petroleum ether / ethyl acetate, 10:1) showed the staring material was consumed. The reaction mixture was quenched with water (250 mL), extracted with ethyl acetate (300 mL x2), the combined organic layer was washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography give 2-(4-bromophenyl)propanenitrile 2 (49 g, 45.7% yield) as an orange oil.
[0465] 1H NMR (400 MHz, CDCl3) δ 7.47-7.43 (m, 2H), 7.19-7.15 (m 2H), 3.82-3.77 (m 1H), 1.56 (d, J = 3.2 Hz, 1H).
[0466] Step 2. General procedure for preparation of Compound (4): To a solution of 2- (4-bromophenyl)propanenitrile 2 (49 g, 233 mmol) in toluene (500 mL) was added tert-butyl prop-2-enoate 3 (59.8 g, 467 mmol), K2CO3 (64.4 g, 467 mmol) and benzyltriethylammonium chloride (10.6 g, 46.7 mmol). The reaction mixture was stirred at 90 °C for 16 hours. HPLC showed the starting material was consumed. The reaction mixture was cooled to RT and filtered, the cake was washed with ethyl acetate (200 mL). The combined organic layer was concentrate to give crude tert-butyl 4-(4-bromophenyl)- 4-cyano-pentanoate 4 (80 g, crude) as an orange oil, which was used into next step without any further purification.
[0467] 1H NMR (400 MHz, CDCl3) δ: 7.47-7.45 (m, 2H), 7.26-7.23 (m, 2H), 2.33-2.29 (m, 1H), 2.18-2.04 (m, 3H), 1.64 (s, 3H), 1.34 (s, 9H).
[0468] Step 3. General procedure for preparation of Compound (6): To a solution of tert-butyl 4-(4-bromophenyl)-4-cyano-pentanoate 4 (130 g, 384 mmol) and tert-butyl piperazine- 1-carboxylate 5 (78.7 g, 423 mmol) in 1,4-dioxane (1500 mL) was added Cs2CO3(250 g, 769 mmol), Pd2(dba)3(12.3 g, 13.45 mmol) and Xphos (9.16 g, 19.2 mmol). The reaction was degassed with N2for 5 min and then stirred at 90 °C for 16 hrs. TLC (petroleum ether / ethyl acetate, 2:1) showed the reaction was finished. The reaction mixture was cooled to RT and filtered. The cake was washed with ethyl acetate (1000 mL), the combined organic layer was concentrated. The residue was purified by MPLC to give tert-butyl 4-[4-(4-tert-butoxy-1-cyano- 1-methyl-4-oxo-butyl)phenyl]piperazine-1-carboxylate 6 (143.5 g, 84.2% yield) as a gray solid.
[0469] 1H NMR (400 MHz, CDCl3) δ: 7.25 (t, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 3.51 (t, J = 4.8 Hz, 2H), 3.08 (t, J = 4.8 Hz, 2H), 2.32-2.13 (m, 1H), 2.11-2.05 (m, 3H), 1.62 (s, 3H), 1.42 (s, 9H), 1.33 (s, 9H).
[0470] Step 4. General procedure for preparation of Compound (7): To a solution of tert-butyl 4-[4-(4-tert-butoxy-1-cyano-1-methyl-4-oxo-butyl)phenyl] piperazine-1-carboxylate 6 (100 g, 225 mmol) in DCE (2000 mL) was added MsOH (65 g, 676 mmol) and TFAA (127 g, 451 mmol). The reaction mixture was stirred at 90 °C for 16hours. TLC (petroleum ether / ethylacetate, 2:1) showed the reaction was finished. The reaction mixture was cooled to RT and concentrated. The crude 7 was used in step without any further purification and base on the theoretical amount (64.8 g) as orange oil.
[0471] Step 5. General procedure for preparation of Compound (C-40): To a solution of 3-methyl-3-(4-piperazin-1-ylphenyl)piperidine-2,6-dione 7 (64.8 g, 226 mmol) in MeCN (1000 mL) was added Boc2O (100 g, 458 mmol) and K2CO3(187 g, 1.35 mol). The reaction mixture was stirred at 20oC for 5 hours. TLC (petroleum ether / ethyl acetate, 1:1) showed the reaction was finished. The reaction mixture was diluted with DCM (1000 mL) and EtOH (1000 mL), stirred for 1hour and filtered, the cake was washed with DCM (1000 mL), the organic layer was concentrated to give crude product, which was combined with page 11, total 230g crude. The mixture was diluted with ethyl acetate (2000 mL), water (1000 mL), stirred at 20 °C for 1hour and then filtered. The cake was dried to give product 85 g (as batch 1). The mother liquor was separated and the organic layer was concentrated, the residue was purified by prep-HPLC to give product 11.2 g. Total 96.2 g of product was obtained. Base on this, 64.8 g of starting material to give product 61.8 g C-40 (yield 71%) as gray solid.
[0472] 1H NMR (400 MHz, CDCl3) δ: 10.86 (s, 1H), 7.12 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 3.44 (t, J = 4.8 Hz, 2H), 3.09 (t, J = 4.8 Hz, 2H), 2.51-2.41 (m, 1H), 2.33-2.30 (m, 3H), 2.07-2.04 (m, 2H), 1.42 (s, 9H), 1.39 (s, 3H).
[0473] CBM intermediates prepared using General Procedure CBM-9 are summarized in Table 10. Table 10. CBM Intermediates Prepared via General Procedure CBM-9 C-General Procedure CBM-10 Example S15. (3R)-3-fluoro-3-[4-(4-piperidyl)phenyl]piperidine-2,6-dione;dihydrochloride (C-46 and C-46i)
[0474] Step 1. Preparation of tert-butyl 3-(4-bromophenyl)-2,6-dioxo-piperidine-1- carboxylate (2): To a suspension of 3-(4-bromophenyl)piperidine-2,6-dione (1) (400 mg, 1.491 mmol) and DMAP (4-Dimethylaminopyridine) (18.2 mg, 0.15 mmol) in MeCN (10 mL) was added Boc2O (645 mg, 2.985 mmol). The reaction was stirred at RT for 2.5 hrs, and monitored by HPLC / TLC. The reaction mixture was partitioned between DCM and sat. NH4Cl. Layers were separated and the aqueous phase was extracted with DCM (1*20 mL). The combined organic layer was dried over Na2SO4, filtered and concentrated to dryness, which was then purified by flash chromatography SiO2120 g eluting with EtOAc in heptane (1 CV 0% then 8 CV 0-30% of EtOAc, following by 4 CV 30% of EtOAc). The desired product came out around 25-30% (@ 225 nm). Pure fractions were collected and concentrated to dryness to afford 2 (285 mg, 0.7740 mmol, 52 % yield) as an orange semi-solid.
[0475] LCMS method 1: Product was not stable in water.
[0476] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.49 (s, 9 H), 2.01 - 2.10 (m, 1 H), 2.27 - 2.41 (m, 1 H), 2.66 - 2.76 (m, 1 H), 2.84 - 2.96 (m, 1 H), 4.11 - 4.20 (m, 1 H), 7.24 (d, J = 8.3 Hz, 2 H), 7.58 (d, J = 8.3 Hz, 2 H).
[0477] Step 2. Preparation of tert-butyl 3-(4-bromophenyl)-3-fluoro-2,6-dioxo- piperidine-1-carboxylate (3): To a flame-dried flask was added 1 M NaHMDS in THF (1.94 mL, 1.94 mmol), and freshly distilled THF (5.5 mL) under nitrogen. The solution was cooled down to –78 °C and a solution of tert-butyl 3-(4-bromophenyl)-2,6-dioxo-piperidine-1- carboxylate (2) (650 mg, 1.77 mmol) in THF (4.5 mL) was added dropwise. After the addition, the dry ice bath was exchanged with an ice bath, and the reaction was stirred at 0 °C for 45 min. The reaction was then cooled back down to –78 °C and a solution of NFSI (612.32 mg, 1.94 mmol) in THF (4.5 mL) was added dropwise. After the addition, the dry ice bath was exchanged once again with an ice bath, and the reaction was stirred at 0 °C for 60 min. Upon completion the reaction mixture was quenched with sat. NH4Cl and then extracted with EtOAc (3 times),and washed with brine (once). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness to afford a crude off-white solid. The crude was purified by normal phase chromatography eluting with EtOAc / Heptane (1 CV 0 % of EtOAc, then 12 CV 0-30 % of EtOAc, following by 3 CV 30% of EtOAc). The product comes out at ~27 % of EtOAc. Fractions containing product were contaminated with NFSI were collected and concentrated to dryness. This mixture was used in the next step without an additional purification step.3 (348 mg, 0.712 mmol, 40 % yield).
[0478] LCMS method 1: 96.6 % purity at 215 nm, [M-Boc+H] + = 286.0.
[0479] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.52 (s, 9 H), 1.99 - 2.05 (m, 1 H), 2.10 - 2.25 (m, 1 H), 2.53 - 2.67 (m, 1 H), 2.79 - 3.04 (m, 1 H), 7.34 - 7.49 (m, 2 H), 7.63 - 7.77 (m, 2 H).
[0480] 19F NMR (377 MHz, DMSO-d6) δ ppm -149.19 - -148.99 (m, 1 F).
[0481] Step 3. Preparation of 3-(4-bromophenyl)-3-fluoro-piperidine-2,6-dione (4): To a flask was added tert-butyl 3-(4-bromophenyl)-3-fluoro-2,6-dioxo-piperidine-1-carboxylate (3) (345. mg, 0.6 mmol), water (7 mL), and MeCN (7 mL). The reaction mixture was stirred at 60 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give a white solid. To remove the residual amounts of NFSI from the previous step, the crude material was purified by reverse phase chromatography eluting with MeCN / 0.1% FA (aq (5-100%). Product came out at around 50-55% of MeCN. Pure fractions were concentrated under reduced pressure to give 4 as a white solid (160 mg, 0.559 mmol, 93 % yield).
[0482] LCMS method 1: 99.9 % purity at 215 nm, [M+ 2H]+= 288.0.
[0483] 1H NMR (400 MHz, DMSO-d6) δ ppm 2.31 - 2.44 (m, 2 H), 2.69 - 2.81 (m, 2 H), 7.41 (d, J = 8.3 Hz, 2 H), 7.68 (d, J = 8.3 Hz, 2 H), 11.44 (br s, 1 H).
[0484] 19F NMR (377 MHz, DMSO-d6) δ ppm -150.17 - -149.95 (m, 1 F).
[0485] Step 4. Preparation of tert-butyl 4-[4-[rac-(3R)-3-fluoro-2,6-dioxo-3- piperidyl]phenyl]piperidine-1-carboxylate (6,6'): To a flame-dried sealed tube was added tert-butyl 4-(p-tolylsulfonyloxy)piperidine-1-carboxylate (5) (195.68 mg, 0.55 mmol), 3-(4- bromophenyl)-3-fluoro-piperidine-2,6-dione (4) (90. mg, 0.31 mmol), NiBr2·DME (9.71 mg, 0.03 mmol), 4,4′-Di-tert-butyl-2,2′-dipyridyl (8.44 mg, 0.03 mmol), KI (54.83 mg, 0.33 mmol), Manganese powder (35.43 mg, 0.64 mmol), DMA (2 mL), and 4-ethylpyridine (0.04 mL, 0.3100 mmol). The reaction mixture was sparged with N2 for 15 min, then the tube was sealed. The reaction mixture was stirred at 800C overnight. Upon completion, the mixture poured in a 0.5 M HCl and extracted with EtOAc (3×). The combined organic phases were washed with brine (1×) and passed through a pad of celite and MgSO4, and concentrated under reduced pressure.The crude was purified by reverse phase chromatography eluting with MeCN (5-60%) / 0.1% F.A(aq.) in water. Product comes out at 60% MeCN. The pure fractions were combined and concentrated under reduced pressure to afford the product as a white solid. The material was sent to chiral SFC to separate the stereoisomers 6,6' (160 mg for both isomers, 0.559 mmol, 93 % yield). After SFC, there were 2 isomers: Chiral resolution 1 named as 6, and Chiral resolution 2 named as 6'. Stereochemistry was arbitrarily assigned.
[0486] LCMS method 1: 99.9 % purity at 215 nm [M-Boc]+= 291.2 m / z.
[0487] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.42 (s, 9 H), 1.46 - 1.58 (m, 2 H), 1.72 - 1.80 (m, 2 H), 2.25 - 2.37 (m, 2 H), 2.66 - 2.93 (m, 5 H), 4.00 - 4.15 (m, 2 H), 7.32 - 7.40 (m, 4 H), 11.36 (br s, 1 H).
[0488] 19F NMR (377 MHz, DMSO-d6) δ ppm -146.87 - -146.48 (m, 1 F).
[0489] Step 5. Preparation of (3R)-3-fluoro-3-[4-(4-piperidyl)phenyl]piperidine-2,6- dione;dihydrochloride (7): To a flask was added tert-butyl 4-[4-[(3R)-3-fluoro-2,6-dioxo-3- piperidyl]phenyl]piperidine-1-carboxylate (6) (85 mg, 0.22 mmol), 1,4-Dioxane (1.5 mL) and 4 M HCl in dioxane (1.36 mL, 5.44 mmol). The reaction mixture was stirred at RT for 1 h. Upon completion, the reaction was co-evaporated with toluene (2×) and MeCN (2×) to afford C-46 (81 mg, 0.2025 mmol, 93 % yield) and used as it for the next step.
[0490] LCMS method 1: 90.7 % purity at 215 nm, [M+H]+= 291.2.
[0491] Step 5'. Preparation of (3R)-3-fluoro-3-[4-(4-piperidyl)phenyl]piperidine-2,6- dione;dihydrochloride (C-46i): To a solution of tert-butyl 4-[4-[(3S)-3-fluoro-2,6-dioxo-3- piperidyl]phenyl]piperidine-1-carboxylate 6' (88. mg, 0.23 mmol) in 1,4-dioxane (1.13 mL) was added HCl in dioxane (1.41 mL, 5.63 mmol). The reaction was stirred at room temperature for 1 h, which was then concentrated in vacuo and chased with MeCN to afford the crude product C- 46i as tan solid (73.5 mg, 0.2249 mmol, 99.9 % yield). Used as is in the next step.
[0492] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+= 291.2.
[0493] CBM intermediates prepared using General Procedure CBM-10 are summarized in Table 11. Table 11. CBM Intermediates Prepared via General Procedure CBM-10 CC-General Procedure CBM-11 (CBM-11A and CBM-11B) General Procedure CBM-11Awherein R7is as defined in Formula (I’) or (I).
[0494] Step-1’: A suspension of (R)-3-(4-bromophenyl)-3-methylpiperidine-2,6-dione 1 (1.0 g, 3.54 mmol), heterocycle 2 (1.5 eq.) and sodium tert-butoxide (3.0 eq.) in toluene (0.089 M) was purged with nitrogen for 5 min. Pd2(dba)3(0.08 eq.) and Xantphos (0.16 eq.) was added to the reaction mixture under nitrogen before heating to 110 °C. After completion of the reaction, RM was poured slowly into 10.0% aqueous solution of acetic acid. RM was then extracted with ethyl acetate. Separated organic layer was washed with water followed by brine solution. Combined organic layer was then dried over sodium sulphate and concentrated under reduced pressure to give the crude product that purified by column chromatography using silica gel to give compound 3.
[0495] Step 2’: To a stirred solution of compound 3 (1.0 eq.) in 1,4-dioxane (0.16 M) was added 4.0 M HCl in dioxane (5.0 eq.) at RT. The resulting solution was stirred for 3 h at RT. Reaction mixture was then concentrated under reduced pressure to give crude product CBM-11 that was used in the next step without further purification.General Procedure CBM-11Bwherein R7is as defined in Formula (I’) or (I).
[0496] Step 1. Preparation of 2-(4-bromophenyl)propanenitrile 2: To a solution of 2-(4- bromophenyl)acetonitrile 1 (5.0 g, 25.5 mmol) in DMF (50 mL) was added sodium tert-butoxide (3.68 g, 38.3 mmol) followed by BH3.NHMe2 (1.878 mL, 25.5 mmol). The resulting reaction mixture was stirred at 80 °C for 1 h. The reaction mixture was cooled to room temperature, treated with ice-cold water, and extracted with EtOAc (2 x 150 mL). The combined organics were dried over Na2SO4and concentrated under reduced pressure to obtain the crude compound. The crude compound was purified by column chromatography using silica gel (230-400 mesh) with 6% ethyl acetate / pet ether to obtain 2-(4-bromophenyl)propanenitrile 2 (2.6 g, 12.38 mmol, 48.5% yield) as a pale yellow oil.
[0497] Step 2. Preparation of tert-butyl (R)-4-(4-bromophenyl)-4-cyanopentanoate 4a and tert-butyl (S)-4-(4-bromophenyl)-4-cyanopentanoate 4b: To a solution of 2-(4- bromophenyl)propanenitrile 2 (3.8 g, 18.09 mmol) in toluene (40 mL) was added tert-butyl acrylate 3’ (4.64 g, 36.2 mmol), K2CO3 (5.00 g, 36.2 mmol), and benzyltriethylammonium chloride (0.824 g, 3.62 mmol). The resulting reaction mixture was heated to 90 °C and stirred for 16 h. The reaction mixture was cooled to room temperature and filtered, and the filtrate was concentrated under reduced pressure to obtain the crude compound. The crude compound was purified by column chromatography using silica gel (230-400 mesh) with 5% ethyl acetate / pet ether to obtain a racemic mixture of tert-butyl 4-(4-bromophenyl)-4-cyanopentanoate (5.5 g, 16.26 mmol, 90% yield) as a pale yellow liquid.4.5 g of the material was purified by chiral SFC to obtain tert-butyl (R)-4-(4-bromophenyl)-4-cyanopentanoate 4a (1.8 g) and tert-butyl (S)-4-(4- bromophenyl)-4-cyanopentanoate 4b (1.76 g).
[0498] SFC Method: CHIRALPAK AD-H, 250 x 4.6 mm, 5.0 μm. Flow: 3.0 mL / min. Co- Solvent: 10.0% IPA.
[0499] Step 3. Preparation of Compound 6: To a stirred solution of tert-butyl (R)-4-(4-bromophenyl)-4-cyanopentanoate 4a (1.0 eq.) in 1,4-dioxane (0.3 M) was added heterocycle 5 (1.1 eq.) followed by Cs2CO3(3.0 eq.). The resulting reaction mixture was degassed for 10 min with nitrogen gas, and then, RuPhos-Pd-G4 (0.02 eq.) was added. The reaction mixture was heated to 90 °C and stirred. The reaction mixture was cooled to room temperature, filtered through celite, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using silica gel to obtain product 6.
[0500] Step 4. Preparation of CBM-11: To a stirred solution of 6 (1.0 eq.) in AcOH (0.2 M) was added H2SO4(2.0 eq.). The resulting reaction mixture was heated to 120 °C and stirred. The reaction mixture was concentrated under reduced pressure to obtain product CBM-11. Example S16. (R)-3-methyl-3-(4-(piperazin-1-yl) phenyl) piperidine-2,6-dione (C-73)
[0501] LCMS Method 1. Kinetex XB - C18, 75 x 3.0 mm, 2.6 μm, Temperature: RT, Flow: 1.0 mL / min, Run Time: 5 minutes, Mobile Phase Conditions: Mobile Phase-A: 5.0 mm Ammonium formate pH 3.3:CH3CN (98:02), Mobile Phase-B: CH3CN: 5.0 mm Ammonium formate pH 3.3 (98:02), Gradient: Initial 80% Mobile Phase A and 20% Mobile Phase B linear gradient to 100% Mobile Phase B for 4.0 min. MSD positive.
[0502] LCMS Method 2. Aquity UPLC BEH C18, 50 x 3.0 mm, 1.7 μm, Temperature: RT, Flow: 1.0 mL / min, Run Time: 5 minutes, Mobile Phase Conditions: Mobile Phase-A: 0.1% TFA in H2O, Mobile Phase-B: 0.1% TFA in ACN, Gradient: Initial 80% Mobile Phase A and 20% Mobile Phase B linear gradient to 100% Mobile Phase B for 3.0 min. MSD positive.
[0503] Step-1’. Preparation of tert-butyl (R)-4-(4-(3-methyl-2,6-dioxopiperidin-3-yl) phenyl) piperazine-1-carboxylate 3’: A suspension of (R)-3-(4-bromophenyl)-3- methylpiperidine-2,6-dione 1’ (1.0 g, 3.54 mmol), tert-butyl piperazine-1-carboxylate 2’ (0.996 g, 5.32 mmol) and sodium tert-butoxide (1.022 g, 10.63 mmol) in toluene (10.0 mL, 0.089 M) was purged with nitrogen for 5 min. Pd2(dba)3(0.26 g, 0.284 mmol) and Xantphos (0.328 g, 0.567 mmol) was added to the RM under nitrogen. RM was then heated to 110 °C for 16 h in a sealed vial. After completion of the reaction, RM was poured slowly into 10.0% aqueous solution of acetic acid. RM was then extracted with ethyl acetate (2 x 25 mL). Separated organic layer was washed with water followed by brine solution (10.0 mL). Combined organic layer wasthen dried over sodium sulphate and concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography using silica gel (100-200 mesh) with 30-50% ethyl acetate in pet ether to give pure tert-butyl (R)-4-(4-(3-methyl-2,6- dioxopiperidin-3-yl)phenyl)piperazine-1-carboxylate 3’ (225 mg, 13.75% yield) as pale yellow solid.
[0504] LCMS method 1: retention time: 2.181 min, 83.19% purity at 220 nm [M+H]+= 388.2
[0505] Step 2’. Preparation of (R)-3-methyl-3-(4-(piperazin-1-yl) phenyl) piperidine- 2,6-dione C-73: To a stirred solution of tert-butyl (R)-4-(4-(3-methyl-2,6-dioxopiperidin-3-yl) phenyl) piperazine-1-carboxylate 3’ (220 mg, 0.476 mmol) in 1,4-dioxane (3.0 mL) was added 4.0 M HCl in dioxane (0.184 mL, 2.38 mmol) at RT. The resulting solution was stirred for 3 h at RT. Reaction mixture was then concentrated under reduced pressure to give crude product (R)- 3-methyl-3-(4-(piperazin-1-yl) phenyl) piperidine-2,6-dione C-73 (231 mg) as a pale yellow solid, which was used in the next step without further purification.
[0506] LCMS method 2: retention time: 0.456 - 0.643 min, 66.24% purity at 220 nm, [M+H]+= 288.2. Example S17. (R)-3-methyl-3-(4-((S)-2-methylpiperazin-1-yl)phenyl)piperidine-2,6-dione (C-80)
[0507] LCMS Method 1. Kinetex XB - C18, 50 x 4.6 mm, 5.0 μm. Temperature: RT, Flow: 1.0 mL / min, run time: 5.5 min. Mobile Phase Conditions: Mobile Phase-A: 0.1% TFA in H2O, Mobile Phase-B: 0.1% TFA in ACN, Gradient: Initial 95% Mobile Phase A and 5% MobilePhase B linear gradient to 95% Mobile Phase B for 2.5 min.
[0508] UPLC Method 2. Aquity BEH - C18, 50 x 2.1 mm, 1.7 μm. Temperature: RT, Flow: 0.7 mL / min, run time: 2.5 min. Mobile Phase Conditions: Mobile Phase-A: 0.1% TFA in H2O, Mobile Phase-B: 0.1% TFA in ACN, Gradient: Initial 95% Mobile Phase A and 5% Mobile Phase B linear gradient to 98% Mobile Phase B for 1.5 min.
[0509] LCMS Method 3. Kinetex XB - C18, 75 x 3.0 mm, 2.6 μm. Temperature: RT, Flow: 1.0 mL / min, run time: 5.0 min. Mobile Phase Conditions: Mobile Phase-A: 5.0 mm Ammonium formate pH 3.3:CH3CN (98:02), Mobile Phase-B: CH3CN: 5.0 mm Ammonium formate pH 3.3 (98:02), Gradient: Initial 98% Mobile Phase A and 2% Mobile Phase B linear gradient to 100% Mobile Phase B for 4 min.
[0510] Step 1’. Preparation of 2-(4-bromophenyl)propanenitrile 2’: To a solution of 2- (4-bromophenyl)acetonitrile 1’ (5.0 g, 25.5 mmol) in DMF (50 mL) was added sodium tert- butoxide (3.68 g, 38.3 mmol) followed by BH3.NHMe2(1.878 mL, 25.5 mmol). The resulting reaction mixture was stirred at 80 °C for 1 h. The reaction mixture was cooled to room temperature, treated with ice-cold water, and extracted with EtOAc (2 x 150 mL). The combined organics were dried over Na2SO4and concentrated under reduced pressure to obtain the crude compound. The crude compound was purified by column chromatography using silica gel (230- 400 mesh) with 6% ethyl acetate / pet ether to obtain 2-(4-bromophenyl)propanenitrile 2’ (2.6 g, 12.38 mmol, 48.5% yield) as a pale yellow oil.
[0511] 1H NMR (400 MHz, CDCl3): δ ppm 1.65 (d, J = 7.2 Hz, 3H), 3.89 (q, J = 7.2 Hz, 1H), 7.24 – 7.27 (m, 2H), 7.53 – 7.56 (m, 2H).
[0512] Step 2’. Preparation of tert-butyl (R)-4-(4-bromophenyl)-4-cyanopentanoate 4a΄ and tert-butyl (S)-4-(4-bromophenyl)-4-cyanopentanoate 4b’: To a solution of 2-(4- bromophenyl)propanenitrile 2’ (3.8 g, 18.09 mmol) in toluene (40 mL) was added tert-butyl acrylate 3’ (4.64 g, 36.2 mmol), K2CO3 (5.00 g, 36.2 mmol), and benzyltriethylammonium chloride (0.824 g, 3.62 mmol). The resulting reaction mixture was heated to 90 °C and stirred for 16 h. The reaction mixture was cooled to room temperature and filtered, and the filtrate was concentrated under reduced pressure to obtain the crude compound. The crude compound was purified by column chromatography using silica gel (230-400 mesh) with 5% ethyl acetate / pet ether to obtain a racemic mixture of tert-butyl 4-(4-bromophenyl)-4-cyanopentanoate (5.5 g, 16.26 mmol, 90% yield) as a pale yellow liquid.4.5 g of the material was purified by chiral SFC to obtain tert-butyl (R)-4-(4-bromophenyl)-4-cyanopentanoate 4a’ (1.8 g) and tert-butyl (S)-4- (4-bromophenyl)-4-cyanopentanoate 4b’ (1.76 g).
[0513] SFC Method: CHIRALPAK AD-H, 250 x 4.6 mm, 5.0 μm. Flow: 3.0 mL / min. Co-Solvent: 10.0% IPA.
[0514] Characterization of tert-butyl (R)-4-(4-bromophenyl)-4-cyanopentanoate 4a’: rt 2.25; ee 97%;1H NMR (400 MHz, CDCl3): δ ppm 1.42 (s, 9H), 1.74 (s, 3H), 2.10 – 2.27 (m, 3H), 2.39 – 2.45 (m, 1H), 7.32 – 7.36 (m, 2H), 7.53 – 7.56 (m, 2H).
[0515] Characterization of tert-butyl (S)-4-(4-bromophenyl)-4-cyanopentanoate 4b’: rt 1.941; ee 99.9%;1H NMR (400 MHz, CDCl3): δ ppm 1.43 (s, 9H), 1.74 (s, 3H), 2.09 – 2.28 (m, 3H), 2.39 – 2.44 (m, 1H), 7.32 – 7.36 (m, 2H), 7.53 – 7.57 (m, 2H).
[0516] Step 3’. Preparation of tert-butyl (S)-4-(4-((R)-5-(tert-butoxy)-2-cyano-5- oxopentan-2-yl)phenyl)-3-methylpiperazine-1-carboxylate 6’: To a stirred solution of tert- butyl (R)-4-(4-bromophenyl)-4-cyanopentanoate 4a’ (2.0 g, 5.91 mmol, 1.0 eq.) in 1,4-dioxane (20.0 mL) was added tert-butyl (S)-3-methylpiperazine-1-carboxylate 5’ (1.303 g, 6.50 mmol, 1.1 eq.) followed by Cs2CO3(5.78 g, 17.74 mmol, 3.0 eq.). The resulting reaction mixture was degassed for 10 min with nitrogen gas, and then, RuPhos-Pd-G4 (0.101 g, 0.118 mmol, 0.02 eq.) was added. The reaction mixture was heated to 90 °C and stirred for 16 h. The reaction mixture was cooled to room temperature, filtered through celite, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using silica gel (230-400 mesh) with 25% ethyl acetate / pet ether to obtain tert- butyl (S)-4-(4-((R)-5-(tert-butoxy)-2-cyano-5-oxopentan-2-yl)phenyl)-3-methylpiperazine-1- carboxylate 6’ (2.2 g, 78% yield) as a colorless gummy liquid.
[0517] LCMS method 1: retention time: 2.859 min, 96.2% purity at 220 nm, [M+H]+= 458.3
[0518] Step 4’. Preparation of (R)-3-methyl-3-(4-((S)-2-methylpiperazin-1- yl)phenyl)piperidine-2,6-dione 7’: To a stirred solution of tert-butyl (S)-4-(4-((R)-5-(tert- butoxy)-2-cyano-5-oxopentan-2-yl)phenyl)-3-methylpiperazine-1-carboxylate 6’ (2.0 g, 4.37 mmol, 1.0 eq.) in AcOH (20.0 mL) was added H2SO4(0.466 mL, 8.74 mmol, 2.0 eq.). The resulting reaction mixture was heated to 120 °C and stirred for 3 h. The reaction mixture was concentrated under reduced pressure to obtain (R)-3-methyl-3-(4-((S)-2-methylpiperazin-1- yl)phenyl)piperidine-2,6-dione 7’ (3.5 g) as a brown color gum, which was used in the next step without further purification.
[0519] UPLC method 2: retention time: 0.809 min, [M+H]+= 302.2
[0520] Step 5’. Preparation of tert-butyl (S)-3-methyl-4-(4-((R)-3-methyl-2,6- dioxopiperidin-3-yl)phenyl)piperazine-1-carboxylate 8’: To a stirred solution of (R)-3- methyl-3-(4-((S)-2-methylpiperazin-1-yl)phenyl)piperidine-2,6-dione 7’ (3.5 g, 4.18 mmol, 1.0 eq.) in acetonitrile (20 mL) at 0 °C was added DIPEA (5.84 mL, 33.4 mmol, 8.0 eq.) and stirredfor 5 min. Then Di-tert-butyl decarbonate (1.941 mL, 8.36 mmol, 2.0 eq.) was added to the reaction mixture, and the resulting reaction mixture was stirred at RT for 6 h. Then, the reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using silica gel (230-400 mesh) with 40% ethyl acetate / pet ether to obtain tert-butyl tert-butyl (S)-3-methyl-4-(4-((R)-3-methyl-2,6- dioxopiperidin-3-yl)phenyl)piperazine-1-carboxylate 8’ (1.45 g, 84% yield) as an off-white solid.
[0521] LCMS method 1: retention time: 2.150 min, 97.3% purity at 220 nm, [M+H]+= 402.3.
[0522] Step 6’. Preparation of (R)-3-methyl-3-(4-((S)-2-methylpiperazin-1- yl)phenyl)piperidine-2,6-dione C-80: To a stirred solution of tert-butyl (S)-3-methyl-4-(4- ((R)-3-methyl-2,6-dioxopiperidin-3-yl)phenyl)piperazine-1-carboxylate 8’ (1.45 g, 3.61 mmol, 1.0 eq.) in DCM (4 mL, 0.903 M) at 0 °C was added 4.0 N HCl in 1,4-dioxane (4.51 mL, 18.06 mmol, 5.0 eq.). The resulting reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated under reduced pressure to obtain crude (R)-3-methyl-3-(4-((S)-2- methylpiperazin-1-yl)phenyl)piperidine-2,6-dione, 2HCl C-80 (1.2 g), which was used in the next step without further purification.
[0523] LCMS method 3: retention time: 1.565 min, 95.17% purity at 220 nm, [M+H]+= 302.1.
[0524] CBM intermediates prepared using General Procedure CBM-11 are summarized in Table 12. Table 12. CBM Intermediates Prepared via General Procedure CBM-11. CC C C C C CGeneral Procedure CBM-12 Example S18. (R)-3-methyl-3-(4-(piperidin-4-yl)phenyl)piperidine-2,6-dione hydrochloride (C-76)
[0525] LCMS Method 1. Kinetex XB - C 18, 75 x 3.0 mm, 2.6 μm, Temperature: RT, Flow: 1.0 mL / min, Run Time: 5 minutes, Mobile Phase Conditions: Mobile Phase-A: 5.0 mm Ammonium formate pH 3.3:CH3CN (98:02), Mobile Phase-B: CH3CN: 5.0 mm Ammoniumformate pH 3.3 (98:02), Gradient: Initial 80% Mobile Phase A and 20% Mobile Phase B linear gradient to 100% Mobile Phase B for 4.0 min. MSD positive.
[0526] Step 1’. Synthesis of tert-butyl (R)-4-(4-(3-methyl-2,6-dioxopiperidin-3- yl)phenyl)piperidine-1-carboxylate 4’: To a mixture of tert-butyl 4-hydroxypiperidine-1- carboxylate 1’ (174.7 mg, 0.868 mmol) and 5,7-di-tert-butyl-3-phenylbenzo[d]oxazol-3-ium.BF4 3’ (314 mg, 0.794 mmol) in 20 mL vial was added anhydrous tert-butyl methyl ether (4.0 mL) and the reaction mixture was stirred at room temperature for 5 min. Then, pyridine (0.064 mL, 0.794 mmol) in 1.0 mL of anhydrous tert-butyl methyl ether was added dropwise at room temperature. The resulting solution was stirred at room temperature for 10 min. A white solid precipitated out during this time. Another 40.0 mL vial was charged with [Ir(dtbbpy)(ppy)2]PF6(6.80 mg, 7.44 μmol), NiBr2(dtbbpy) (12.08 mg, 0.025 mmol), quinuclidine (97 mg, 0.868 mmol), (R)-3-(4-bromophenyl)-3-methylpiperidine-2,6-dione 2’ (140 mg, 0.496 mmol) and phthalimide (16.79 mg, 0.114 mmol). N,N-Dimethylacetamide (5.0 mL) was added to this vial under nitrogen atmosphere.
[0527] The tert-butyl methyl ether suspension was transferred to a syringe. Then a syringe filter was installed on the syringe, and the tert-butyl methyl ether solution was injected into the dimethylacetamide solution. The reaction was degassed with nitrogen for 15 min and closed with a screw cap. The reaction mixture's vial was irradiated under blue LED light for 2 h under constant stirring. The reaction mixture was diluted with water (10 mL) and extracted with DCM (20 mL). The organic layer was concentrated under reduced pressure and purified by column chromatography on silica gel with 30% ethyl acetate / pet ether to afford compound tert-butyl (R)-4-(4-(3-methyl-2,6-dioxopiperidin-3-yl)phenyl)piperidine-1-carboxylate 4’ (90 mg, 47.0% yield) as an off-white solid.
[0528] LCMS method 1: retention time 2.82 min, 99.09% purity at 220 nm, [M+H-Boc]+= 287.2
[0529] Step 2’. Preparation of (R)-3-methyl-3-(4-(piperidin-4-yl)phenyl)piperidine-2,6- dione hydrochloride C-76: To a stirred solution of tert-butyl (R)-4-(4-(3-methyl-2,6- dioxopiperidin-3-yl)phenyl)piperidine-1-carboxylate 4’ (140 mg, 0.362 mmol) in DCM (1.5 mL) was added 4.0 N HCl in dioxane (1.5 mL) at RT. The resulting solution was stirred for 3 h at RT. Reaction mixture was then concentrated under reduced pressure to give crude product (R)- 3-methyl-3-(4-(piperidin-4-yl)phenyl)piperidine-2,6-dione hydrochloride C-76 (120 mg), which was used in the next step without further purification.
[0530] LCMS method 1: retention time 1.647 min, 98.14% purity at 220 nm, [M+H]+= 287.2.
[0531] CBM intermediates prepared using General Procedure CBM-12 are summarized in Table 13. Table 13. CBM Intermediates Prepared via General Procedure CBM-12. C-7Synthesis of the TBM molecule
[0532] The numbering of the intermediate compounds referred to in this section is limited to each section only. For instance, intermediate 3 in General Procedure TBM-1 and intermediate 3 in General Procedure TBM-3 are not the same compounds as they are from different sections. General Procedure TBM-1wherein Ring B is heteroaryl; R4is C3-C6cycloalkyl; and R0is as defined in Formula (I’) or (I).
[0533] Step 1: To a solution of ethyl 4,6-dichloropyridine-3-carboxylate 1 (1 eq.) in MeCN (0.45 M) was added amine 2 (3 eq.). The reaction was stirred at temperature. Upon completion by LCMS, the reaction mixture was cooled to room temperature and reaction was purified to afford 3.
[0534] Step 2 (option 1): To reaction vessel was added ethyl 6-chloro-4-(amino)pyridine-3- carboxylate 3 (1 eq.), heterocyclic anline 4 (1.2 eq.), Xantphos (0.05 eq.), Cs2CO3(1.4 eq.) and Pd2(dba)3(0.05 eq.) in 1,4-Dioxane (0.2 M). The solution was sparged with nitrogen for 5 min, the tube was sealed and stirred at 150°C. Upon LCMS indication of conversion, the reaction mixture cooled to room temperature mixture prior to purification by reverse phase column chromatography to afford product 5.
[0535] Step 2 (option 2): To reaction vessel was added ethyl 6-chloro-4-(amino)pyridine-3- carboxylate 3 (1 eq.), heterocyclic anline 4 (1.5 eq.), p-toluenesulfonic acid monohydrate (0.3 eq.) and ethanol (3 mL). The tube was purged with nitrogen, sealed and stirred at 105 °C. Upon LCMS indication of conversion, EtOH was removed under vacuum and the residue purified by reverse phase flash chromatography to afford product 5.
[0536] Step 3: In a round-bottom flask were added ethyl 4-(amino)-6-[heterocyclic]pyridine-3-carboxylate 5 (1 eq.), lithium hydroxide monohydrate (5 eq.), THF (1 mL), MeOH (1 mL), and water (1 mL). The reaction was stirred at 60 °C. Upon LCMS indication of conversion, volatiles were removed under vacuum and the residue taken up with water (5 mL). A 6 M aqueous solution of HCl was added to reach pH 3. The precipitate was filtered off and dried under vacuum to afford product TBM-1. Example S19.6-(1,3-benzothiazol-6-ylamino)-4-(cyclopentylamino)pyridine-3-carboxylic acid (A-1)
[0537] Step 1’. Preparation of ethyl 6-chloro-4-(cyclopentylamino)pyridine-3- carboxylate (3’): Ethyl 4,6-dichloropyridine-3-carboxylate (1’) (10 g, 45.4 mmol, 1.0 equiv) was added to a a solution of cyclopentanamine (2’) (17.9 mL, 182 mmol, 4.0 equiv) in MeCN (100 mL), then the reaction mixture was stirred at 65 °C overnight. The reaction mixture was cooled to room temperature and water (400 mL) was added. The suspension was sonicated and then stirred at 0 °C for 1 hour. The solid was filtered, rinsed with water, and dried under high vacuum to yield 3’ (11.9 g, 44.1 mmol, 97% yield) as a brown solid.
[0538] LCMS method 1: 96.5 % purity at 215 nm, [M+H]+= 269.2.
[0539] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.30 (t, J = 7.1 Hz, 3 H), 1.40 - 1.51 (m, 2 H), 1.56 - 1.73 (m, 4 H), 2.02 (dq, J = 12.2, 6.0 Hz, 2 H), 3.97 (sxt, J = 6.3 Hz, 1 H), 4.29 (q, J = 7.1 Hz, 2 H), 6.82 (s, 1 H), 8.08 (br d, J = 7.0 Hz, 1 H), 8.52 (s, 1 H).
[0540] Step 2’. Preparation of ethyl 6-(1,3-benzothiazol-6-ylamino)-4- (cyclopentylamino)pyridine-3-carboxylate (5’): 1,3-Benzothiazol-6-amine (4’) (4.19 g, 27.9 mmol, 1.5 equiv), ethyl 6-chloro-4-(cyclopentylamino)pyridine-3-carboxylate (3’) (5 g, 18.6 mmol, 1.0 equiv) and PTSA∙H2O (1.42 g, 7.44 mmol, 0.4 equiv) were mixed with ethanol (37.2 mL) in a sealed tube and the reaction mixture was stirred at 105 °C for 40 hours. The organic solvents were evaporated under reduced pressure, then the crude mixture was taken up in the minimum amount of EtOAc and basified with saturated NaHCO3(aq) until the product crashedout. The precipitate was filtered and triturated with 1:1 MeCN / H2O, then it was filtered again and rinsed with water to yield 5’ (4.72 g, 12.34 mmol, 66% yield) as a green solid.
[0541] LCMS method 1: 98.5 % purity at 215 nm, [M+H]+= 383.2.
[0542] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.29 (t, J = 7.1 Hz, 3 H), 1.49 (br dd, J = 11.9, 5.9 Hz, 2 H), 1.56 - 1.78 (m, 4 H), 1.97 - 2.05 (m, 2 H), 3.39 - 3.43 (m, 1 H), 3.78 (dq, J = 12.0, 6.0 Hz, 1 H), 4.23 (q, J = 7.1 Hz, 2 H), 6.06 (s, 1 H), 7.56 (dd, J = 8.8, 1.7 Hz, 1 H), 7.78 (br d, J = 6.2 Hz, 1 H), 7.95 (d, J = 8.8 Hz, 1 H), 8.57 (s, 1 H), 8.62 (d, J = 1.3 Hz, 1 H), 9.16 (s, 1 H), 9.42 (s, 1 H).
[0543] Step 3. Preparation of 6-(1,3-benzothiazol-6-ylamino)-4- (cyclopentylamino)pyridine-3-carboxylic acid (A-1): A solution of LiOH∙H2O (2.59 g, 61.7 mmol, 5.0 equiv) in water (15 mL) was added to a solution of ethyl 6-(1,3-benzothiazol-6- ylamino)-4-(cyclopentylamino)pyridine-3-carboxylate (5’) (4.72 g, 12.3 mmol, 1.0 equiv) in THF (15 mL) and methanol (15 mL), then the reaction mixture was stirred at 80 °C for 1 hour. The organic solvents were evaporated under reduced pressure, then the crude mixture was diluted with water (75 mL) and acidified with 3.0 M HCl(aq) to pH = 1. The precipitate was filtered, rinsed thoroughly with water and dried under high vacuum to yield A-1 (4.03 g, 11.2 mmol, 91% yield) as a tan solid.
[0544] LCMS method 2: 98.7 % purity at 215 nm, [M+H]+= 355.1.
[0545] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.41 - 1.55 (m, 2 H), 1.55 - 1.72 (m, 4 H), 1.92 - 2.10 (m, 2 H), 3.75 - 3.87 (m, 1 H), 6.11 (s, 1 H), 7.55 (br d, J = 8.2 Hz, 1 H), 8.05 (br d, J = 8.8 Hz, 1 H), 8.38 (br d, J = 3.3 Hz, 1 H), 8.43 (br s, 2 H), 9.27 (s, 1 H), 10.02 (br s, 1 H), 12.95 (br s, 1 H). Example S20.6-(2-chloro-4-cyano-anilino)-4-(isopropylamino)pyridine-3-carboxylic acid (A-53)
[0546] LCMS Method 1. Column: Luna C18 (2) 50 X 3 mm, 3 um. Temperature: 45 ℃, Flow: 1.5 mL / min, run time: 2.5 min. Mobile phase conditions: Initial 95 % H2O 0.1 % FA / 5 % MeCN 0.1 % FA, linear gradient to 95 % MeCN 0.1 % FA over 1.3 min then hold for 1.2 minute at 95 % MeCN 0.1 % FA. MSD: ESI Positive
[0547] LCMS Method 3. Kinetex Polar C182.6 um, 50 x 3.0 mm. Temperature: 45 ℃, Flow: 1.2mL / min, Run time: 3 min. Mobile phase conditions: Initial 95% H2O + 0.1% FA / 5%MeCN + 0.1% FA then linear gradient to 95% MeCN for 1.5 min then hold for 1.5 min at 95% MeCN. MSD: Positive
[0548] Step 1’’. Preparation of ethyl 6-chloro-4-(isopropylamino)pyridine-3- carboxylate (3’’): To a solution of ethyl 4,6-dichloropyridine-3-carboxylate 1’’ (5 g, 22.72 mmol, 1 eq.) in MeCN (50 mL, 0.45 M) was added propan-2-amine 2’’ (5.86 mL, 68.17 mmol, 3 eq.). The reaction was stirred at 65 °C. After an overnight period, LCMS showed complete conversion into compound 3’’. The reaction mixture was cooled to room temperature, water was added, and the solution was sonicated for 1 minute and stirred for 1 hour at 0 °C. The precipitate was filtered and dried under vacuum, affording 3’’ (5.35 g, 97 % yield) as a light pink solid.
[0549] LCMS method 1: 99.9 % purity at 215 nm [M+H]+= 243.2.
[0550] 1H NMR (400 MHz, chloroform-d) δ ppm 1.29 (d, J = 6.4 Hz, 6 H), 1.40 (t, J = 7.1 Hz, 3 H), 3.69 (dq, J = 13.3, 6.7 Hz, 1 H), 4.34 (q, J = 7.3 Hz, 2 H), 6.55 (s, 1 H), 8.11 (br s, 1 H), 8.67 (s, 1 H).
[0551] Step 2’. Preparation of ethyl 6-(2-chloro-4-cyano-anilino)-4- (isopropylamino)pyridine-3-carboxylate (5’’): To a flame dried sealed tube was added ethyl 6-chloro-4-(isopropylamino)pyridine-3-carboxylate 3’ (100 mg, 0.41 mmol, 1 eq.), 4-amino-3- chloro-benzonitrile 4’’ (75.44 mg, 0.49 mmol, 1.2 eq.), Xantphos (11.92 mg, 0.02 mmol, 0.05 eq.), Cs2CO3(187.9 mg, 0.58 mmol, 1.4 eq.) and Pd2(dba)3(18.86 mg, 0.02 mmol, 0.05 eq.) in 1,4-Dioxane (2 mL, 0.2 M). The solution was sparged with nitrogen for 5 min, the tube was sealed and stirred at 150 °C. After an overnight period, LCMS showed 77 % conversion into compound 5’. The reaction was cooled to room temperature and the mixture was passed over celite and the pad was washed with EtOAc. The solvent was evaporated under reduced pressure and the residue was purified by reverse phase FC purification (50 g C18 column, liquid deposit (DMSO), 5% MeOH / 0.1% HCOOH over 4 CV, then 5 to 95% MeOH / 0.1% HCOOH over 15 CV, product came out around 70 % MeOH). The pure tubes were combined and concentrated to dryness, affording 5’’ (105 mg, 55 % yield) as a red oil.
[0552] LCMS method 3: 77.5 % purity at 215 nm [M+H]+= 359.1.
[0553] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.24 (d, J = 6.4 Hz, 6 H), 1.30 (t, J = 6.8 Hz, 3 H), 3.61 - 3.71 (m, 1 H), 4.25 (q, J = 7.1 Hz, 2 H), 6.58 (s, 1 H), 7.66 - 7.72 (m, 1 H), 7.74 - 7.78 (m, 1 H), 8.00 (d, J = 1.7 Hz, 1 H), 8.43 (d, J = 8.8 Hz, 1 H), 8.54 (s, 1 H), 8.84 (s, 1 H)
[0554] Step 3’. Preparation of 6-(2-chloro-4-cyano-anilino)-4- (isopropylamino)pyridine-3-carboxylic acid (A-53): To a round bottom flask was added ethyl 6-(2-chloro-4-cyano-anilino)-4-(isopropylamino)pyridine-3-carboxylate 5’ (105 mg, 0.29 mmol, 1 eq.) and LiOH∙H2O (61.39 mg, 1.46 mmol, 5 equiv) in H2O:THF:MeOH (0.49 mL: 0.49 mL;0.49 mL, 0.2 M), then the reaction mixture was stirred at room temperature. After 1 hour, LCMS showed complete conversion into compound 6’’. The organic solvents were evaporated under reduced pressure, then the crude mixture was purified by reverse phase FC purification (50 g C18 column, liquid deposit (DMSO), 5% MeCN / 0.1% HCOOH over 4 CV, then 5 to 95% MeCN / 0.1% HCOOH over 15 CV, product came out around 35 % MeCN). The pure tubes were combined and concentrated to dryness, affording A-53 (40 mg, 38 % yield) as a white solid.
[0555] LCMS method 3: 91.5 % purity at 215 nm, [M+H]+= 331.1.
[0556] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.23 (d, J = 6.4 Hz, 6 H), 3.60 - 3.70 (m, 1 H), 6.57 (s, 1 H), 7.69 (dd, J = 8.7, 2.1 Hz, 1 H), 7.94 - 8.02 (m, 2 H), 8.45 (d, J = 8.8 Hz, 1 H), 8.50 (s, 1 H), 8.77 (s, 1 H), 12.70 (br s, 1 H). Example S21.4-(cyclopropylamino)-6-[(2-oxo-3H-1,3-benzothiazol-6-yl)amino]pyridine-3- carboxylic acid (A-59)
[0557] LCMS Method 1. Column: Luna C18 (2) 50 X 3 mm, 3 um. Temperature: 45 °C, Flow: 1.5 mL / min, run time: 2.5 min. Mobile phase conditions: Initial 95 % H2O 0.1 % FA / 5 % MeCN 0.1 % FA, linear gradient to 95 % MeCN 0.1 % FA over 1.3 min then hold for 1.2 minute at 95 % MeCN 0.1 % FA. MSD: ESI Positive.
[0558] Step 1’’’. Preparation of ethyl 6-chloro-4-(cyclopropylamino)pyridine-3- carboxylate (3’’’): A 250 mL round bottom flask was loaded with tert-butyl 4,6- dichloropyridine-3-carboxylate 1’’’ (1.5 g, 6.82 mmol, 1 eq.), MeCN (50 mL) and cyclopropanamine 2’’’ (1.26 mL, 20.45 mmol, 3 eq.) and the mixture was stirred at 70 °C. After 18 h, LCMS showed complete conversion. Volatiles were removed under vacuum and the residue was purified by normal phase flash chromatography (40 g silica column; elution: 0% EtOAc / Heptane for 3 CVs, 0% to 20 % EtOAc / Heptane over 13 CVs). Fractions were collected and concentrated to give 3’’’ (1.5 g, 6.232 mmol, 92 % yield) as a white solid.
[0559] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+= 241.2.
[0560] 1H NMR (400 MHz, CDCl3) δ ppm 0.61 - 0.66 (m, 2 H), 0.88 - 0.94 (m, 2 H), 1.39 - 1.42 (t, J = 7.2 Hz, 3 H), 2.47 - 2.55 (m, 1 H), 4.35 (q, J = 7.1 Hz, 2 H), 6.98 (s, 1 H), 8.23 (br s, 1 H), 8.68 (s, 1 H).
[0561] Step 2’’’. Preparation of ethyl 4-(cyclopropylamino)-6-[(2-oxo-3H-1,3- benzothiazol-6-yl)amino]pyridine-3-carboxylate (5’’’): To a sealed tube were added ethyl 6- chloro-4-(cyclopropylamino)pyridine-3-carboxylate 3’’’ (100 mg, 0.42 mmol, 1 eq.), 6-aminobenzo[d]thiazol-2(3H)-one 4’’ (104 mg, 0.62 mmol, 1.5 eq.), p-toluenesulfonic acid monohydrate (24 mg, 0.12 mmol, 0.3 eq.) and ethanol (3 mL). The tube was purged with nitrogen, sealed and stirred at 105 °C. After 2 days, LCMS showed 70 % conversion. EtOH was removed under vacuum and the residue purified by reverse phase flash chromatography (liquid deposit (DMSO), elution: 5% MeCN / water over 10 CV, 5%-40% MeCN / water over 10 CV and 40%-100 MeCN / water over 10 CV. Product came out of the column about 98% of MeCN. The fractions were combined and concentrated to give 5’’’ (100 mg, 0.2457 mmol, 60 % yield) as an off-white solid.
[0562] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+= 371.1.
[0563] 1H NMR (400 MHz, DMSO-d6) δ ppm 0.53 - 0.61 (m, 2 H), 0.76 - 0.84 (m, 2 H), 1.29 (t, J = 7.1 Hz, 3 H), 4.24 (q, J = 7.1 Hz, 2 H), 6.33 (s, 1 H), 7.05 - 7.14 (m, J = 8.6 Hz, 1 H), 7.30 - 7.37 (m, 1 H), 7.48 (d, J = 8.1 Hz, 1 H), 7.87 (s, 1 H), 7.98 (br s, 1 H), 8.44 (s, 1 H), 9.47 (br s, 1 H), 11.81 (br s, 1 H).
[0564] Step 3’’’. Preparation of 4-(cyclopropylamino)-6-[(2-oxo-3H-1,3-benzothiazol-6- yl)amino]pyridine-3-carboxylic acid (A-59): In a round-bottom flask were added ethyl 4- (cyclopropylamino)-6-[(2-oxo-3H-1,3-benzothiazol-6-yl)amino]pyridine-3-carboxylate 5’’’ (100 mg, 0.27 mmol, 1 eq.), lithium hydroxide monohydrate (32 mg, 1.35 mmol, 5 eq.), THF (1 mL), MeOH (1 mL), and water (1 mL). The reaction was stirred at 60 °C. After 6 h, LCMS showed complete conversion. Volatiles were removed under vacuum and the residue taken up with water (5 mL). A 6 M aqueous solution of HCl was added to reach pH 3. The precipitate was filtered off and dried under vacuum to give A-59 (73 mg, 0.213 mmol, 79 % yield) as brown solid.
[0565] LCMS method 1: 85.2 % purity at 215 nm, [M+H]+= 343.1.
[0566] 1H NMR (400 MHz, DMSO-d6) δ ppm 0.56 - 0.65 (m, 2 H), 0.76 - 0.85 (m, 2 H), 2.54 - 2.59 (m, 1 H), 6.34 (s, 1 H), 7.18 (d, J = 8.6 Hz, 1 H), 7.26 - 7.36 (m, 1 H), 7.76 (s, 1 H), 8.32 (s, 1 H), 8.41 - 8.58 (m, 1 H), 9.95 (br s, 1 H), 11.99 (s, 1 H), 13.22 (br s, 1 H).
[0567] TBM intermediates prepared using General Procedure TBM-1 are summarized in Table 14. Table 14. TBM Intermediates Prepared via General Procedure TBM-1General Procedure TBM-2 Example S22.1-(4-(cyclopentylamino)-5-ethynylpyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine- 5-carbonitrile (A-9) N Cl
[0568] Step 1’. Preparation of 2-chloro-N-cyclopentyl-5-iodopyridin-4-amine (3’): To a stirred solution of 2-chloro-5-iodo-pyridin-4-amine (1.25 g, 4.91 mmol) (1’) in DMF (6.7293mL) at 0 °C was added NaH (654.98 mg, 9.82 mmol) in small portions, the reaction was stirred at room temperature for 1 hour. The reaction mixture was heated to 80 °C and stirred for 30 minutes at this temperature. Bromocyclopentane (1.05 mL, 9.82mmol) (2’) was added dropwise at that temperature and the reaction was stirred at 80 °C overnight. The reaction was quenched with NH4Cl(sat) solution and extracted with EtOAc. The org phase was washed with brine (x3). The aq. phases were extracted with EtOAc (x3). Combined org phases were washed with brine and dried (MgSO4) before concentration to dryness. Purification by normal phase flash chromatography, pre-adsorbed on SiO2onto a 80 g SNAP column, eluted from 1 to 50% EtOAc / heptanes over 10 CVs. The desired product came out in the first UV active peak (18% EA), fractions were combined and concentrated under reduce pressure to afford 1.2 g (28% yield) of the desired product (3’) and 1.69 g of starting material was recovered.
[0569] LCMS (3.0 min run, Low pH): rt = 1.9670 min; [M+H]+= 323.0 m / z
[0570] Step 2’. Preparation of 5-((tert-butyldimethylsilyl)ethynyl)-2-chloro-N- cyclopentylpyridin-4-amine (4’): 2-chloro-N-cyclopentyl-5-iodo-pyridin-4-amine (2.6 g, 8.06mmol) (3’), tert-butyl-ethynyl-dimethyl-silane (1.43 mL, 7.66mmol), CuI (383.77 mg, 2.02mmol), NEt3(22.47 mL, 161.21mmol) in DMF (37.201mL) were degassed with N2. Then, PdCl2(PPh3)2(565.75 mg, 0.8100mmol) was added to the mixture, it was bubbled for 10 minutes with N2. The reaction was stirred at room temperature until full conversion was observed by LCMS. The crude mixture was diluted with H2O and was extracted with MTBE (2x), MeTHF (2x) the organic layers were combined. The organic layers were washed with HCl 1M, NaHCO3(sat.) and brine, it was dried with MgSO4, filtered and concentrated under reduce pressure for purification. Purification via normal phase chromatography, pre-adsorbed on SiO2, eluted onto a 80g SNAP column from 2 to 20% EtOAc / heptane over 15 CVs, product eluted at 8% EA. The fractions from the major peak were combined and concentrated under reduce pressure to afford 2.75 g (66% yield) of the desired product (4’) as a white solid.
[0571] LCMS (3.5 min run, Low pH): pdt rt = 2.499 min; [M+H]+= 335.4 m / z.
[0572] Step 3’. Preparation of 1-(5-((tert-butyldimethylsilyl)ethynyl)-4- (cyclopentylamino)pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile (6’): 5-[2-[tert- butyl(dimethyl)silyl]ethynyl]-2-chloro-N-cyclopentyl-pyridin-4-amine (2.75 g, 8.21mmol) (4’), 1H-pyrazolo[3,4-b]pyridine-5-carbonitrile (0.66 mL, 9.85mmol) (5’), Xantphos (1520.14 mg, 2.63mmol), Zn(OAc)2(1506.36 mg, 8.21mmol) in 1,4-Dioxane (50mL) were degassed with N2. Then, Pd2(dba)3.CHCl3(1127.7 mg, 1.23mmol) was added to the mixture, it was bubbled for 10 minutes with N2. The rxn mixture was stirred at 105 °C for 10 h and showed incomplete conversion (~50%). At RT additional Zn(OAc)2(753.18 mg, 4.1mmol), Xantphos (1425.13 mg,2.46mmol), Pd2(dba)3(751.8 mg, 0.8200mmol)were added to the mixture, and was bubbled for 10 minutes with N2. The rxn mixture was stirred at 105 °C for another 10 h, where LCMS showed full conversion. The reaction mixture was passed over celite, washed with MeTHF, the solvent has been concentrated under reduce pressure prior to purification via normal phase flash chromatography, pre-adsorbed on SiO2, eluted onto a 80 g SNAP column from 1 to 65 % EtOAc / heptanes over 15 CVs. The fractions from the last peak (ca.58% EtOAc / heptanes) were combined and concentrated under reduce pressure to afford final product (6’) 1.5 g (41% yield).
[0573] LCMS (2.5 min run, Low pH): rt = 2.278 min; [M+H]+= 443.2 m / z.
[0574] Step 4’. Preparation of 1-(4-(cyclopentylamino)-5-ethynylpyridin-2-yl)-1H- pyrazolo[3,4-b]pyridine-5-carbonitrile (A-9): To a stirring solution of 1-[5-[2-[tert- butyl(dimethyl)silyl]ethynyl]-4-(cyclopentylamino)-2-pyridyl]pyrazolo[3,4-b]pyridine-5- carbonitrile (265. mg, 0.6000mmol) in THF (5.9869mL) was added, at 0 °C, a solution of TBAF (2.39 mL, 2.39 mmol) 1 M in THF. The mixture was stirred while warming up to room temperature until LCMS demonstrated full conversion. The crude mixture was concentrated to dryness. Then, it was quenched with NH4Cl and diluted in EtOAc. The organic layer was washed with NaHCO3and brine, dried over MgSO4, filtered and concentrated under reduce pressure before purification via reverse FC (MeOH / 0.1%FA aq., 5% to 100% MeOH in 17 CV, product exit at 41% MeOH) to afford A-9, M = 80 mg, 95% pure at 215 nm.
[0575] LCMS (2.5 min run, Low pH): 1.677 min; [M+H]+= 329.1 m / z.
[0576] TBM intermediates prepared using General Procedure TBM-2 are summarized in Table 15. Table 15. TBM Intermediates Prepared via General Procedure TBM-2General Procedure TBM-3R4is as defined in Formula (I’) or (I) and X’, Y’, and Z’ are selected from C, N, O, and S.
[0577] Step 1. Preparation of tert-butyl 4,6-dichloropyridine-3-carboxylate (2): To a solution of 4,6-dichloropyridine-3-carboxylic acid 1 (1 eq.) and DMAP (0.2 eq.) in THF (0.52 M) at 70 °C was added dropwise tert-butoxycarbonyl tert-butyl carbonate (2 eq.) in THF (0.52 M), over 2 hours with an addition funnel. The reaction mixture was then stirred at 70 °C for another hour. THF was evaporated under reduced pressure and the residue was purified by normal phase flash chromatography to affrod product 2.
[0578] Step 2. Preparation of tert-butyl 6-chloro-4-(amino)pyridine-3-carboxylate (4): To a solution of tert-butyl 4,6-dichloropyridine-3-carboxylate 2 (1 eq.) in MeCN (0.45 M) was added amine 3 (3 eq.). The reaction was stirred at 70°C. Upon LCMS indication of conversion, the reaction mixture was cooled to room temperature, water (350 mL) was added, a white semi- solid formed. The resulting slurry was stirred for 1 h at 0 °C. The aqueous solution was extracted 2×DCM and 2×MeTHF. The solvent was evaporated under reduced pressure and the residue was purified by normal phase flash chromatography to afford product 4.
[0579] In some cases, DIPEA was added to help promote the SNAr reaction, particuarly when using a salt form of an amine.
[0580] Step 3. Preparation of tert-Butyl 6-(heterobicyclic)-4-(amino)pyridine-3- carboxylate (6): A round bottomed flask was loaded with 4 (1.0 eq.), 5 (1.1 eq.), XantPhos (0.3 eq.), Zn(OAc)2(0.6 eq.) and Pd2(dba)3·CHCl3(0.15 eq.).1,4-dioxane (0.2 M) was added, the mixture was sonicated and then nitrogen was sparged through the mixture for 5 min. The mixure was stirred at 110 °C for 16 h. The mixture was passed over Celite, washed with DCM. The solution was dry-packed with silica. Purification by normal phase flash chromatography (heptanes / EtOAc) afforded 6.
[0581] Step 4. Preparation TBM-3: TFA (30 eq.) was added to a solution of 6 (1.0 eq.) in DCM (0.9 M) at room temperature. The solution was stirred at 45 °C for 2 h. Solvent wasremoved under vacuum. Residual TFA was co-evaporated with toluene (2X) then with MeCN. The residue was dried under high vacuum to give a yellow solid. MTBE was added to the solid and the mixture was sonicated and stirred at room temperature for 16 h. The suspension was filtrated over a Büchner funnel and rinced with MTBE to give TBM-3.
[0582] Similar acidic conditions can be used in the ester hydroylsis. Example S23.6-(5-cyanopyrazolo[3,4-b]pyridin-1-yl)-4-(cyclopentylamino)pyridine-3-
[0583] LCMS Method 1. Column: Luna C18(2) 50 X 3mm, 3um. Temperature: 45C, Flow: 1.5 mL / min, Run time: 2.5 min. Mobile phase conditions: Initial 95% H2O 0.1% FA / 5% MeCN 0.1% FA, linear gradient to 95% MeCN 0.1% FA over 1.3 min then hold for 1.2 minute at 95% MeCN 0.1% FA. MSD: ESI Positive
[0584] Step 1’. Preparation of tert-butyl 4,6-dichloropyridine-3-carboxylate (2’): To a solution of 4,6-dichloropyridine-3-carboxylic acid 1’ (20.0 g, 104.2 mmol, 1 eq.) and DMAP (2.5 g, 20.8 mmol, 0.2 eq.) in THF (150 mL, 0.52 M) at 70°C was added dropwise tert- butoxycarbonyl tert-butyl carbonate (45.4 g, 208.3 mmol, 2 eq.) in THF (50 mL, 0.52 M), over 2 hours with an addition funnel. The reaction mixture was then stirred at 70°C for another hour. THF was evaporated under reduced pressure and the residue was purified by normal phase flash chromatography (380 g column, solid deposit, elution 0 to 15 % Hept. / EtOAc over 15 CV). Fractions were combined and concentrated, affording 2’ (22 g, 85 % yield) as a light yellow oil.
[0585] LCMS method 1: 99.9 % purity at 215 nm [M+H]+= 248.2.
[0586] 1H NMR (400 MHz, chloroform-d) δ ppm 1.63 (s, 9 H), 7.45 (s, 1 H), 8.77 (s, 1 H).
[0587] Step 2’. Preparation of tert-butyl 6-chloro-4-(cyclopentylamino)pyridine-3- carboxylate (4’): To a solution of tert-butyl 4,6-dichloropyridine-3-carboxylate 2’ (2.02 g, 8.13mmol, 1 eq.) in MeCN (18 mL, 0.45 M) was added cyclopentanamine 3’ (2.41 mL, 24.38 mmol, 3 eq.). The reaction was stirred at 70°C. After 2.5 h, LCMS showed complete conversion into compound 4’. The reaction mixture was cooled to room temperature, water (350 mL) was added, a white semi-solid formed. The resulting slurry was stirred for 1 h at 0 °C. No precipitate formed. The aqueous solution was extracted 2×DCM and 2×MeTHF. The solvent was evaporated under reduced pressure and the residue was purified by normal phase flash chromatography (40 g column, solid deposit, elution 0% to 30% EtOAc / Heptane over 15 CV). Fractions were combined and concentrated, affording 4’ (2.4 g, 99% yield) as a colorless oil.
[0588] LCMS method 1: 99.9 % purity at 215 nm [M+H]+= 297.2.
[0589] 1H NMR (400 MHz, chloroform-d) δ ppm 1.45 - 1.54 (m, 11 H), 1.55 - 1.64 (m, 2 H), 1.66 - 1.76 (m, 2 H), 1.94 - 2.05 (m, 2 H), 3.67 - 3.78 (m, 1 H), 6.46 (s, 1 H), 8.12 (br. d, J = 5.1 Hz, 1 H), 8.50 (s, 1 H).
[0590] Step 3’. Preparation of tert-butyl 6-(5-cyanopyrazolo[3,4-b]pyridin-1-yl)-4- (cyclopentylamino)pyridine-3-carboxylate (6’): To a flame dried sealed tube was added tert- butyl 6-chloro-4-(cyclopentylamino)pyridine-3-carboxylate 4’ (1.0 g, 3.37 mmol, 1 eq.), 1H- pyrazolo[3,4-b]pyridine-5-carbonitrile 5’ (631.3 mg, 4.38 mmol, 1.3 eq.), Xantphos (623.8 mg, 1.08 mmol, 0.3 eq.), Zn(OAc)2(197.8 mg, 1.08 mmol, 0.3 eq.) and Pd2(dba)3·CHCl3(523.1 mg, 0.51 mmol, 0.15 eq.) in 1,4-dioxane (13.5 mL, 0.25 M). The solution was sparged with nitrogen for 35 min, sealed and stirred at 110 °C. After an overnight period, LCMS showed complete conversion into compound 6’. The mixture was passed over celite and the pad was washed with DCM. The solvent was evaporated under reduced pressure and the residue was purified by normal phase flash chromatography (40 g gold column, solid deposit, elution 20 to 100% EtOAc / Heptane over 15 CV). Fractions were combined and concentrated, affording 6’ (1.29 g, 87% yield) as a yellow solid.
[0591] LCMS method 1: 92.3 % purity at 215 nm [M+H]+= 405.2.
[0592] 1H NMR (400 MHz, chloroform-d) δ ppm 1.55 (s, 9 H), 1.60 - 1.72 (m, 4 H), 1.75 - 1.84 (m, 2 H), 2.10-2.18 (m, 2 H), 3.92 - 4.03 (m, 1 H), 7.82 (br. s, 1 H), 8.56 (s, 1 H), 8.68 (d, J = 1.7 Hz, 1 H), 8.74 (s, 1 H), 8.93 (br. s, 1 H), 8.98 (d, J = 2.0 Hz, 1 H).
[0593] Step 4’. Preparation of 6-(5-cyanopyrazolo[3,4-b]pyridin-1-yl)-4- (cyclopentylamino)pyridine-3-carboxylic acid (A-7): To a solution of tert-butyl 6-(5- cyanopyrazolo[3,4-b]pyridin-1-yl)-4-(cyclopentylamino)pyridine-3-carboxylate 6’ (0.8 g, 1.98 mmol, 1 eq.) in anhydrous DCM (11.6 mL, 0.17 M), under nitrogen atmosphere was added TFA (4.8 mL, 59.3 mmol, 30 eq.) and the reaction was stirred at room temperature. After an overnight stirring, LCMS showed complete conversion into compound 7’. The solvent was removed under reduced pressure and the residue was co-evaporated with toluene (3 x) followed by MeCN (2 x), affording a yellow semi-solid to which was added H2O (50 mL) / MeCN (10 mL) and the mixture was sonicated 3-5 min. The solids were stirred for 10 min at room temperature, filtered, and washed with water and MeCN (until white solid), affording A-7 (0.9 g, 99% yield) as a white solid.
[0594] LCMS method 1: 93.2 % purity at 215 nm [M+H]+= 349.2.
[0595] 1H NMR (400 MHz, chloroform-d) δ ppm 1.50 - 1.61 (m, 2 H), 1.62 - 1.76 (m, 4 H), 2.04 - 2.17 (m, 2 H), 3.95 - 4.04 (m, 1 H), 7.46 (s, 1 H), 8.40 (br. d, J = 6.4 Hz, 1 H), 8.67 (s, 1H), 8.77 (s, 1 H), 9.03 (d, J = 2.0 Hz, 1 H), 9.09 (d, J = 2.0 Hz, 1 H), 13.25 (br. s, 1 H). Example S24.6-(6-amino-5-cyano-pyrazolo[3,4-b]pyridin-1-yl)-4-[(1-methylsulfonyl-4- piperidyl)amino]pyridine-3-carboxylic acid (A52)
[0596] LCMS Method 1. Column: Luna C18 (2) 50 X 3 mm, 3 um. Temperature: 45 ℃, Flow: 1.5 mL / min, run time: 2.5 min. Mobile phase conditions: Initial 95 % H2O 0.1 % FA / 5 % MeCN + 0.1 % FA, linear gradient to 95 % MeCN 0.1 % FA over 1.3 min then hold for 1.2 minute at 95 % MeCN 0.1 % FA. MSD: ESI Positive.
[0597] Step 1’’. Preparation of tert-butyl 6-chloro-4-[(1-methylsulfonyl-4- piperidyl)amino]pyridine-3-carboxylate (4’’): To a solution of 3’’ (3.46 g, 19.41 mmol) and 2’ (1.26 g, 5.08 mmol) in MeCN (19 mL) was added DIPEA (5.3 mL, 30.47 mmol) at RT and the resulting mixture was stirred at 65 ºC. After 4 days, volatiles were evaporated and the residue was partitioned between EtOAc and water. The aqueous phase was extracted to EtOAc (2×). Combined organic phases were washed with saturated NaHCO3and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (EtOAc / heptanes) to afford 4’’ (1.9 g, 94% yield) as a white solid.
[0598] LCMS method 1: 98.1 % purity at 215 nm, [M+H]+= 390.1.
[0599] 1H NMR (400 MHz, CDCl3) δ ppm 1.58 (s, 9 H), 1.75 (dtd, J = 13.4, 9.7, 3.8 Hz, 2 H), 2.10 - 2.19 (m, 2 H), 2.84 (s, 3 H), 2.99 - 3.09 (m, 2 H), 3.48 - 3.58 (m, 1 H), 3.72 (dt, J = 12.3, 4.1 Hz, 2 H), 6.51 (s, 1 H), 8.38 (d, J = 7.6 Hz, 1 H), 8.63 (s, 1 H).
[0600] Step 2’’. Preparation of tert-butyl 6-(6-amino-5-cyano-pyrazolo[3,4-b]pyridin-1- yl)-4-[(1-methylsulfonyl-4-piperidyl)amino]pyridine-3-carboxylate (6’’): A sealed tube was charged with 4’’ (300 mg, 0.77 mmol), 5’’ (134 mg, 0.85 mmol), Xantphos (133 mg, 0.23 mmol), Pd2(dba)3·CHCl3(119 mg, 0.12 mmol), Zn(OAc)2(141 mg, 0.77 mmol) in 1,4-dioxane (3.8 mL). Then nitrogen was sparged through the mixture for 15 minutes. The tube was sealed and reaction mixture was heated at 105 °C for 16 h. The reaction mixture was cooled down to room temperature and filtered through a pad of celite. The filter cake was washed with DCM and the filtrate was concentrated to dryness. The residue was purified by reverse-phase C18 flash chromatography (MeOH / 0.1 % aqueous formic acid) to afford tert-butyl 6’’ (127 mg, 32% yield) as a yellow solid.
[0601] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+= 513.2.
[0602] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.58 (s, 9 H), 1.59 - 1.67 (m, 2 H), 2.08 - 2.19 (m, 2 H), 2.90 (s, 3 H), 2.98 - 3.11 (m, 2 H), 3.50 - 3.58 (m, 2 H), 3.70 - 3.85 (m, 1 H), 7.25 (s, 2 H), 7.46 (s, 1 H), 8.07 (br d, J = 7.3 Hz, 1 H), 8.20 (s, 1 H), 8.54 (s, 1 H), 8.71 (s, 1 H).
[0603] Step 3’’. Preparation of 6-(6-amino-5-cyano-pyrazolo[3,4-b]pyridin-1-yl)-4-[(1- methylsulfonyl-4-piperidyl)amino]pyridine-3-carboxylic acid (A-52): To a solution of 6’’ (127 mg, 0.25 mmol) in MeCN (1.0 mL) was added 4 M HCl in 1,4-dioxane (3.1 mL, 12.39 mmol). The reaction mixture was stirred at room temperature. After 18 h, volatiles were removed in vacuo and the residue was co-evaporated with MeCN (2×). The crude solid was triturated in MeCN which afforded A-52 (115 mg, quant.) as a yellow solid.
[0604] LCMS method 1: 99.9 % purity at 215 nm, [M+H]+=457.1.
[0605] 1H NMR (400 MHz, DMSO-d6) δ ppm 1.57 - 1.70 (m, 2 H), 2.09 - 2.20 (m, 2 H), 2.91 (s, 3 H), 3.04 - 3.14 (m, 2 H), 3.82 - 3.93 (m, 2 H), 4.14 (dd, J = 5.6, 3.4 Hz, 1 H), 7.44 (d, J = 3.9 Hz, 1 H), 7.62 - 7.75 (m, 3 H), 8.31 (s, 1 H), 8.59 (s, 1 H), 8.67 (s, 1 H).
[0606] TBM intermediates prepared using General Procedure TBM-3 are summarized in Table 16. Table 16. TBM Intermediates Prepared via General Procedure TBM-3General Procedure TBM-4 R4NH N NN 1 Step 1 3 Step 2 NC 5SnC MeO Stepwherein R4is as defined in Formula (I’) or (I).
[0607] Step 1. Preparation of 2-chloro-N-alkyl-5-nitropyridin-4-amine 3: To a solution of 2,4-dichloro-5-nitropyridine 1 (1.0 equiv.) in acetonitrile (1.0 M) was added alkyl amine 2 (1.5 equiv.) and DIPEA (2 equiv.) at RT and this resulting solution was stirred at 40 °C for 2 h. The solution was then cooled to room temperature and concentrated under reduced pressure (70% volume). Finally, ice-cold water was added to the reaction mixture and stirred for 10 min to afford a pale yellow solid. The solid was filtered, washed with water, and dried to give compound 3.
[0608] Step 2. Preparation of 1-(4-(alkyl-amino)-5-nitropyridin-2-yl)-1H-pyrazolo[3,4- b] pyridine-5-carbonitrile 5: To a solution of 2-chloro-N-alkyl-5-nitropyridin-4-amine 3 (1.0 equiv) in 1,4-dioxane was added 1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 4 (1.2 equiv.), Xantphos (0.1 equiv) and K2CO3 (2.0 equiv). The resulting mixture was purged with nitrogen gas for 10 min, then was added Pd2dba3(0.05 equiv.). The resulting mixture was stirred at 100 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite bed, washed with ethyl acetate, and concentrated under reduced pressure to give the crude product. The crude was purified by flash column chromatography on silica gel to give pure compound 5.
[0609] Step 3. Preparation of 1-(5-amino-4-(alkyl-amino)pyridin-2-yl)-1H-pyrazolo[3,4- b]pyridine-5-carbonitrile 6: To a stirred solution of 1-(4-(alkyl-amino)-5-nitropyridin-2-yl)- 1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 5 (1.5 equiv.) in MeOH (0.15 M) at RT was added tin(II) chloride (5.0 equiv). The resulting solution was stirred at 70 °C for 16 h. The reaction mixture was cooled to RT and treated with ice-cold sat. sodium bicarbonate (50 mL) solutionand extracted with 10% methanol in DCM (3 x 50 mL). The combined organic layer was dried over sodium sulphate and concentrated under reduced pressure to give the crude compound. The crude product was purified by flash column chromatography using silica gel with methanol / DCM to afford compound 6.
[0610] Step 4. Preparation of 1-(5-azido-4-(alkyl-amino)pyridin-2-yl)-1H-pyrazolo[3,4- b]pyridine-5-carbonitrile TBM-4: To a solution of 1-(5-amino-4-(alkyl-amino)pyridin-2-yl)- 1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 6 (1.0 equiv.) in acetonitrile (0.3 M) was added DMAP (1.5 equiv.) and ADMP (1.5 equiv.). The resulting solution was stirred for 16 h at RT. The reaction mixture was diluted with ice-cold water and extracted with ethyl acetate (3 x 20 mL). The combined organic layer was washed with brine, dried over sodium sulphate and then concentrated under reduced pressure to give the crude product TBM-4 that was used in the next step without further purification. Example S25.1-(5-azido-4-(cyclopropylamino)pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine-5- carbonitrile (A-63)
[0611] LCMS Method 1. Kinetex XB - C18, 75 x 3.0 mm, 2.6 μm, Temperature: RT, Flow: 1.0 mL / min, Run Time: 5 minutes, Mobile Phase Conditions: Mobile Phase-A: 5...
Claims
CLAIMS 1. A compound of Formula (I’):or a pharmaceutically acceptable salt thereof, wherein: Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups; each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, -(6- to 10–membered bridged heterocyclylene)-, and C1-C6alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group; L1is -NH- or a bond; L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or -(C1-C6alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N, O, and S; L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)(C1-C6alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C6alkylene)z-, -(7- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups;L is , phenylene, -N(H)(phenylene), 5- to 6-membered heteroarylene, -N(H)(5- to 6-membered heteroarylene)-, 8- to 10-membered fused bicyclic heteroarylene, or 5- to 6- membered heterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1-3 heteroatoms selected from N, S, and O; R1aand R1bare each H or are taken together to form an oxo group; R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group; or R3and R11are taken together to form a C3-C6cycloalkylene group; Y is NH, O, or a bond; R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1- C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups; W is O, -NR5-, or a bond; R5is H or C1-C6alkyl; each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group; each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl, halo, -CN, or -OH; each R9is independently H or C1-C6alkyl; each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group; each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl; or R11and R3are taken together to form a C3-C6cycloalkylene group; x is 0 or 1; y is 0, 1, 2, 3, 4, or 5;each z is independently 0 or 1; X is N or CR13; R13is H, halo, -OH, or C1-C6alkyl; Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (I):(I) wherein: Ring A is phenyl, monocyclic 5- to 6-membered heteroaryl, or fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms independently selected from N, O, and S, each of which is optionally substituted by 1-3 R0groups; each R0is independently selected from halo, -CN, -NH2, -NH(C1-C6alkyl), C1-C6alkyl, C3-C6cycloalkyl, and C1-C6alkoxy, or two R0groups are taken together to form an oxo group; L1is -NH- or a bond; L2is -NHC(O)-, -C(O)NH-, -SO2NH-, -NHSO2-, or 5-membered heteroarylene containing 1-3 heteroatoms selected from N, O, and S; L3is -NR9(C1-C6alkylene)NR9-, -NR9C(O)(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C6alkylene)z-, -NR9(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -O(C1-C6alkylene)z(4- to 7-membered heterocyclylene)-, -(6- to 10- membered bridged heterocyclylene)(C1-C6alkylene)z-, -(9- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1- C6alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1-5 R7groups;L is , phenylene, 5- to 6-membered heteroarylene, or 5- to 6-membered heterocyclylene, wherein the phenylene, heteroarylene, or heterocyclylene is optionally substituted by 1-4 R10groups, and wherein the heteroarylene and heterocyclylene contain 1- 3 heteroatoms selected from N and O; R1aand R1bare each H or are taken together to form an oxo group; R2and R3are independently H, C1-C6alkyl, or halo, or R2and R3are taken together to form an oxo group; or R3and R11are taken together to form a C3-C6cycloalkylene group; Y is NH or O; R4is C3-C6cycloalkyl, C1-C6alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1- C6alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C6alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1-3 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-5 R8groups; W is O, -NR5-, or a bond; R5is H or C1-C6alkyl; each R6is independently C1-C6alkyl, halo, or -OH, or two R6groups are taken together to form a bridging C1-C3alkylene group; each R7is independently C1-C6alkyl, halo, C1-C6haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; each R8is independently -SO2(C1-C6alkyl), -C(O)(C1-C6alkyl), C1-C6alkyl, C1-C6haloalkyl, halo, -CN, or -OH; each R9is independently H or C1-C6alkyl; each R10is independently C1-C6alkoxy, C1-C6alkyl, halo, or -OH, or two R10groups are taken together to form an oxo group; each R11and R12is independently H, halo, C3-C6cycloalkyl, -OH, -NH(C1-C6alkyl), C1-C6haloalkyl, or C1-C6alkyl; or R11and R3are taken together to form a C3-C6cycloalkylene group; x is 0 or 1; y is 0, 1, 2, 3, 4, or 5; each z is independently 0 or 1;X is N or CR13; R13is H, halo, or C1-C6alkyl; Z1is CH or N; and Z2is CH or N, provided that Z1and Z2are not both N.
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein Ring A is: (i) phenyl optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, and C1-C3alkoxy; (ii) a monocyclic 6-membered heteroaryl containing 1-2 heteroatoms independently selected from N and O, and optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, and C1-C3alkoxy; or (iii) a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 2-4 heteroatoms independently selected from N, O, and S, and optionally substituted by 1-3 R0groups; and each R0is independently selected from halo, -CN, -NH2, -NH(C1-C3alkyl), C1-C3alkyl, C3-C6cycloalkyl, -(6- to 8-membered bridged heterocyclylene)-, and C1-C3alkoxy, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O, or two R0groups are taken together to form an oxo group.
4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein Ring A is:.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein: L2is -NHC(O)- or -(C1-C3alkylene)z(5-membered heteroarylene)-, wherein the heteroarylene contains 1-3 heteroatoms selected from N and O.
6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein:.
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein: L4is ,.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein:; W is O, -NR5-, or a bond; and R5is H or C1-C3alkyl.
9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein: X is N.
10. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein: X is CR13; and R13is H, halo, -OH, or C1-C3alkyl.
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein: Y is NH; R4is C3-C6cycloalkyl, C1-C3alkylene-(C3-C6cycloalkyl), 4- to 6-membered heterocyclyl, C1-C3alkylene-(4- to 6-membered heterocyclyl), 5- to 6-membered heteroaryl, C1-C3alkylene-(5- to 6-membered heteroaryl), C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl- OH, or C1-C6alkyl-CN, wherein the heterocyclyl and heteroaryl contain 1 or 2 heteroatoms selected from N and O, and wherein the cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted by 1-2 R8groups; and each R8is independently -SO2(C1-C3alkyl), -C(O)(C1-C3alkyl), C1-C3alkyl, C1-C3haloalkyl, halo, -CN, or -OH.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein: R4is methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH2CH(CH3)2, -CH2CF3, -CH2CH2F, -CH2CF2CH3, -CH(CH3)CF3, -CH2CH2CF3, -CH(CH3)CH2OH, -CH2C(CH3)2OH, -CH2CN, -CH(CH3)CN, -C(CH3)2CN, -CH(CH2CH3)CN, -CH2CH(CH3)CN,.
13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein: L3is -NR9(C1-C3alkylene)NR9-, -NR9C(O)(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, -(4- to 7-membered heterocyclylene)CR11R12-, -(4- to 7-membered heterocyclylene)(CO)z-, -(4- to 7-membered heterocyclylene)(NR9)z-, -(NR9)z(4- to 7- membered heterocyclylene)(C1-C3alkylene)z-, -NR9(C1-C3alkylene)z(4- to 7-membered heterocyclylene)-, -NR9C(O)(phenylene)NR9-, -(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, -O(C1-C3alkylene)z(4- to 7-membered heterocyclylene)(C1-C3alkylene)z-, -(6- to 10-membered bridged heterocyclylene)(C1-C3alkylene)z-, -(7- to 10-membered fused bicyclic heterocyclylene)(C1-C6alkylene)z-, or -(O)z(6- to 10-membered spiro heterocyclylene)(C1-C3alkylene)z-, wherein the heterocyclylene contains 1-3 heteroatoms selected from N and O and is optionally substituted by 1 or 2 R7groups; each z is independently 0 or 1; each R9is independently H or C1-C3alkyl; each R7is independently C1-C3alkyl, halo, C1-C3haloalkyl, or -OH, or two R7groups are taken together to form an oxo group; and each R11and R12is independently H or -CH3.
14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein: L3is15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Ia) or (Ia’):(Ia ) wherein: Ring A is a fused bicyclic 9- to 10-membered heteroaryl containing 2-4 heteroatomsindependently selected from N, O, and S, optionally substituted by 1-3 R0groups; R4is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl-OH, or C1-C6alkyl-CN; and Z3and Z4are independently N or CH, provided that at least one of Z3and Z4is N.
16. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (If) or (If’):.
17. A compound selected from the compounds of Table 1 or a pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition comprising the compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
19. A method of modulating interleukin-1 (IL1) receptor-associated kinase 4 (IRAK4) activity comprising contacting IRAK4 with an effective amount of the compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 18.
20. A method of treating an inflammatory or autoimmune disease in a subject in need thereof, comprising administering to the subject an effective amount of the compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 18, optionally wherein the inflammatory or autoimmune disease is atopic dermatitis, asthma, lupus, rheumatoid arthritis, familial mediterranean fever, psoriasis, generalized pustular psoriasis, cryoprin-associated periodic syndrome, hidradenitis suppurativa, Bechet’s syndrome, or familial cold autoinflammatory syndrome.
